nct_id,phase,sponsor_name,sponsor_type,study_title,cohort,age_min,age_max,type_lung_nsclc_adeno,type_lung_nsclc_large,type_lung_nsclc_squamous,type_lung_sclc,stage_i,stage_ii,stage_iii,stage_iv,stage_sclc_ls,stage_sclc_es,status_newly_diagnosed,status_relapse,status_refractory,marker_alk_oncogene,marker_egfr_mutation,marker_kras_mutation,treatment_radiation,treatment_radiation_exclusion_period_mo,treatment_chemo_systemic,treatment_chemo_systemic_exclusion_period_mo,treatment_chemo_adjuvant,treatment_chemo_adjuvant_exclusion_period_mo,treatment_tki,treatment_tki_exclusion_period_mo,eligibility_criteria_text
NCT02367794,Phase 3,Hoffmann-La Roche,Industry,"A Phase III, Open-label, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination With Carboplatin+Paclitaxel or Atezolizumab in Combination With Carboplatin+Nab-Paclitaxel Versus Carboplatin+Nab-Paclitaxel in Chemotherapy-naive Patients With Stage IV Squamous Non-small Cell Lung Cancer",1,18,150,,,include,,,,,include,,,,,,,,,,,,,,,,,"        Inclusion Criteria:          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1          -  Histologically or cytologically confirmed, treatment-naÌøve Stage IV squamous NSCLC          -  Previously obtained archival tumor tissue or tissue obtained from biopsy at screening          -  Measurable disease as defined by RECIST v1.1          -  Adequate hematologic and end organ function        Exclusion Criteria:          -  Active or untreated central nervous system (CNS) metastasis          -  Malignancies other than NSCLC within 5 years prior to randomization, with the             exception of those with a negligible risk of metastasis or death treated with             expected curative outcome          -  Pregnant or lactating women          -  History of autoimmune disease          -  History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced             pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening             chest Computed Tomography (CT) scan, History of radiation pneumonitis in the             radiation field (fibrosis) is permitted          -  Positive test for Human Immunodeficiency Virus (HIV)          -  Active hepatitis B or hepatitis C          -  Prior treatment with cluster of differentiation 137 (CD137) agonists or immune             checkpoint blockade therapies, anti-programmed death-1 (anti-PD-1), and             anti-programmed death-ligand 1 (anti-PD-L1) therapeutic antibody          -  Severe infection within 4 weeks prior to randomization          -  Significant history of cardiovascular disease      "
NCT00858364,Phase 3,Amgen,Industry,"A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 åµg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy",1,18,150,include,include,include,,,,,include,,,,exclude,,,,,,,,,,,,,"        Inclusion Criteria:          -  Subjects with stage IV NSCLC (not recurrent or re-staged).          -  Expected to receive at least 2 additional cycles (at least 6 total weeks) of first             line myelosuppressive cyclic chemotherapy after randomization. Subjects should not be             expected to receive only maintenance chemotherapy.          -  Eastern Cooperative Oncology Group performance status of 0 or 1 as assessed within 21             days prior to randomization.          -  18 years of age or older at screening.          -  Life expectancy greater than 6 months based on the judgment of the investigator and             documented during screening.          -  Hemoglobin level less than or equal to 11.0 g/dL as assessed by the local laboratory;             sample obtained within 7 days prior to randomization (retest in screening is             acceptable).          -  Adequate serum folate (greater than or equal to 2 ng/mL) and vitamin B12 (greater             than or equal to 200 pg/mL) levels assessed by central laboratory (supplementation             and retest acceptable) during screening.          -  Subjects must have had a baseline scan (CT, MRI, or PET/CT) of the chest to assess             disease burden before starting on first line chemotherapy for NSCLC and those images             must have been reviewed by the investigator prior to randomization. If the scan was             performed more than 28 days prior to randomization, an additional scan must be             performed and reviewed by the investigator to confirm that the patient has not             progressed before randomization.          -  Before any study-specific procedure, the appropriate written informed consent must be             obtained from the subject or a legally accepted representative.        Exclusion Criteria:          -  Known primary benign or malignant hematologic disorder which can cause anemia.          -  History of, or current active cancer other than NSCLC, with the exception of             curatively resected non-melanomatous skin cancer, curatively treated cervical             carcinoma in situ, or other primary solid tumors curatively treated with no known             active disease present and no curative treatment administered for the last 3 years.          -  Received any prior adjuvant or neoadjuvant therapy for NSCLC.          -  Subjects with a history of brain metastasis.          -  Uncontrolled hypertension (systolic BP > 160 mmHg or diastolic BP > 100 mmHg), or as             determined by the investigator during screening.          -  History of neutralizing antibody activity to rHuEPO or darbepoetin alfa.          -  Uncontrolled angina, uncontrolled heart failure, or uncontrolled cardiac arrhythmia             as determined by the investigator at screening. Subjects with known myocardial             infarction within 6 months prior to randomization.          -  Subjects with a history of seizure disorder taking anti-seizure medication within 30             days prior to randomization.          -  Clinically significant systemic infection or uncontrolled chronic inflammatory             disease (eg, rheumatoid arthritis, inflammatory bowel disease) as determined by the             investigator during screening.          -  Known seropositivity for HIV or diagnosis of AIDS, positive for hepatitis B surface             antigen, or seropositive for hepatitis C virus          -  History of pure red cell aplasia          -  History of deep venous thrombosis or embolic event (eg, pulmonary embolism) within 6             months prior to randomization.          -  Transferrin saturation < 20% and ferritin < 50 ng/mL as assessed by the central             laboratory during screening. Subjects must have both to be excluded (supplementation             and retest acceptable).          -  Abnormal renal function (serum creatinine level > 2X ULN) as assessed by the central             laboratory during screening.          -  Abnormal liver function (total bilirubin > 2X ULN or liver enzymes ALT or AST > 2.5X             ULN for subjects without liver metastasis or ‰ä´ 5X ULN for subjects with liver             metastasis) as assessed by the central laboratory during screening. Subjects with             documented Gilbert's Disease may be eligible.          -  Received any RBC transfusion within 28 days prior to randomization.          -  Plan to receive any RBC transfusion between randomization and study day 1.          -  Known previous treatment failure to ESAs (eg, rHuEPO, darbepoetin alfa).          -  ESA therapy within the 28 days prior to randomization.          -  Known hypersensitivity to recombinant ESAs or the excipients contained within the             investigational product.          -  Less than 30 days since receipt of any investigational product or device.             Investigational use/receipt of a medicinal product or device that has been approved             by the country's local regulatory authority for any indication is permitted.          -  Subjects of reproductive potential who are pregnant, breast feeding or not willing to             use effective contraceptive precautions during the study and for at least one month             after the last dose of investigational product in the judgment of the investigator             (including females of childbearing potential who are partners of male subjects).          -  Previously randomized to this study.          -  Investigator has concerns regarding the ability of the subject to give written             informed consent and/or to comply with study procedures (including availability for             follow up visits).      "
NCT02366143,Phase 3,Hoffmann-La Roche,Industry,"A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin + Paclitaxel With or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy-NaÌøve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)",1,18,150,include,include,,,,,,include,,,,,,,,,,,,,,,,,"        Inclusion Criteria:          -  18 years of age or older          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1          -  Histologically or cytologically confirmed, treatment-naÌøve Stage IV non-squamous             NSCLC          -  Previously obtained archival tumor tissue or tissue obtained from a biopsy at             screening          -  Measurable disease as defined by RECIST v1.1          -  Adequate hematologic and end organ function        Exclusion Criteria:          -  Active or untreated central nervous system (CNS) metastases          -  Malignancies other than NSCLC within 5 years prior to randomization, with the             exception of those with a negligible risk of metastasis or death treated with             expected curative outcome          -  Pregnant or lactating women          -  History of autoimmune disease          -  History of idiopathic pulmonary fibrosis, organizing pneumonia, drug induced             pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening             chest Computed Tomography (CT) scan. History of radiation pneumonitis in the             radiation field (fibrosis) is permitted.          -  Positive test for Human Immunodeficiency Virus (HIV)          -  Active hepatitis B or hepatitis C          -  Prior treatment with CD137 agonists or immune checkpoint blockade therapies, anti             PD1, and anti-PD-L1 therapeutic antibody          -  Severe infection within 4 weeks prior to randomization          -  Significant history of cardiovascular disease      "
NCT02364999,Phase 3,Pfizer,Industry,"A Phase 3 Randomized, Double-blind Study Of Pf- 06439535 Plus Paclitaxel-carboplatin And Bevacizumab Plus Paclitaxel -Carboplatin For The First-line Treatment Of Patients With Advanced Non-squamous Non-small Cell Lung Cancer.",1,18,150,include,include,,,,,include,include,,,require,,,exclude,exclude,,,,exclude,1800,,,,,"        Inclusion Criteria:          -  Male and female patients age at least 18 years of age, or age of consent in the             region.          -  Newly diagnosed Stage IIIB or IV non-small cell lung cancer (according to Revised             International System for Staging Lung Cancer criteria of 2010) or recurrent non-small             cell lung cancer (NSCLC).          -  Histologically or cytologically confirmed diagnosis of predominately non-squamous             NSCLC.          -  Be eligible to receive study treatment of bevacizumab, paclitaxel, and carboplatin             based on local standard of care, for the treatment of advanced or metastatic             non-squamous NSCLC.        Exclusion Criteria:          -  Small cell lung cancer (SCLC) or combination SCLC and NSCLC. Squamous-cell tumors and             mixed adenosquamous carcinomas of predominantly squamous nature.          -  Evidence of a tumor that compresses or invades major blood vessels or tumor             cavitation that is likely to bleed.          -  Known sensitizing EGFR mutations (for example, deletion 19 or L858R) or EML4-ALK             translocation positive mutations.          -  Prior systemic therapy for NSCLC; prior neoadjuvant or adjuvant therapy is allowed if             surgical resection for primary disease was performed.      "
NCT02364999,Phase 3,Pfizer,Industry,"A Phase 3 Randomized, Double-blind Study Of Pf- 06439535 Plus Paclitaxel-carboplatin And Bevacizumab Plus Paclitaxel -Carboplatin For The First-line Treatment Of Patients With Advanced Non-squamous Non-small Cell Lung Cancer.",2,18,150,include,include,,,include,include,,,,,,require,,exclude,exclude,,,,exclude,1800,,,,,"        Inclusion Criteria:          -  Male and female patients age at least 18 years of age, or age of consent in the             region.          -  Newly diagnosed Stage IIIB or IV non-small cell lung cancer (according to Revised             International System for Staging Lung Cancer criteria of 2010) or recurrent non-small             cell lung cancer (NSCLC).          -  Histologically or cytologically confirmed diagnosis of predominately non-squamous             NSCLC.          -  Be eligible to receive study treatment of bevacizumab, paclitaxel, and carboplatin             based on local standard of care, for the treatment of advanced or metastatic             non-squamous NSCLC.        Exclusion Criteria:          -  Small cell lung cancer (SCLC) or combination SCLC and NSCLC. Squamous-cell tumors and             mixed adenosquamous carcinomas of predominantly squamous nature.          -  Evidence of a tumor that compresses or invades major blood vessels or tumor             cavitation that is likely to bleed.          -  Known sensitizing EGFR mutations (for example, deletion 19 or L858R) or EML4-ALK             translocation positive mutations.          -  Prior systemic therapy for NSCLC; prior neoadjuvant or adjuvant therapy is allowed if             surgical resection for primary disease was performed.      "
NCT02477826,Phase 3,Bristol-Myers Squibb,Industry,"An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Subjects With Chemotherapy-NaÌøve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)",1,18,150,include,include,include,,,,,include,,,,,,,,,,,exclude,1800,,,,,"        For more information regarding BMS clinical trial participation, please visit        www.BMSStudyConnect.com        Inclusion Criteria:          -  Subjects with histologically confirmed Stage IV or recurrent NSCLC squamous or             non-squamous histology, with no prior systemic anticancer therapy          -  Subjects must have programmed death-ligand 1 (PD -L1) immunohistochemical (IHC)             testing, with results, performed by the central lab during the Screening period          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of ‰ä_ 1          -  Measurable disease by CT or MRI per response evaluation criteria in solid tumors             version 1.1 (RECIST 1.1) criteria        Exclusion Criteria:          -  Subjects with untreated Central nervous system (CNS) metastases are excluded          -  Subjects with an active, known or suspected autoimmune disease are excluded          -  Any positive test for hepatitis B virus or hepatitis C virus or human             immunodeficiency virus (HIV) indicating acute or chronic infection      "
NCT02477826,Phase 3,Bristol-Myers Squibb,Industry,"An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Subjects With Chemotherapy-NaÌøve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)",2,18,150,include,include,include,,include,include,include,,,,,require,,,,,,,exclude,1800,,,,,"        For more information regarding BMS clinical trial participation, please visit        www.BMSStudyConnect.com        Inclusion Criteria:          -  Subjects with histologically confirmed Stage IV or recurrent NSCLC squamous or             non-squamous histology, with no prior systemic anticancer therapy          -  Subjects must have programmed death-ligand 1 (PD -L1) immunohistochemical (IHC)             testing, with results, performed by the central lab during the Screening period          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of ‰ä_ 1          -  Measurable disease by CT or MRI per response evaluation criteria in solid tumors             version 1.1 (RECIST 1.1) criteria        Exclusion Criteria:          -  Subjects with untreated Central nervous system (CNS) metastases are excluded          -  Subjects with an active, known or suspected autoimmune disease are excluded          -  Any positive test for hepatitis B virus or hepatitis C virus or human             immunodeficiency virus (HIV) indicating acute or chronic infection      "
NCT02152631,Phase 3,Eli Lilly and Company,Industry,JUNIPER: A Randomized Phase 3 Study of Abemaciclib Plus Best Supportive Care Versus Erlotinib Plus Best Supportive Care in Patients With Stage IV NSCLC With a Detectable KRAS Mutation Who Have Progressed After Platinum-Based Chemotherapy,1,18,150,include,include,include,,,,,include,,,,,,,,require,,,require,,,,,,"        Inclusion Criteria:          -  Have confirmed diagnosis of stage IV non-small cell lung cancer (NSCLC) according to             the American Joint Committee on Cancer Staging Handbook.          -  Determined to have detectable mutations in codons 12 or 13 of the kirsten rat sarcoma             (KRAS) oncogene by an investigational assay at the study JPBK central laboratory. A             KRAS positive mutation result in codons 12 or 13 of the KRAS oncogene from tumor             tissue per local laboratory will be permitted in no more than 10% of randomized             participants.          -  Have progressed after platinum-based chemotherapy (with or without maintenance             therapy) AND have received one additional therapy which may include an immune             checkpoint inhibitor or other anti-cancer therapy for advanced and/or metastatic             disease OR is judged by the physician as ineligible for further standard second-line             chemotherapy. Participants who have progressed after platinum-based chemotherapy and             an immune checkpoint inhibitor (immunotherapy) e.g. pembrolizumab or nivolumab alone             or in combination with other agents are eligible.          -  Have measureable disease as defined by the Response Evaluation Criteria in Solid             Tumors (RECIST 1.1).          -  Have a performance status (PS) of 0 to 1 on the Eastern Cooperative Oncology Group             (ECOG) scale.          -  Have discontinued all previous therapies for cancer (including chemotherapy,             radiotherapy, immunotherapy, and investigational therapy) for at least 21 days for             myelosuppressive agents or 14 days for nonmyelosuppressive agents prior to receiving             study drug.        Exclusion Criteria:          -  Have received treatment with a drug that has not received regulatory approval for any             indication within 14 or 21 days of the initial dose of study drug for a             nonmyelosuppressive or myelosuppressive agent, respectively.          -  Have a personal history of any of the following conditions: presyncope or syncope of             either unexplained or cardiovascular etiology, ventricular arrhythmia (including but             not limited to ventricular tachycardia and ventricular fibrillation), or sudden             cardiac arrest.          -  Have the presence of unstable central nervous system (CNS) metastasis. History of CNS             metastasis or stable CNS metastases is allowed (no longer requiring active therapy             such as steroid medications). Participants with a history of CNS metastases must have             a brain scan (for example, magnetic resonance imaging [MRI]) within 28 days of             randomization to document stability, even if there have been no changes in symptoms.      "
NCT02272413,Phase 3,Boehringer Ingelheim,Industry,"A Multicenter, Randomized, Double-blind Phase III Trial to Evaluate Efficacy and Safety of BI 695502 Plus Chemotherapy Versus Avastinå¨ Plus Chemotherapy in Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer",1,18,150,include,include,,,,,,include,,,,,,require_alk_or_egfr,require_alk_or_egfr,,exclude,12,exclude,12,,,,,"        Inclusion criteria:        Adult patients aged >=18 years with histologically or cytologically confirmed advanced        nonsquamous non-small cell lung cancer (nsNSCLC). Mixed tumors should be categorized        according to the predominant histology.        Note: NSCLC should be predominantly nonsquamous. Recurrent or metastatic disease (Stage        IV) with an indication for therapy with paclitaxel + carboplatin + Avastinå¨.        Patients harboring tumors with unknown or without activating epidermal growth factor        receptor (EGFR) / anaplastic lymphoma receptor tyrosine kinase (ALK) mutation maybe        included provided chemotherapy is standard of care. At least one measurable lesion        according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 based on        independent central review.        Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1.        Adequate hepatic, renal, and bone marrow function:        Life expectancy > 6 months based on clinical judgment. Further inclusion criteria apply.        Exclusion criteria:        Prior therapy with monoclonal antibodies or small molecule inhibitors against Vascular        Endothelial Growth Factor (VEGF) or VEGF receptors, including Avastinå¨.        Prior systemic therapy for metastatic disease. Prior systemic anticancer therapy or        radiotherapy for locally advanced nsNSCLC if completed <12 months prior to Screening.        Previous malignancy other than NSCLC in the last 5 years except for basal cell cancer of        the skin or pre-invasive cancer of the cervix.        Symptomatic brain metastasis. Diagnosis of small cell carcinoma of the lung, squamous cell        carcinoma of the lung, NSCLC not specified (NS) or NSCLC not otherwise specified(NOS).        Any unresolved toxicity > Common Toxicity Criteria Grade 1 (except alopecia) from previous        anticancer therapy (including radiotherapy).        History or evidence of inherited bleeding diathesis or coagulopathy with the risk of        bleeding. Thrombotic or hemorrhagic event =< 6 months prior to Screening. Further        exclusion criteria apply.      "
NCT02272413,Phase 3,Boehringer Ingelheim,Industry,"A Multicenter, Randomized, Double-blind Phase III Trial to Evaluate Efficacy and Safety of BI 695502 Plus Chemotherapy Versus Avastinå¨ Plus Chemotherapy in Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer",2,18,150,include,include,,,,,,include,,,,,,,,,exclude,12,require,,,,,,"        Inclusion criteria:        Adult patients aged >=18 years with histologically or cytologically confirmed advanced        nonsquamous non-small cell lung cancer (nsNSCLC). Mixed tumors should be categorized        according to the predominant histology.        Note: NSCLC should be predominantly nonsquamous. Recurrent or metastatic disease (Stage        IV) with an indication for therapy with paclitaxel + carboplatin + Avastinå¨.        Patients harboring tumors with unknown or without activating epidermal growth factor        receptor (EGFR) / anaplastic lymphoma receptor tyrosine kinase (ALK) mutation maybe        included provided chemotherapy is standard of care. At least one measurable lesion        according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 based on        independent central review.        Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1.        Adequate hepatic, renal, and bone marrow function:        Life expectancy > 6 months based on clinical judgment. Further inclusion criteria apply.        Exclusion criteria:        Prior therapy with monoclonal antibodies or small molecule inhibitors against Vascular        Endothelial Growth Factor (VEGF) or VEGF receptors, including Avastinå¨.        Prior systemic therapy for metastatic disease. Prior systemic anticancer therapy or        radiotherapy for locally advanced nsNSCLC if completed <12 months prior to Screening.        Previous malignancy other than NSCLC in the last 5 years except for basal cell cancer of        the skin or pre-invasive cancer of the cervix.        Symptomatic brain metastasis. Diagnosis of small cell carcinoma of the lung, squamous cell        carcinoma of the lung, NSCLC not specified (NS) or NSCLC not otherwise specified(NOS).        Any unresolved toxicity > Common Toxicity Criteria Grade 1 (except alopecia) from previous        anticancer therapy (including radiotherapy).        History or evidence of inherited bleeding diathesis or coagulopathy with the risk of        bleeding. Thrombotic or hemorrhagic event =< 6 months prior to Screening. Further        exclusion criteria apply.      "
NCT02272413,Phase 3,Boehringer Ingelheim,Industry,"A Multicenter, Randomized, Double-blind Phase III Trial to Evaluate Efficacy and Safety of BI 695502 Plus Chemotherapy Versus Avastinå¨ Plus Chemotherapy in Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer",3,18,150,include,include,,,include,include,include,,,,,require,,require_alk_or_egfr,require_alk_or_egfr,,exclude,12,exclude,12,,,,,"        Inclusion criteria:        Adult patients aged >=18 years with histologically or cytologically confirmed advanced        nonsquamous non-small cell lung cancer (nsNSCLC). Mixed tumors should be categorized        according to the predominant histology.        Note: NSCLC should be predominantly nonsquamous. Recurrent or metastatic disease (Stage        IV) with an indication for therapy with paclitaxel + carboplatin + Avastinå¨.        Patients harboring tumors with unknown or without activating epidermal growth factor        receptor (EGFR) / anaplastic lymphoma receptor tyrosine kinase (ALK) mutation maybe        included provided chemotherapy is standard of care. At least one measurable lesion        according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 based on        independent central review.        Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1.        Adequate hepatic, renal, and bone marrow function:        Life expectancy > 6 months based on clinical judgment. Further inclusion criteria apply.        Exclusion criteria:        Prior therapy with monoclonal antibodies or small molecule inhibitors against Vascular        Endothelial Growth Factor (VEGF) or VEGF receptors, including Avastinå¨.        Prior systemic therapy for metastatic disease. Prior systemic anticancer therapy or        radiotherapy for locally advanced nsNSCLC if completed <12 months prior to Screening.        Previous malignancy other than NSCLC in the last 5 years except for basal cell cancer of        the skin or pre-invasive cancer of the cervix.        Symptomatic brain metastasis. Diagnosis of small cell carcinoma of the lung, squamous cell        carcinoma of the lung, NSCLC not specified (NS) or NSCLC not otherwise specified(NOS).        Any unresolved toxicity > Common Toxicity Criteria Grade 1 (except alopecia) from previous        anticancer therapy (including radiotherapy).        History or evidence of inherited bleeding diathesis or coagulopathy with the risk of        bleeding. Thrombotic or hemorrhagic event =< 6 months prior to Screening. Further        exclusion criteria apply.      "
NCT02272413,Phase 3,Boehringer Ingelheim,Industry,"A Multicenter, Randomized, Double-blind Phase III Trial to Evaluate Efficacy and Safety of BI 695502 Plus Chemotherapy Versus Avastinå¨ Plus Chemotherapy in Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer",4,18,150,include,include,,,include,include,include,,,,,require,,,,,exclude,12,require,,,,,,"        Inclusion criteria:        Adult patients aged >=18 years with histologically or cytologically confirmed advanced        nonsquamous non-small cell lung cancer (nsNSCLC). Mixed tumors should be categorized        according to the predominant histology.        Note: NSCLC should be predominantly nonsquamous. Recurrent or metastatic disease (Stage        IV) with an indication for therapy with paclitaxel + carboplatin + Avastinå¨.        Patients harboring tumors with unknown or without activating epidermal growth factor        receptor (EGFR) / anaplastic lymphoma receptor tyrosine kinase (ALK) mutation maybe        included provided chemotherapy is standard of care. At least one measurable lesion        according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 based on        independent central review.        Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1.        Adequate hepatic, renal, and bone marrow function:        Life expectancy > 6 months based on clinical judgment. Further inclusion criteria apply.        Exclusion criteria:        Prior therapy with monoclonal antibodies or small molecule inhibitors against Vascular        Endothelial Growth Factor (VEGF) or VEGF receptors, including Avastinå¨.        Prior systemic therapy for metastatic disease. Prior systemic anticancer therapy or        radiotherapy for locally advanced nsNSCLC if completed <12 months prior to Screening.        Previous malignancy other than NSCLC in the last 5 years except for basal cell cancer of        the skin or pre-invasive cancer of the cervix.        Symptomatic brain metastasis. Diagnosis of small cell carcinoma of the lung, squamous cell        carcinoma of the lung, NSCLC not specified (NS) or NSCLC not otherwise specified(NOS).        Any unresolved toxicity > Common Toxicity Criteria Grade 1 (except alopecia) from previous        anticancer therapy (including radiotherapy).        History or evidence of inherited bleeding diathesis or coagulopathy with the risk of        bleeding. Thrombotic or hemorrhagic event =< 6 months prior to Screening. Further        exclusion criteria apply.      "
NCT02538666,Phase 3,Bristol-Myers Squibb,Industry,"A Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination With Ipilimumab, or Placebo as Maintenance Therapy in Subjects With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based First Line Chemotherapy (CheckMate 451: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 451)",1,18,150,,,,include,,,,,,include,,,,,,,,,require,,,,,,"        For more information regarding BMS clinical trial participation, please visit        www.BMSStudyConnect.com        Inclusion Criteria:          -  Subjects with histologically or cytologically confirmed extensive stage disease SCLC          -  Ongoing response of stable disease or better following 4 cycles of platinum-based             first line chemotherapy          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1        Exclusion Criteria:          -  Subjects with symptomatic Central Nervous System (CNS) metastases          -  Subjects receiving consolidative chest radiation          -  Subjects with active, known, or suspected autoimmune disease are excluded          -  All side effects attributed to prior anti-cancer therapy must have resolved to Grade             1 or baseline      "
NCT02367781,Phase 3,Hoffmann-La Roche,Industry,"A Phase III Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Nab-Paclitaxel for Chemotherapy-Naive Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer",1,18,150,include,include,,,,,,include,,,,,,,,,,,,,,,,,"        Inclusion Criteria:          -  18 years of age or older          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1          -  Histologically or cytologically confirmed, treatment-naive Stage IV non-squamous             NSCLC          -  Measurable disease, as defined by RECIST v1.1          -  Previously obtained archival tumor or tissue obtained from a biopsy at screening          -  Adequate hematologic and end organ function        Exclusion Criteria:          -  Active or untreated central nervous system (CNS) metastases          -  Malignancies other than NSCLC within 5 years prior to randomization, with the             exception of those with a negligible risk of metastasis or death treated with             expected curative outcome          -  Pregnant or lactating women          -  History of autoimmune disease          -  History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced             pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening             chest computed tomography (CT) scan; history of radiation pneumonitis in the             radiation field (fibrosis) is permitted          -  Positive test for Human Immunodeficiency Virus (HIV)          -  Active hepatitis B or hepatitis C          -  Prior treatment with CD137 agonists or immune checkpoint blockade therapies,             anti-PD-1, and anti-PD-L1 therapeutic antibody          -  Severe infection within 4 weeks prior to randomization          -  Significant history of cardiovascular disease      "
NCT02542293,Phase 3,AstraZeneca,Industry,"A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination With Tremelimumab Therapy Versus Standard of Care Platinum-Based Chemotherapy in First-Line Treatment of Patients With Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC)",1,18,130,include,include,include,,,,,include,,,,,,exclude,exclude,,,,exclude,1800,,,,,"        Inclusion Criteria:        For inclusion in the study, patients should fulfill the following criteria:          -  Aged at least 18 years          -  Documented evidence of Stage IV NSCLC          -  No activating EGFR mutation or ALK rearrangement          -  No prior chemotherapy or any other systemic therapy for recurrent/metastatic NSCLC          -  World Health Organization (WHO) Performance Status of 0 or 1        Exclusion Criteria:        Patients should not enter the study if any of the following exclusion criteria are        fulfilled:          -  Mixed small cell lung cancer and NSCLC histology          -  Brain metastases or spinal cord compression unless asymptomatic, treated and stable             (not requiring steroids)          -  Prior exposure to IMT, including, but not limited to, other antiCTLA4, antiPD1, anti             PDL1,or antiPDL2 antibodies, excluding therapeutic anticancer vaccines          -  Active or prior documented inflammatory bowel disease (eg, Crohn's disease,             ulcerative colitis)      "
NCT02576574,Phase 3,EMD Serono,Industry,"A Phase III, Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Platinum-based Doublet as a First-line Treatment of Recurrent or Stage IV PD-L1+ Non-small Cell Lung Cancer",1,18,150,include,include,include,,,,,include,,,,,,exclude,exclude,,,,exclude,1800,,,,,"        Inclusion Criteria:          -  Male or female subjects aged greater than or equal to (>=) 18 years          -  Tumor determined to be positive for PD-L1 expression per the evaluation of a central             laboratory          -  Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 1          -  At least 1 lesion that can be measured.          -  Subjects with histologically confirmed metastatic or recurrent non-small cell lung             cancer (NSCLC)          -  Subjects must not have received any treatment for systemic lung cancer, and have an             estimated life expectancy of more than 12 weeks          -  Other protocol defined criteria could apply        Exclusion Criteria:          -  Subjects whose disease harbors an activating epidermal growth factor receptor (EGFR)             mutation, or an anaplastic lymphoma kinase (ALK) rearrangement          -  Prior therapy with any antibody or drug targeting T cell coregulatory proteins,             concurrent anticancer treatment, or immunosuppressive agents          -  Subjects with known severe hypersensitivity reactions to monoclonal antibodies,             history of anaphylaxis, or uncontrolled asthma, and persisting toxicity related to             prior therapy of Grade greater than (>) 1          -  Subjects with brain metastases are excluded, except those meeting the following             criteria: brain metastases that have been treated locally and are clinically stable             for at least 2 weeks prior to enrollment, subjects must be either off steroids or on             a stable or decreasing dose of less than (<) 10 mg daily prednisone (or equivalent),             and do not have ongoing neurological symptoms that are related to the brain             localization of the disease          -  Other protocol defined criteria could apply      "
NCT02576574,Phase 3,EMD Serono,Industry,"A Phase III, Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Platinum-based Doublet as a First-line Treatment of Recurrent or Stage IV PD-L1+ Non-small Cell Lung Cancer",2,18,150,include,include,include,,include,include,include,,,,,require,,exclude,exclude,,,,exclude,1800,,,,,"        Inclusion Criteria:          -  Male or female subjects aged greater than or equal to (>=) 18 years          -  Tumor determined to be positive for PD-L1 expression per the evaluation of a central             laboratory          -  Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 1          -  At least 1 lesion that can be measured.          -  Subjects with histologically confirmed metastatic or recurrent non-small cell lung             cancer (NSCLC)          -  Subjects must not have received any treatment for systemic lung cancer, and have an             estimated life expectancy of more than 12 weeks          -  Other protocol defined criteria could apply        Exclusion Criteria:          -  Subjects whose disease harbors an activating epidermal growth factor receptor (EGFR)             mutation, or an anaplastic lymphoma kinase (ALK) rearrangement          -  Prior therapy with any antibody or drug targeting T cell coregulatory proteins,             concurrent anticancer treatment, or immunosuppressive agents          -  Subjects with known severe hypersensitivity reactions to monoclonal antibodies,             history of anaphylaxis, or uncontrolled asthma, and persisting toxicity related to             prior therapy of Grade greater than (>) 1          -  Subjects with brain metastases are excluded, except those meeting the following             criteria: brain metastases that have been treated locally and are clinically stable             for at least 2 weeks prior to enrollment, subjects must be either off steroids or on             a stable or decreasing dose of less than (<) 10 mg daily prednisone (or equivalent),             and do not have ongoing neurological symptoms that are related to the brain             localization of the disease          -  Other protocol defined criteria could apply      "
NCT02588261,Phase 3,"Astellas Pharma Global Development, Inc.",Industry,"An Open-label, Randomized Phase 3 Efficacy Study of ASP8273 vs Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations",1,18,150,include,,,,,,include,include,,,require,,,,,,,,,,,,,,"        Inclusion Criteria:          -  Subject agrees not to participate in another interventional study while on treatment.          -  Female subject must either:               -  Be of nonchildbearing potential: postmenopausal (defined as at least 1 year                  without any menses) prior to Screening, or documented surgically sterile               -  Or, if of childbearing potential: Agree not to try to become pregnant during the                  study and for 28 days after the final study drug administration; And have a                  negative serum pregnancy test at Screening; And, if heterosexually active, agree                  to consistently use 2 forms of highly effective birth control (at least 1 of                  which must be a highly effective method and one must be a barrier method)                  starting at Screening and throughout the study period and for 28 days after the                  final study drug administration.          -  Female subject must not be breastfeeding at Screening or during the study period, and             for 28 days after the final study drug administration.          -  Female subject must not donate ova starting at Screening and throughout the study             period, and for 28 days after the final study drug administration.          -  Male subject and their female spouse/partners who are of childbearing potential must             be using highly effective contraception consisting of 2 forms of birth control (1 of             which must be a barrier method) starting at Screening and continue throughout the             study period and for 90 days after the final study drug administration.          -  Male subject must not donate sperm starting at Screening and throughout the study             period and for 90 days after the final study drug administration.          -  Subject has Eastern Cooperative Oncology Group (ECOG) performance status ‰ä_ 2.          -  Subject has histologically confirmed locally advanced, metastatic or unresectable             Stage IIIB/IV adenocarcinoma NSCLC (newly diagnosed or recurrent). Subjects with             mixed histology are eligible if adenocarcinoma is the predominant histology.          -  Subject has predicted life expectancy ‰ä´ 12 weeks in the opinion of the investigator.          -  Subject must meet all of the following criteria on the laboratory tests that will be             analyzed centrally within 7 days prior to the first dose of study drug. In case of             multiple laboratory data within this period, the most recent data should be used.               -  Neutrophil count > 1,000/mm3               -  Platelet count ‰ä´ 7.5 x 104 /mm3               -  Hemoglobin > 8.0 g/dL               -  Serum creatinine èâ 2.0 x upper limit of normal (ULN) or an estimated glomerular                  filtration rate (eGFR) of > 50 mL/min as calculated by the Cockcroft Gault                  Method               -  Total bilirubin èâ1.5 x ULN (except for subjects with documented Gilbert's                  syndrome)               -  AST and ALT èâ 3.0 x ULN or ‰ä_ 5 x ULN if subject has documented liver metastases               -  Serum sodium level is ‰ä´ 130 mmol/L          -  Subject has an EGFR activating mutation (exon 19 deletion or exon 21 L858R), with or             without T790M mutation, by local or central testing on examination of a NSCLC FFPE             specimen (archival or fresh biopsy). Subjects harboring both exon 19 deletion and             exon 21 L858R mutations are not eligible. A tissue sample from the same block used to             determine eligibility by local testing should be available to send to the central lab             for confirmatory testing. Subjects randomized based on local results indicating             presence of EGFR mutation may remain on study if central results are discordant.          -  Subject must have at least 1 measureable lesion based on RECIST V1.1. Previously             irradiated lesions will not be considered as measurable lesions.        Exclusion Criteria:          -  Subject has received intervening anticancer treatment or previous treatment with             chemotherapy for metastatic disease other than palliative local radiation to painful             bone metastases completed at least 1 week prior to the first dose of study drug. The             administration of neoadjuvant or adjuvant chemotherapy is allowed as long as it has             finalized ‰ä´ 6 months before the first dose of study drug.          -  Subject has received a prior treatment with a therapeutic agent targeting EGFR (e.g.,             afatinib, dacomitinib, ASP8273, etc).          -  Subject has received investigational therapy within 28 days or 5 half-lives prior to             the first dose of study drug.          -  Subject has received radiotherapy within 1 week prior to the first dose of study             drug. If the subject received radiotherapy > 1 week prior to study treatment, the             irradiated lesion cannot be the only lesion used for evaluating response.          -  Subject has symptomatic central nervous system (CNS) metastasis. Subject with             previously treated brain or CNS metastases are eligible provided that the subject has             recovered from any acute effects of radiotherapy, does not have brain metastasis             related symptoms, is not requiring systemic steroids for at least 2 weeks prior to             study drug administration, and any whole brain radiation therapy was completed at             least 4 weeks prior to study drug administration, or any stereotactic radiosurgery             (SRS) was completed at least 2 weeks prior to study drug administration. Steroid             inhaler use or ointment treatment for other concomitant medical disease is permitted.          -  Subject has received blood transfusions or hematopoietic factor therapy within 14             days prior to the first dose of study drug.          -  Subject has had a major surgical procedure (other than a biopsy) within 14 days prior             to the first dose of study drug, or one is planned during the course of the study.          -  Subject has a known history of a positive test for human immunodeficiency virus (HIV)             infection.          -  Subject has known history of serious hypersensitivity reaction to a known ingredient             of ASP8273, erlotinib or gefitinib.          -  Subject has evidence of an active infection requiring systemic therapy within 14 days             prior to the planned first dose of study drug.          -  Subject has severe or uncontrolled systemic diseases including uncontrolled             hypertension (blood pressure > 150/100 mmHg) or active bleeding diatheses.          -  Subject has history of drug-induced interstitial lung disease (ILD) or any evidence             of active ILD.          -  Subject has ongoing cardiac arrhythmia that is Grade ‰ä´ 2 or uncontrolled atrial             fibrillation of any grade.          -  Subject currently has Class 3 or 4 New York Heart Association congestive heart             failure.          -  Subject has history of severe/unstable angina, myocardial infarction or             cerebrovascular accident within 6 months prior to the planned first dose of study             drug.          -  Subject has history of gastrointestinal ulcer or gastrointestinal bleeding within 3             months prior to the planned first dose of study drug.          -  Subject has concurrent corneal disorder or any ophthalmologic condition which, in the             investigator's opinion, makes the subject unsuitable for study participation (i.e.,             advanced cataracts, glaucoma).          -  Subject has difficulty taking oral medication or any digestive tract dysfunction or             inflammatory bowel disease that would interfere with the intestinal absorption of             drug.          -  Subject has another past or active malignancy which requires treatment. Prior             carcinoma in situ or non-melanoma skin cancer after curative resection are permitted.          -  Subject has any condition which, in the investigator's opinion, makes the subject             unsuitable for study participation.          -  Subject has received potent CYP 3A4 inhibitors within 7 days prior to first dose of             study drug or proton pump inhibitors such as omeprazole within 14 days prior to first             dose of study drug.      "
NCT02588261,Phase 3,"Astellas Pharma Global Development, Inc.",Industry,"An Open-label, Randomized Phase 3 Efficacy Study of ASP8273 vs Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations",2,18,150,include,,,,,,include,include,,,,require,,,,,,,,,,,,,"        Inclusion Criteria:          -  Subject agrees not to participate in another interventional study while on treatment.          -  Female subject must either:               -  Be of nonchildbearing potential: postmenopausal (defined as at least 1 year                  without any menses) prior to Screening, or documented surgically sterile               -  Or, if of childbearing potential: Agree not to try to become pregnant during the                  study and for 28 days after the final study drug administration; And have a                  negative serum pregnancy test at Screening; And, if heterosexually active, agree                  to consistently use 2 forms of highly effective birth control (at least 1 of                  which must be a highly effective method and one must be a barrier method)                  starting at Screening and throughout the study period and for 28 days after the                  final study drug administration.          -  Female subject must not be breastfeeding at Screening or during the study period, and             for 28 days after the final study drug administration.          -  Female subject must not donate ova starting at Screening and throughout the study             period, and for 28 days after the final study drug administration.          -  Male subject and their female spouse/partners who are of childbearing potential must             be using highly effective contraception consisting of 2 forms of birth control (1 of             which must be a barrier method) starting at Screening and continue throughout the             study period and for 90 days after the final study drug administration.          -  Male subject must not donate sperm starting at Screening and throughout the study             period and for 90 days after the final study drug administration.          -  Subject has Eastern Cooperative Oncology Group (ECOG) performance status ‰ä_ 2.          -  Subject has histologically confirmed locally advanced, metastatic or unresectable             Stage IIIB/IV adenocarcinoma NSCLC (newly diagnosed or recurrent). Subjects with             mixed histology are eligible if adenocarcinoma is the predominant histology.          -  Subject has predicted life expectancy ‰ä´ 12 weeks in the opinion of the investigator.          -  Subject must meet all of the following criteria on the laboratory tests that will be             analyzed centrally within 7 days prior to the first dose of study drug. In case of             multiple laboratory data within this period, the most recent data should be used.               -  Neutrophil count > 1,000/mm3               -  Platelet count ‰ä´ 7.5 x 104 /mm3               -  Hemoglobin > 8.0 g/dL               -  Serum creatinine èâ 2.0 x upper limit of normal (ULN) or an estimated glomerular                  filtration rate (eGFR) of > 50 mL/min as calculated by the Cockcroft Gault                  Method               -  Total bilirubin èâ1.5 x ULN (except for subjects with documented Gilbert's                  syndrome)               -  AST and ALT èâ 3.0 x ULN or ‰ä_ 5 x ULN if subject has documented liver metastases               -  Serum sodium level is ‰ä´ 130 mmol/L          -  Subject has an EGFR activating mutation (exon 19 deletion or exon 21 L858R), with or             without T790M mutation, by local or central testing on examination of a NSCLC FFPE             specimen (archival or fresh biopsy). Subjects harboring both exon 19 deletion and             exon 21 L858R mutations are not eligible. A tissue sample from the same block used to             determine eligibility by local testing should be available to send to the central lab             for confirmatory testing. Subjects randomized based on local results indicating             presence of EGFR mutation may remain on study if central results are discordant.          -  Subject must have at least 1 measureable lesion based on RECIST V1.1. Previously             irradiated lesions will not be considered as measurable lesions.        Exclusion Criteria:          -  Subject has received intervening anticancer treatment or previous treatment with             chemotherapy for metastatic disease other than palliative local radiation to painful             bone metastases completed at least 1 week prior to the first dose of study drug. The             administration of neoadjuvant or adjuvant chemotherapy is allowed as long as it has             finalized ‰ä´ 6 months before the first dose of study drug.          -  Subject has received a prior treatment with a therapeutic agent targeting EGFR (e.g.,             afatinib, dacomitinib, ASP8273, etc).          -  Subject has received investigational therapy within 28 days or 5 half-lives prior to             the first dose of study drug.          -  Subject has received radiotherapy within 1 week prior to the first dose of study             drug. If the subject received radiotherapy > 1 week prior to study treatment, the             irradiated lesion cannot be the only lesion used for evaluating response.          -  Subject has symptomatic central nervous system (CNS) metastasis. Subject with             previously treated brain or CNS metastases are eligible provided that the subject has             recovered from any acute effects of radiotherapy, does not have brain metastasis             related symptoms, is not requiring systemic steroids for at least 2 weeks prior to             study drug administration, and any whole brain radiation therapy was completed at             least 4 weeks prior to study drug administration, or any stereotactic radiosurgery             (SRS) was completed at least 2 weeks prior to study drug administration. Steroid             inhaler use or ointment treatment for other concomitant medical disease is permitted.          -  Subject has received blood transfusions or hematopoietic factor therapy within 14             days prior to the first dose of study drug.          -  Subject has had a major surgical procedure (other than a biopsy) within 14 days prior             to the first dose of study drug, or one is planned during the course of the study.          -  Subject has a known history of a positive test for human immunodeficiency virus (HIV)             infection.          -  Subject has known history of serious hypersensitivity reaction to a known ingredient             of ASP8273, erlotinib or gefitinib.          -  Subject has evidence of an active infection requiring systemic therapy within 14 days             prior to the planned first dose of study drug.          -  Subject has severe or uncontrolled systemic diseases including uncontrolled             hypertension (blood pressure > 150/100 mmHg) or active bleeding diatheses.          -  Subject has history of drug-induced interstitial lung disease (ILD) or any evidence             of active ILD.          -  Subject has ongoing cardiac arrhythmia that is Grade ‰ä´ 2 or uncontrolled atrial             fibrillation of any grade.          -  Subject currently has Class 3 or 4 New York Heart Association congestive heart             failure.          -  Subject has history of severe/unstable angina, myocardial infarction or             cerebrovascular accident within 6 months prior to the planned first dose of study             drug.          -  Subject has history of gastrointestinal ulcer or gastrointestinal bleeding within 3             months prior to the planned first dose of study drug.          -  Subject has concurrent corneal disorder or any ophthalmologic condition which, in the             investigator's opinion, makes the subject unsuitable for study participation (i.e.,             advanced cataracts, glaucoma).          -  Subject has difficulty taking oral medication or any digestive tract dysfunction or             inflammatory bowel disease that would interfere with the intestinal absorption of             drug.          -  Subject has another past or active malignancy which requires treatment. Prior             carcinoma in situ or non-melanoma skin cancer after curative resection are permitted.          -  Subject has any condition which, in the investigator's opinion, makes the subject             unsuitable for study participation.          -  Subject has received potent CYP 3A4 inhibitors within 7 days prior to first dose of             study drug or proton pump inhibitors such as omeprazole within 14 days prior to first             dose of study drug.      "
NCT02395172,Phase 3,"EMD Serono Research & Development Institute, Inc.",Industry,"A Phase III Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Docetaxel in Subjects With Non-small Cell Lung Cancer That Has Progressed After a Platinum-containing Doublet",1,18,150,include,include,,,,,include,include,,,,,,exclude,exclude,,,,require,,,,,,"        Inclusion Criteria          -  Signed written informed consent before any trial related procedure          -  Male or female subjects aged greater than or equal to (>=) 18 years          -  Availability of a formalin-fixed, paraffin-embedded block containing tumor tissue or             7 unstained tumor slides suitable for PD-L1 expression assessment          -  Tumor determined to be evaluable for PD-L1 expression per the evaluation of a central             laboratory          -  Subjects with histologically confirmed Stage IIIb/IV or recurrent NSCLC who have             experienced disease progression          -  Subjects must have progressed after an acceptable therapy defined as follows:               1. Subjects must have progressed during or after a minimum of 2 cycles of 1 course                  of a platinum based combination therapy administered for the treatment of a                  metastatic disease. A history of continuation (use of a non platinum agent from                  initial combination) or switch (use of a different agent) maintenance therapy is                  permitted provided there was no progression after the initial combination. A                  switch of agents during treatment for the management of toxicities is also                  permitted provided there was no progression after the initial combination OR               2. Subjects must have progressed within 6 months of completion of a platinum-based                  adjuvant, neoadjuvant, or definitive chemotherapy, or concomitant chemoradiation                  regimen for locally advanced disease          -  Subjects with non-squamous cell NSCLC of unknown epidermal growth factor receptor             (EGFR) mutation status will require testing (local laboratory, or central laboratory             if local testing is not available). Subjects with a tumor that harbors an activating             EGFR mutation will not be eligible          -  Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 1 at trial             entry          -  Estimated life expectancy of more than 12 weeks          -  Adequate hematological function defined by White Blood Cell (WBC) count >= 2.5 ÌÑ             10^9/L with absolute neutrophil count (ANC) >= 1.5 ÌÑ 10^9/L, lymphocyte count >=0.5 ÌÑ             10^9/L, platelet count >= 100 ÌÑ 10^9/L, and hemoglobin >= 9 gram per deciliter (g/dL)             (may have been transfused)          -  Adequate hepatic function defined by a total bilirubin level less than or equal to             (<=) 1.5 ÌÑ the upper limit of normal (ULN) range and aspartate aminotransferase (AST)             and alanine aminotransferase (ALT) levels <= 2.5 ÌÑ ULN for all subjects          -  Adequate renal function defined by an estimated creatinine clearance > 30 milliliter             per minute (mL/min) according to the Cockcroft-Gault formula (or local institutional             standard method).        Other protocol defined inclusion criteria could apply        Exclusion criteria          -  In the United States only, subjects with a squamous cell histology will be excluded          -  Systemic anticancer therapy administered after disease progression during or             following a platinum based combination          -  Subjects with non-squamous cell NSCLC whose disease harbors EGFR mutation(s) and/or             anaplastic lymphoma kinase (ALK) rearrangement will not be eligible for this trial.             Subjects of unknown ALK and/or EGFR mutation status will require testing at screening             (local laboratory, or central laboratory if local testing is not available)          -  Prior therapy with any antibody/drug targeting T cell coregulatory proteins (immune             checkpoints) such as PD-1, PD L1, or cytotoxic T lymphocyte antigen-4 (CTLA-4).          -  Concurrent anticancer treatment          -  Major surgery for any reason, except diagnostic biopsy, within 4 weeks of             randomization and/or if the subject has not fully recovered from the surgery within 4             weeks of randomization          -  Subjects receiving immunosuppressive agents (such as steroids) for any reason should             be tapered off these drugs before initiation of the trial treatment.          -  All subjects with brain metastases, except those meeting the following criteria:               1. Brain metastases have been treated locally, and               2. No ongoing neurological symptoms that are related to the brain localization of                  the disease          -  Active autoimmune disease that might deteriorate when receiving an immunostimulatory             agent:               1. Subjects with diabetes type I, vitiligo, psoriasis, hypo- or hyperthyroid                  disease not requiring immunosuppressive treatment are eligible               2. Subjects requiring hormone replacement with corticosteroids are eligible if the                  steroids are administered only for the purpose of hormonal replacement and at                  doses less than or equal to (<=)10 milligram (mg) or equivalent prednisone per                  day               3. Administration of steroids through a route known to result in a minimal systemic                  exposure are acceptable          -  Previous or ongoing administration of systemic steroids for the management of an             acute allergic phenomenon is acceptable as long as it is anticipated that the             administration of steroids will be completed in 14 days, or that the daily dose after             14 days will be <=10 mg per day of equivalent prednisone        Other protocol defined exclusion criteria could apply      "
NCT02395172,Phase 3,"EMD Serono Research & Development Institute, Inc.",Industry,"A Phase III Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Docetaxel in Subjects With Non-small Cell Lung Cancer That Has Progressed After a Platinum-containing Doublet",2,18,150,include,include,,,include,include,,,,,,require,,exclude,exclude,,,,require,,,,,,"        Inclusion Criteria          -  Signed written informed consent before any trial related procedure          -  Male or female subjects aged greater than or equal to (>=) 18 years          -  Availability of a formalin-fixed, paraffin-embedded block containing tumor tissue or             7 unstained tumor slides suitable for PD-L1 expression assessment          -  Tumor determined to be evaluable for PD-L1 expression per the evaluation of a central             laboratory          -  Subjects with histologically confirmed Stage IIIb/IV or recurrent NSCLC who have             experienced disease progression          -  Subjects must have progressed after an acceptable therapy defined as follows:               1. Subjects must have progressed during or after a minimum of 2 cycles of 1 course                  of a platinum based combination therapy administered for the treatment of a                  metastatic disease. A history of continuation (use of a non platinum agent from                  initial combination) or switch (use of a different agent) maintenance therapy is                  permitted provided there was no progression after the initial combination. A                  switch of agents during treatment for the management of toxicities is also                  permitted provided there was no progression after the initial combination OR               2. Subjects must have progressed within 6 months of completion of a platinum-based                  adjuvant, neoadjuvant, or definitive chemotherapy, or concomitant chemoradiation                  regimen for locally advanced disease          -  Subjects with non-squamous cell NSCLC of unknown epidermal growth factor receptor             (EGFR) mutation status will require testing (local laboratory, or central laboratory             if local testing is not available). Subjects with a tumor that harbors an activating             EGFR mutation will not be eligible          -  Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 1 at trial             entry          -  Estimated life expectancy of more than 12 weeks          -  Adequate hematological function defined by White Blood Cell (WBC) count >= 2.5 ÌÑ             10^9/L with absolute neutrophil count (ANC) >= 1.5 ÌÑ 10^9/L, lymphocyte count >=0.5 ÌÑ             10^9/L, platelet count >= 100 ÌÑ 10^9/L, and hemoglobin >= 9 gram per deciliter (g/dL)             (may have been transfused)          -  Adequate hepatic function defined by a total bilirubin level less than or equal to             (<=) 1.5 ÌÑ the upper limit of normal (ULN) range and aspartate aminotransferase (AST)             and alanine aminotransferase (ALT) levels <= 2.5 ÌÑ ULN for all subjects          -  Adequate renal function defined by an estimated creatinine clearance > 30 milliliter             per minute (mL/min) according to the Cockcroft-Gault formula (or local institutional             standard method).        Other protocol defined inclusion criteria could apply        Exclusion criteria          -  In the United States only, subjects with a squamous cell histology will be excluded          -  Systemic anticancer therapy administered after disease progression during or             following a platinum based combination          -  Subjects with non-squamous cell NSCLC whose disease harbors EGFR mutation(s) and/or             anaplastic lymphoma kinase (ALK) rearrangement will not be eligible for this trial.             Subjects of unknown ALK and/or EGFR mutation status will require testing at screening             (local laboratory, or central laboratory if local testing is not available)          -  Prior therapy with any antibody/drug targeting T cell coregulatory proteins (immune             checkpoints) such as PD-1, PD L1, or cytotoxic T lymphocyte antigen-4 (CTLA-4).          -  Concurrent anticancer treatment          -  Major surgery for any reason, except diagnostic biopsy, within 4 weeks of             randomization and/or if the subject has not fully recovered from the surgery within 4             weeks of randomization          -  Subjects receiving immunosuppressive agents (such as steroids) for any reason should             be tapered off these drugs before initiation of the trial treatment.          -  All subjects with brain metastases, except those meeting the following criteria:               1. Brain metastases have been treated locally, and               2. No ongoing neurological symptoms that are related to the brain localization of                  the disease          -  Active autoimmune disease that might deteriorate when receiving an immunostimulatory             agent:               1. Subjects with diabetes type I, vitiligo, psoriasis, hypo- or hyperthyroid                  disease not requiring immunosuppressive treatment are eligible               2. Subjects requiring hormone replacement with corticosteroids are eligible if the                  steroids are administered only for the purpose of hormonal replacement and at                  doses less than or equal to (<=)10 milligram (mg) or equivalent prednisone per                  day               3. Administration of steroids through a route known to result in a minimal systemic                  exposure are acceptable          -  Previous or ongoing administration of systemic steroids for the management of an             acute allergic phenomenon is acceptable as long as it is anticipated that the             administration of steroids will be completed in 14 days, or that the daily dose after             14 days will be <=10 mg per day of equivalent prednisone        Other protocol defined exclusion criteria could apply      "
NCT02409342,Phase 3,Hoffmann-La Roche,Industry,"A Phase III, Open Label, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) Compared With a Platinum Agent (Cisplatin or Carboplatin) in Combination With Either Pemetrexed or Gemcitabine for PD-L1-Selected, Chemotherapy-Naive Patients With Stage IV Non-Squamous Or Squamous Non-Small Cell Lung Cancer",1,18,150,include,include,include,,,,,include,,,require,,,exclude,exclude,,exclude,1800,exclude,1800,exclude,1800,,,"        Inclusion Criteria:          -  Histologically or cytologically confirmed, Stage IV non-squamous or squamous NSCLC          -  No prior treatment for Stage IV non-squamous or squamous NSCLC, unless participant             had a previously detected sensitizing epidermal growth factor receptor (EGFR)             mutation or anaplastic lymphoma kinase (ALK) fusion oncogene          -  Tumor PD-L1 expression as determined by immunohistochemistry (IHC) assay of archival             tumor tissue or tissue obtained at screening          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1          -  Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST             v1.1)          -  Adequate hematologic and end-organ function        Exclusion Criteria:          -  Active or untreated central nervous system (CNS) metastases as determined by Computed             Tomography (CT) or magnetic resonance imaging (MRI) evaluation          -  Malignancies other than NSCLC within 5 years prior to randomization, with the             exception of those with a negligible risk of metastasis or death treated with             expected curative outcome          -  Pregnant or lactating women          -  History of autoimmune disease          -  History of idiopathic pulmonary fibrosis, organizing pneumonia, drug induced             pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening             chest CT scan. History of radiation pneumonitis in the radiation field (fibrosis) is             permitted          -  Positive test for Human Immunodeficiency Virus (HIV)          -  Active hepatitis B or hepatitis C          -  Prior treatment with cluster of differentiation (CD) 137 agonists or immune             checkpoint blockade therapies, anti PD1, and anti-PD-L1 therapeutic antibody          -  Severe infection within 4 weeks prior to randomization          -  Significant history of cardiovascular disease      "
NCT02409342,Phase 3,Hoffmann-La Roche,Industry,"A Phase III, Open Label, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) Compared With a Platinum Agent (Cisplatin or Carboplatin) in Combination With Either Pemetrexed or Gemcitabine for PD-L1-Selected, Chemotherapy-Naive Patients With Stage IV Non-Squamous Or Squamous Non-Small Cell Lung Cancer",2,18,150,include,include,include,,,,,include,,,,,,require_alk_or_egfr,require_alk_or_egfr,,,,,,,,,,"        Inclusion Criteria:          -  Histologically or cytologically confirmed, Stage IV non-squamous or squamous NSCLC          -  No prior treatment for Stage IV non-squamous or squamous NSCLC, unless participant             had a previously detected sensitizing epidermal growth factor receptor (EGFR)             mutation or anaplastic lymphoma kinase (ALK) fusion oncogene          -  Tumor PD-L1 expression as determined by immunohistochemistry (IHC) assay of archival             tumor tissue or tissue obtained at screening          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1          -  Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST             v1.1)          -  Adequate hematologic and end-organ function        Exclusion Criteria:          -  Active or untreated central nervous system (CNS) metastases as determined by Computed             Tomography (CT) or magnetic resonance imaging (MRI) evaluation          -  Malignancies other than NSCLC within 5 years prior to randomization, with the             exception of those with a negligible risk of metastasis or death treated with             expected curative outcome          -  Pregnant or lactating women          -  History of autoimmune disease          -  History of idiopathic pulmonary fibrosis, organizing pneumonia, drug induced             pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening             chest CT scan. History of radiation pneumonitis in the radiation field (fibrosis) is             permitted          -  Positive test for Human Immunodeficiency Virus (HIV)          -  Active hepatitis B or hepatitis C          -  Prior treatment with cluster of differentiation (CD) 137 agonists or immune             checkpoint blockade therapies, anti PD1, and anti-PD-L1 therapeutic antibody          -  Severe infection within 4 weeks prior to randomization          -  Significant history of cardiovascular disease      "
NCT02027428,Phase 3,Celgene Corporation,Industry,"A Phase III, Randomized, Open-Label, Multi-Center, Safety and Efficacy Study to Evaluate Nab-Paclitaxel (Abraxaneå¨) as Maintenance Treatment After Induction With Nab-Paclitaxel Plus Carboplatin in Subjects With Squamous Cell Non-Small Cell Lung Cancer (NSCLC)",1,18,150,,,include,,,,include,include,,,,,,,,,,,exclude,1800,exclude,12,,,"        Inclusion Criteria:          -  1. Age ‰ä´ 18 years of age at the time of signing the Informed Consent Form. 2.             Understand and voluntarily provide written consent to the Informed Consent Form prior             to conducting any study related assessments/procedures.             3. Able to adhere to the study visit schedule and other protocol requirements Disease             Specific 4. Histologically or cytologically confirmed Stage IIIB or IV squamous cell             Non Small Cell Lung Cancer at study entry.             5. No other current active malignancy requiring anticancer therapy.             6. Radiographically documented measurable disease at study entry (as defined by the             RECIST v1.1 criteria).             7. No prior chemotherapy for the treatment of metastatic disease at study entry.             Adjuvant chemotherapy is permitted providing cytotoxic chemotherapy was completed 12             months prior to starting the study and without disease recurrence.             8. Absolute neutrophil count ‰ä´ 1500 cells/mm3. 9. Platelets ‰ä´ 100,000 cells/mm3. 10.             Hemoglobin ‰ä´ 9 g/dL. 11. Aspartate transaminase/serum glutamic oxaloacetic             transaminase, alanine transaminase/serum glutamic pyruvic transaminase ‰ä_ 2.5 ÌÑ upper             limit of normal range or ‰ä_ 5.0 ÌÑ upper limit of normal range if liver metastases.             12. Total bilirubin ‰ä_ 1.5 ÌÑ upper limit of normal range except in cases of Gilbert's             disease and liver metastases.             13. Creatinine ‰ä_ 1.5 mg/dL. 14. Expected survival of > 12 weeks for the Induction             part of the study. 15. Eastern Cooperative Oncology Group performance status 0 or 1.             16. For Maintenance part of the study, subjects must have received at least one dose             of nab-paclitaxel in each of the 4 cycles during Induction Pregnancy 17. Females of             childbearing potential [defined as a sexually mature woman who (1) have not undergone             hysterectomy (the surgical removal of the uterus) or bilateral oophorectomy (the             surgical removal of both ovaries) or (2) have not been naturally postmenopausal for             at least 24 consecutive months (i.e., has had menses at any time during the preceding             24 consecutive months)] must:               1. agree to take a pregnancy test prior to starting study medication and throughout                  the study participation.               2. commit to complete abstinence from heterosexual contact, or agree to use medical                  doctor-approved contraception throughout the study without interruption, and                  while receiving study medication or for a longer period if required by local                  regulations.                  Male subjects must:               3. agree to complete abstinence from heterosexual contact or use a condom during                  sexual contact with a female of child bearing potential while receiving study                  medication and within 6 months after last dose of study medication, even if he                  has undergone a successful vasectomy.                  18. Females must abstain from breastfeeding during study participation and 3                  months after IP discontinuation.                  Exclusion Criteria:          -  The presence of any of the following will exclude a subject from enrollment into the             Induction and Maintenance parts of the study (except if specified at study entry             only):               1. Evidence of active brain metastases, including leptomeningeal involvement (prior                  evidence of brain metastasis are permitted only if treated and stable and off                  therapy for ‰ä´ 4 weeks prior to first dose of study drug).               2. Only evidence of disease is non measurable at study entry.               3. Preexisting peripheral neuropathy of Grade 2, 3, or 4 (per Common Terminology                  Criteria for Adverse Events v4.0).               4. Venous thromboembolism within 6 months prior to signing Informed Consent Form.               5. Current congestive heart failure (New York Heart Association class II-IV).               6. History of the following within 6 months prior to first administration of a                  study drug: a myocardial infarction, severe/unstable angina pectoris,                  coronary/peripheral artery bypass graft, New York Heart Association (NYHA) Class                  III-IV heart failure, uncontrolled hypertension, clinically significant cardiac                  dysrhythmia or clinically significant ECG abnormality, cerebrovascular accident,                  transient ischemic attack, or seizure disorder.7. Treatment with any                  investigational product within 28 days prior to signing Informed Consent Form.             8. History of allergy or hypersensitivity to nab-paclitaxel or carboplatin. 9.             Currently enrolled in any other clinical protocol or investigational trial that             involved administration of experimental therapy and/or therapeutic devices.             10. Any other clinically significant medical condition and/or organ dysfunction that             will interfere with the administration of the therapy according to this protocol.             11. Subject has any other malignancy within 5 years prior to randomization.             Exceptions include the following: squamous cell carcinoma of the skin, in-situ             carcinoma of the cervix, uteri, non-melanomatous skin cancer, carcinoma in situ of             the breast, or incidental histological finding of prostate cancer (TNM stage of T1a             or T1b) ‰ÛÓ all treatments that should have been completed 6 months prior to signing             ICF.             12. Subject has received radiotherapy ‰ä_ 4 weeks or limited field radiation for             palliation ‰ä_ 2 weeks prior to starting IP, and/or from whom ‰ä´ 30% of the bone marrow             was irradiated. Prior radiation therapy to a target lesion is permitted only if there             has been clear progression of the lesion since radiation was completed.             13. Pregnant and nursing females.      "
NCT02411448,Phase 3,Eli Lilly and Company,Industry,"A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination With Ramucirumab or Placebo in Previously Untreated Patients With EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer",1,18,150,include,include,include,,,,,include,,,,,,,exclude,,,,,,,,,,"        Inclusion Criteria:          -  Cytologically or histologically confirmed diagnosis of Stage IV NSCLC as defined by             the American Joint Committee on Cancer Staging Criteria for Lung Cancer (AJCC 7th             edition 2009).          -  Eligible for first-line treatment with erlotinib based on documented evidence of             tumor harboring an activating EGFR mutation (Example 19 del and L858R).          -  Mandatory provision of adequate archived stage IV NSCLC tissue sample.          -  At least one measurable lesion.          -  Life expectancy of at least 3 months.        Exclusion Criteria:          -  Known T790M EGFR mutation.          -  Known leptomeningeal carcinomatosis, uncontrolled/unstable spinal cord compression,             or brain metastases.          -  Serious illness or medical condition.          -  Ongoing treatment with CYP3A4 inducers or strong/moderate inhibitors.          -  Ongoing therapy with nonsteroidal anti-inflammatory drugs for more than 2 months.          -  History of gross hemoptysis.          -  Significant bleeding disorders.          -  Radiologically documented evidence of major blood vessel invasion or encasement by             cancer.          -  Radiographic evidence of intratumor cavitation.          -  History of gastrointestinal perforation within last 6 months.          -  History of bowel obstruction, inflammatory enteropathy or extensive intestinal             resection.          -  History of any arterial thrombotic event within 6 months prior to enrollment.          -  The participant has any known significant ophthalmologic abnormalities of the surface             of the eye.      "
NCT02713867,Phase 3,Bristol-Myers Squibb,Industry,"A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks",1,18,150,include,include,include,,,,include,include,,,,,,,,,,,,,,,,,"        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please        visit www.BMSStudyConnect.com        Inclusion Criteria:          -  Histologically or cytologically documented Squamous or non-Squamous Non-small cell             lung cancer (NSCLC) (Stage IIIB/IV), or recurrent or progressive disease following             multimodal therapy          -  Patients must have received pre-study nivolumab for up to 12 months and have 2             consecutive tumor assessments confirming Complete response (CR), Partial response             (PR), or Stable disease (SD)          -  Measurable disease before start of pre-study nivolumab treatment          -  Eastern Cooperative Oncology Group (ECOG) Performance status (PS) 0-2        Exclusion Criteria:          -  Carcinomatous meningitis          -  Untreated, symptomatic Central nervous system (CNS) metastases          -  Symptomatic interstitial lung disease        Other protocol defined inclusion/exclusion criteria could apply      "
NCT02713867,Phase 3,Bristol-Myers Squibb,Industry,"A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks",2,18,150,include,include,include,,include,include,,,,,,require,,,,,,,,,,,,,"        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please        visit www.BMSStudyConnect.com        Inclusion Criteria:          -  Histologically or cytologically documented Squamous or non-Squamous Non-small cell             lung cancer (NSCLC) (Stage IIIB/IV), or recurrent or progressive disease following             multimodal therapy          -  Patients must have received pre-study nivolumab for up to 12 months and have 2             consecutive tumor assessments confirming Complete response (CR), Partial response             (PR), or Stable disease (SD)          -  Measurable disease before start of pre-study nivolumab treatment          -  Eastern Cooperative Oncology Group (ECOG) Performance status (PS) 0-2        Exclusion Criteria:          -  Carcinomatous meningitis          -  Untreated, symptomatic Central nervous system (CNS) metastases          -  Symptomatic interstitial lung disease        Other protocol defined inclusion/exclusion criteria could apply      "
NCT01630733,Phase 3,OncoGenex Technologies,Industry,"A Multinational, Randomized, Open-Label Phase III Study of Custirsen (TV-1011/OGX-011) In Combination With Docetaxel Versus Docetaxel As A Second-Line Treatment In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer",1,18,150,include,include,include,,,,,include,,,,,,,exclude,,,,require,,,,,,"        Inclusion Criteria:          1. Patients must have a histologically or cytologically confirmed, unresectable,             advanced or metastatic (Stage IV per AJCC 7th edition TNM staging) NSCLC          2. Males or females ‰ä´ 18 years of age at screening.          3. Life expectancy of > 12 weeks from screening, according to the investigator's             assessment.          4. Patients must have received one prior line of platinum-based systemic anticancer             therapy for advanced or metastatic NSCLC. Prior maintenance therapy is allowed and             will be considered as the same line of therapy when continued at the end of a             treatment regimen.          5. Patients must have documented radiological disease progression either during or after             the first-line therapy.          6. Patients must have at least one measurable lesion per RECIST 1.1 criteria.          7. ECOG performance status of 0 or 1 at screening.          8. Have adequate values, bone marrow, renal and liver functions at screening as defined             below:               -  Absolute neutrophil count (ANC) ‰ä´ 1.5 x 109/L               -  Platelet count ‰ä´ 100 x 109/L               -  Hemoglobin ‰ä´ 9 g/dL               -  Serum creatinine ‰ä_ 1.5 x upper limit of normal (ULN)               -  Total Bilirubin ‰ä_ 1.0 x ULN (unless elevated secondary to benign conditions such                  as Gilbert's disease)               -  AST and ALT ‰ä_ 1.5 x ULN          9. Resolution of any toxic effects of prior therapy to Grade ‰ä_1 according to NCI CTCAE,             version 4.0 (exception of alopecia and ‰ä_ Grade 2 peripheral neuropathy).         10. Females of child-bearing potential must have negative serum pregnancy test within 72             hours before randomization.         11. Women of child-bearing potential will practice a highly effective method of birth             control during and for 3 months after the chemotherapy/ custirsen last dose. Men of             reproductive potential who are not surgically sterile must agree to abstain from             sexual activity or use medically accepted and highly effective method of             contraception during and for 6 months after the chemotherapy/custirsen last dose.         12. Patients must be willing and able to give written informed consent prior to any             protocol-specific procedures being performed and comply with the protocol             requirements for the duration of the study.        Exclusion Criteria:          1. Patients treated with any systemic anti-cancer therapy for NSCLC within 21 days prior             to randomization (6 weeks for Bevacizumab).          2. Radiotherapy ‰ä_ 2 weeks prior to randomization. Patients must have recovered from all             radiotherapy-related toxicities.          3. Major surgical procedure within 4 weeks prior to randomization. Patient must have             recovered from all surgery-related complications.          4. Patients with known CNS metastases (Patients with any clinical signs of CNS             metastases must have a CT or MRI of the brain to rule out CNS metastases in order to             be eligible for participation in the study). Patients who have had brain metastases             treated with radiotherapy or surgically removed with no residual disease confirmed by             imaging; patients should be clinically stable and off corticosteroid treatment at             least 3 weeks prior to randomization).          5. Patients with current diagnosis or a history of another active primary malignancy             (except in situ carcinoma of the cervix, adequately treated non-melanomatous skin             cancers, clinically localized prostate cancer, superficial bladder cancer or other             malignancy treated at least 5 years previously with no evidence of recurrence).          6. Severe or unstable medical conditions such as heart failure, ischemic heart disease,             uncontrolled hypertension, uncontrolled diabetes mellitus, psychiatric condition, as             well as an ongoing cardiac arrhythmia requiring medication (‰ä´ Grade 2, according to             NCI CTCAE v4.0) or any other significant or unstable concurrent medical illness that             in the opinion of the Investigator would preclude protocol therapy.          7. A history of events such as myocardial infarction, cerebrovascular accident or acute             hepatitis within 3 months of randomization or treatment of a major active infection             within one month of randomization, or any other significant event that in the opinion             of the Investigator would preclude protocol therapy.          8. Planned concomitant participation in another clinical trial of an experimental agent,             vaccine, or device. Concomitant participation in observational studies is acceptable.          9. Female patients who are breastfeeding.         10. Patients previously treated with docetaxel for NSCLC or with known severe             hypersensitivity to taxane therapies.         11. Patients with known and documented EGFR mutation who have not received an EGFR             inhibitor.      "
NCT01630733,Phase 3,OncoGenex Technologies,Industry,"A Multinational, Randomized, Open-Label Phase III Study of Custirsen (TV-1011/OGX-011) In Combination With Docetaxel Versus Docetaxel As A Second-Line Treatment In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer",2,18,150,include,include,include,,,,,include,,,,,,,require,,,,require,,,,require,,"        Inclusion Criteria:          1. Patients must have a histologically or cytologically confirmed, unresectable,             advanced or metastatic (Stage IV per AJCC 7th edition TNM staging) NSCLC          2. Males or females ‰ä´ 18 years of age at screening.          3. Life expectancy of > 12 weeks from screening, according to the investigator's             assessment.          4. Patients must have received one prior line of platinum-based systemic anticancer             therapy for advanced or metastatic NSCLC. Prior maintenance therapy is allowed and             will be considered as the same line of therapy when continued at the end of a             treatment regimen.          5. Patients must have documented radiological disease progression either during or after             the first-line therapy.          6. Patients must have at least one measurable lesion per RECIST 1.1 criteria.          7. ECOG performance status of 0 or 1 at screening.          8. Have adequate values, bone marrow, renal and liver functions at screening as defined             below:               -  Absolute neutrophil count (ANC) ‰ä´ 1.5 x 109/L               -  Platelet count ‰ä´ 100 x 109/L               -  Hemoglobin ‰ä´ 9 g/dL               -  Serum creatinine ‰ä_ 1.5 x upper limit of normal (ULN)               -  Total Bilirubin ‰ä_ 1.0 x ULN (unless elevated secondary to benign conditions such                  as Gilbert's disease)               -  AST and ALT ‰ä_ 1.5 x ULN          9. Resolution of any toxic effects of prior therapy to Grade ‰ä_1 according to NCI CTCAE,             version 4.0 (exception of alopecia and ‰ä_ Grade 2 peripheral neuropathy).         10. Females of child-bearing potential must have negative serum pregnancy test within 72             hours before randomization.         11. Women of child-bearing potential will practice a highly effective method of birth             control during and for 3 months after the chemotherapy/ custirsen last dose. Men of             reproductive potential who are not surgically sterile must agree to abstain from             sexual activity or use medically accepted and highly effective method of             contraception during and for 6 months after the chemotherapy/custirsen last dose.         12. Patients must be willing and able to give written informed consent prior to any             protocol-specific procedures being performed and comply with the protocol             requirements for the duration of the study.        Exclusion Criteria:          1. Patients treated with any systemic anti-cancer therapy for NSCLC within 21 days prior             to randomization (6 weeks for Bevacizumab).          2. Radiotherapy ‰ä_ 2 weeks prior to randomization. Patients must have recovered from all             radiotherapy-related toxicities.          3. Major surgical procedure within 4 weeks prior to randomization. Patient must have             recovered from all surgery-related complications.          4. Patients with known CNS metastases (Patients with any clinical signs of CNS             metastases must have a CT or MRI of the brain to rule out CNS metastases in order to             be eligible for participation in the study). Patients who have had brain metastases             treated with radiotherapy or surgically removed with no residual disease confirmed by             imaging; patients should be clinically stable and off corticosteroid treatment at             least 3 weeks prior to randomization).          5. Patients with current diagnosis or a history of another active primary malignancy             (except in situ carcinoma of the cervix, adequately treated non-melanomatous skin             cancers, clinically localized prostate cancer, superficial bladder cancer or other             malignancy treated at least 5 years previously with no evidence of recurrence).          6. Severe or unstable medical conditions such as heart failure, ischemic heart disease,             uncontrolled hypertension, uncontrolled diabetes mellitus, psychiatric condition, as             well as an ongoing cardiac arrhythmia requiring medication (‰ä´ Grade 2, according to             NCI CTCAE v4.0) or any other significant or unstable concurrent medical illness that             in the opinion of the Investigator would preclude protocol therapy.          7. A history of events such as myocardial infarction, cerebrovascular accident or acute             hepatitis within 3 months of randomization or treatment of a major active infection             within one month of randomization, or any other significant event that in the opinion             of the Investigator would preclude protocol therapy.          8. Planned concomitant participation in another clinical trial of an experimental agent,             vaccine, or device. Concomitant participation in observational studies is acceptable.          9. Female patients who are breastfeeding.         10. Patients previously treated with docetaxel for NSCLC or with known severe             hypersensitivity to taxane therapies.         11. Patients with known and documented EGFR mutation who have not received an EGFR             inhibitor.      "
NCT02657434,Phase 3,Hoffmann-La Roche,Industry,"A Phase III, Open-Label, Randomized Study of Atezolizumab (MPDL3280A, Anti-Pd-L1 Antibody) in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Patients Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer",1,18,150,include,include,,,,,,include,,,require,,,exclude,exclude,,exclude,6,exclude,6,exclude,6,,,"        Inclusion Criteria:          -  Male or female, 18 years of age or older          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1          -  Histologically or cytologically confirmed, Stage IV non-squamous NSCLC          -  No prior treatment for Stage IV non-squamous NSCLC. Participants with a sensitizing             mutation in the epidermal growth factor receptor (EGFR) gene or with an anaplastic             lymphoma kinase (ALK) fusion oncogene are excluded.          -  Participants who have received prior neo-adjuvant, adjuvant chemotherapy, or             chemoradiotherapy with curative intent for non-metastatic disease must have             experienced a treatment-free interval of at least 6 months from randomization since             the last chemotherapy or completion of chemoradiotherapy          -  Known programmed death-ligand 1 (PD-L1) tumor status as determined by an             immunohistochemistry (IHC) assay performed by a central laboratory on previously             obtained archival tumor tissue or tissue obtained from a biopsy at screening          -  Measurable disease, as defined by Response Evaluation Criteria in Solid Tumors             Version 1.1 (RECIST v1.1)          -  Adequate hematologic and end organ function          -  For women of childbearing potential: agreement to remain abstinent or use             contraceptive methods that result in a failure rate of less than (<) 1 percent (%)             per year during the treatment period and for at least 90 days after the last dose of             study treatment          -  For men: agreement to remain abstinent or use contraceptive measures and agreement to             refrain from donating sperm        Exclusion Criteria:        Cancer-Specific Exclusions          -  Active or untreated central nervous system (CNS) metastases as determined by computed             tomography (CT) or magnetic resonance imaging (MRI) evaluation during screening and             prior radiographic assessments          -  Spinal cord compression not definitively treated with surgery and/or radiation or             previously diagnosed and treated spinal cord compression without evidence that             disease has been clinically stable for >= 2 weeks prior to randomization          -  Leptomeningeal disease          -  Uncontrolled tumor-related pain          -  Uncontrolled or symptomatic hypercalcemia (greater than [>] 1.5 millimole/Liter             ionized calcium or calcium > 12 milligram/deciliter or corrected serum calcium >upper             limit of normal)          -  Malignancies other than NSCLC within 5 years prior to randomization          -  Known tumor PD-L1 expression status from other clinical studies (e.g., participants             whose PD-L1 expression status was determined during screening for entry into a study             with anti-PD-1 or anti-PD L1 antibodies but were not eligible are excluded)        General Medical Exclusions:          -  History of severe allergic, anaphylactic, or other hypersensitivity reactions to             chimeric or humanized antibodies or fusion proteins          -  History of certain autoimmune disease          -  History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced             pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis          -  Severe infections within 4 weeks prior to randomization          -  Significant cardiovascular disease, such as New York Heart Association cardiac             disease (Class II or greater), myocardial infarction within 3 months prior to             randomization, unstable arrhythmias, or unstable angina        Exclusion Criteria Related to Medications and Chemotherapy:          -  Any approved anti-cancer therapy, including chemotherapy, or hormonal therapy within             3 weeks prior to initiation of study treatment          -  Prior treatment with CD137 agonists or immune checkpoint blockade therapies,             anti-PD-1, and anti-PD-L1 therapeutic antibodies          -  Treatment with systemic immunostimulatory agents within 4 weeks prior to             randomization          -  Treatment with systemic immunosuppressive medications        Exclusion Criteria Related to Chemotherapy:          -  History of allergic reactions to cisplatin, carboplatin, or other platinum-containing             compounds          -  Participants with hearing impairment (cisplatin)          -  Grade >= 2 peripheral neuropathy as defined by National Cancer Institute Common             Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0 criteria (cisplatin)          -  Creatinine clearance (CRCL) =< 60 milliliter (mL)/minute (min) for cisplatin or < 45             mL/min for carboplatin      "
NCT02657434,Phase 3,Hoffmann-La Roche,Industry,"A Phase III, Open-Label, Randomized Study of Atezolizumab (MPDL3280A, Anti-Pd-L1 Antibody) in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Patients Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer",2,18,150,include,include,,,,,,include,,,,,,require_alk_or_egfr,require_alk_or_egfr,,,,,,,,,,"        Inclusion Criteria:          -  Male or female, 18 years of age or older          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1          -  Histologically or cytologically confirmed, Stage IV non-squamous NSCLC          -  No prior treatment for Stage IV non-squamous NSCLC. Participants with a sensitizing             mutation in the epidermal growth factor receptor (EGFR) gene or with an anaplastic             lymphoma kinase (ALK) fusion oncogene are excluded.          -  Participants who have received prior neo-adjuvant, adjuvant chemotherapy, or             chemoradiotherapy with curative intent for non-metastatic disease must have             experienced a treatment-free interval of at least 6 months from randomization since             the last chemotherapy or completion of chemoradiotherapy          -  Known programmed death-ligand 1 (PD-L1) tumor status as determined by an             immunohistochemistry (IHC) assay performed by a central laboratory on previously             obtained archival tumor tissue or tissue obtained from a biopsy at screening          -  Measurable disease, as defined by Response Evaluation Criteria in Solid Tumors             Version 1.1 (RECIST v1.1)          -  Adequate hematologic and end organ function          -  For women of childbearing potential: agreement to remain abstinent or use             contraceptive methods that result in a failure rate of less than (<) 1 percent (%)             per year during the treatment period and for at least 90 days after the last dose of             study treatment          -  For men: agreement to remain abstinent or use contraceptive measures and agreement to             refrain from donating sperm        Exclusion Criteria:        Cancer-Specific Exclusions          -  Active or untreated central nervous system (CNS) metastases as determined by computed             tomography (CT) or magnetic resonance imaging (MRI) evaluation during screening and             prior radiographic assessments          -  Spinal cord compression not definitively treated with surgery and/or radiation or             previously diagnosed and treated spinal cord compression without evidence that             disease has been clinically stable for >= 2 weeks prior to randomization          -  Leptomeningeal disease          -  Uncontrolled tumor-related pain          -  Uncontrolled or symptomatic hypercalcemia (greater than [>] 1.5 millimole/Liter             ionized calcium or calcium > 12 milligram/deciliter or corrected serum calcium >upper             limit of normal)          -  Malignancies other than NSCLC within 5 years prior to randomization          -  Known tumor PD-L1 expression status from other clinical studies (e.g., participants             whose PD-L1 expression status was determined during screening for entry into a study             with anti-PD-1 or anti-PD L1 antibodies but were not eligible are excluded)        General Medical Exclusions:          -  History of severe allergic, anaphylactic, or other hypersensitivity reactions to             chimeric or humanized antibodies or fusion proteins          -  History of certain autoimmune disease          -  History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced             pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis          -  Severe infections within 4 weeks prior to randomization          -  Significant cardiovascular disease, such as New York Heart Association cardiac             disease (Class II or greater), myocardial infarction within 3 months prior to             randomization, unstable arrhythmias, or unstable angina        Exclusion Criteria Related to Medications and Chemotherapy:          -  Any approved anti-cancer therapy, including chemotherapy, or hormonal therapy within             3 weeks prior to initiation of study treatment          -  Prior treatment with CD137 agonists or immune checkpoint blockade therapies,             anti-PD-1, and anti-PD-L1 therapeutic antibodies          -  Treatment with systemic immunostimulatory agents within 4 weeks prior to             randomization          -  Treatment with systemic immunosuppressive medications        Exclusion Criteria Related to Chemotherapy:          -  History of allergic reactions to cisplatin, carboplatin, or other platinum-containing             compounds          -  Participants with hearing impairment (cisplatin)          -  Grade >= 2 peripheral neuropathy as defined by National Cancer Institute Common             Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0 criteria (cisplatin)          -  Creatinine clearance (CRCL) =< 60 milliliter (mL)/minute (min) for cisplatin or < 45             mL/min for carboplatin      "
NCT02578680,Phase 3,Merck Sharp & Dohme Corp.,Industry,"A Randomized, Double-Blind, Phase III Study of Platinum+ Pemetrexed Chemotherapy With or Without Pembrolizumab (MK-3475) in First Line Metastatic Non-squamous Non-small Cell Lung Cancer Subjects (KEYNOTE-189)",1,18,150,include,include,,,,,,include,,,,,,,,,exclude,6,exclude,1800,,,,,"        Inclusion Criteria:          -  Has a histologically-confirmed or cytologically confirmed diagnosis of stage IV             non-squamous NSCLC.          -  Has confirmation that epidermal growth factor receptor (EGFR) or anaplastic lymphoma             kinase (ALK)-directed therapy is not indicated.          -  Has measurable disease.          -  Has not received prior systemic treatment for their advanced/metastatic NSCLC.          -  Can provide tumor tissue.          -  Has a life expectancy of at least 3 months.          -  Has a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG)             Performance Status.          -  Has adequate organ function          -  If female of childbearing potential, is willing to use adequate contraception for the             course of the study through 120 days after the last dose of study medication or             through 180 days after last dose of chemotherapeutic agents.          -  If male with a female partner(s) of child-bearing potential, must agree to use             adequate contraception starting with the first dose of study medication through 120             days after the last dose of study medication or through 180 days after last dose of             chemotherapeutic agents.        Exclusion Criteria:          -  Has predominantly squamous cell histology NSCLC.          -  Is currently participating and receiving study therapy or has participated in a study             of an investigational agent and received study therapy or used an investigational             device within 4 weeks prior to administration of pembrolizumab.          -  Before the first dose of study medication: a) Has received prior systemic cytotoxic             chemotherapy for metastatic disease, b) Has received antineoplastic biological             therapy (e.g., erlotinib, crizotinib, cetuximab), c) Had major surgery (<3 weeks             prior to first dose)          -  Received radiation therapy to the lung that is >30 Gy within 6 months of the first             dose of study medication.          -  Completed palliative radiotherapy within 7 days of the first dose of study             medication.          -  Is expected to require any other form of antineoplastic therapy while on study.          -  Received a live-virus vaccination within 30 days of planned start of study             medication.          -  Has clinically active diverticulitis, intra-abdominal abscess, gastrointestinal             obstruction, or abdominal carcinomatosis.          -  Known history of prior malignancy except if participant has undergone potentially             curative therapy with no evidence of that disease recurrence for 5 years since             initiation of that therapy, except for successful definitive resection of basal cell             carcinoma of the skin, superficial bladder cancer, squamous cell carcinoma of the             skin, in situ cervical cancer, or other in situ cancers.          -  Has known active central nervous system (CNS) metastases and/or carcinomatous             meningitis.          -  Previously had a severe hypersensitivity reaction to treatment with another             monoclonal antibody (mAb).          -  Known sensitivity to any component of cisplatin, carboplatin or pemetrexed.          -  Has active autoimmune disease that has required systemic treatment in past 2 years.          -  Is on chronic systemic steroids.          -  Is unable to interrupt aspirin or other nonsteroidal anti-inflammatory drugs             (NSAIDs), other than an aspirin dose ‰ä_1.3 g per day, for a 5-day period (8-day period             for long-acting agents, such as piroxicam).          -  Is unable or unwilling to take folic acid or vitamin B12 supplementation.          -  Had prior treatment with any other anti-programmed cell death-1 (PD-1), or PD-ligand             1 (PD-L1) or PD-L2 agent or an antibody targeting other immuno-regulatory receptors             or mechanisms. Has participated in any other pembrolizumab study and has been treated             with pembrolizumab.          -  Has an active infection requiring therapy.          -  Has known history of Human Immunodeficiency Virus (HIV).          -  Has known active Hepatitis B or C.          -  Has known psychiatric or substance abuse disorder that would interfere with             cooperation with the requirements of the trial.          -  Is a regular user (including ""recreational use"") of any illicit drugs or had a recent             history (within the last year) of substance abuse (including alcohol).          -  Has symptomatic ascites or pleural effusion.          -  Has interstitial lung disease or a history of pneumonitis that required oral or IV             glucocorticoids to assist with management.          -  Is pregnant or breastfeeding, or expecting to conceive or father children prior to             120 days after the last dose of study medication or through 180 days after last dose             of chemotherapeutic agents.      "
NCT02763579,Phase 3,Hoffmann-La Roche,Industry,"A Phase I/III, Randomized, Double-Blind, Placebo-Controlled Study of Carboplatin Plus Etoposide With or Without Atezolizumab (Anti PD-L1 Antibody) in Patients With Untreated Extensive-Stage Small Cell Lung Cancer",1,18,150,,,,include,,,,,,include,,,,,,,,,,,,,,,"        Inclusion Criteria:          -  Participants 18 years of age or older          -  Histologically or cytologically confirmed ES-SCLC (per the Veterans Administration             Lung Study Group [VALG] staging system)          -  No prior treatment for ES-SCLC          -  ECOG performance status of 0 or 1          -  Measurable disease, as defined by RECIST v1.1          -  Adequate hematologic and end organ function        Exclusion Criteria:          -  Active or untreated central nervous system (CNS) metastases as determined by computed             tomography (CT) or magnetic resonance imaging (MRI) evaluation          -  Malignancies other than SCLC within 5 years prior to randomization, with the             exception of those with a negligible risk of metastasis or death treated with             expected curative outcome          -  Pregnant or lactating women          -  History of autoimmune disease          -  History of idiopathic pulmonary fibrosis, organizing pneumonia, drug induced             pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening             chest Computed Tomography (CT) scan. History of radiation pneumonitis in the             radiation field (fibrosis) is permitted.          -  Positive test for Human Immunodeficiency Virus (HIV)          -  Active hepatitis B or hepatitis C          -  Severe infections at the time of enrollment          -  Significant cardiovascular disease          -  Prior treatment with cluster of differentiation 137 (CD137) agonists or immune             checkpoint blockade therapies, anti-PD1, and anti-PD-L1 therapeutic antibody      "
NCT00551733,Phase 3,CTI BioPharma,Industry,Paclitaxel Poliglumex (CT-2103)/Carboplatin vs Paclitaxel/Carboplatin for the Treatment of Chemotherapy-NaÌøve Advanced Non-Small Cell Lung Cancer (NSCLC) in Women With Estradiol >30 pg/mL,1,18,150,include,include,include,,,,include,include,,,,,,,,,,,exclude,1800,,,,,"        DISEASE CHARACTERISTICS:          -  Histologically or cytologically confirmed diagnosis of non-small cell lung cancer             (NSCLC)               -  Cytologic specimens obtained by brushings, washings, or needle aspiration of a                  defined lesion or from a pleural effusion are acceptable; sputum cytology alone                  is not acceptable for determining cell type          -  Must meet one of the following criteria:               -  Recurrent disease following completion of radiation or surgery               -  Stage IIIB disease and not a candidate for combined modality therapy (primary                  radiation therapy or surgery)               -  Stage IV disease          -  Patients may have either measurable or nonmeasurable disease according to RECIST             criteria          -  Baseline estradiol > 30 pg/mL               -  Patients on hormone replacement therapy are eligible provided baseline estradiol                  > 30 pg/mL          -  Patients with known brain metastases must have received standard antitumor treatment             (e.g. whole brain radiation, stereotactic radioablation, or surgery) for their CNS             metastases as defined by the site's institutional standards               -  Neurologic function must have been stable for 2 weeks before randomization and                  patients must either be off steroid therapy for their brain metastases or on a                  tapering regimen               -  Patients must have recovered from therapy for their brain metastases with no                  evidence of significant unstable neurological symptoms within the 4 weeks before                  study randomization          -  No evidence of small cell carcinoma, carcinoid, or mixed small cell/non-small cell             histology        PATIENT CHARACTERISTICS:          -  Female          -  ECOG performance score 0-2          -  Life expectancy ‰ä´ 12 weeks          -  Absolute neutrophil count ‰ä´ 1,500/mmå_          -  Platelet count ‰ä´ 100,000/mmå_          -  Hemoglobin ‰ä´ 10 g/dL (may be achieved with transfusion)          -  Creatinine ‰ä_ 1.5 times upper limit of normal (ULN)          -  Total bilirubin ‰ä_ 1.5 times ULN (CTC grade 1) (patients with Gilbert syndrome or             other hereditary bilirubin defects may be included regardless of bilirubin levels)          -  SGOT and SGPT ‰ä_ 2.5 times ULN (CTC grade 0 or 1) (5 times ULN [CTC grade 0 to 2] if             due to liver metastases)          -  Alkaline phosphatase ‰ä_ 2.5 times ULN except for elevated alkaline phosphatase with             laboratory documentation that demonstrates bone origin          -  No pregnant women or nursing mothers          -  Negative pregnancy test          -  Fertile patients must use effective contraception during and for 6 months after study             participation          -  No known hypersensitivity to study drugs or excipients          -  Meets all of the following criteria:               -  No weight loss > 10% in previous 6 months               -  Lactate dehydrogenase (LDH) ‰ä_ 600 IU/L (central laboratory) regardless of weight                  loss               -  LDH ‰ä_ 400 IU/L (central laboratory) and no weight loss ‰ä´ 5% in previous 6 months               -  BMI ‰ä_ 35          -  No concurrent primary malignancies except for carcinoma in situ or non-melanoma skin             cancer          -  No neuropathy grade 2 or greater          -  No clinically significant active infection for which active therapy is underway          -  No unstable medical conditions including unstable angina or myocardial infarction             within the past 6 months               -  Patients with evidence of cardiac conduction abnormalities are eligible if their                  cardiac status is stable          -  No circumstance that would preclude completion of the study or the required follow-up        PRIOR CONCURRENT THERAPY:          -  See Disease Characteristics          -  Recovered from major surgery          -  At least 7 days since prior local palliative radiotherapy          -  At least 30 days since prior radiation therapy with curative intent          -  At least 4 weeks since prior investigational therapy, unless local requirements are             more stringent          -  No prior systemic chemotherapy for the treatment of lung cancer, including systemic             radiosensitizers used to treat brain metastases or any biologic agents          -  No concurrent non-protocol-specified systemic antitumor therapy          -  No concurrent amifostine, investigational agents, other cytotoxic agents for this             disease          -  No concurrent radiotherapy (with the exception of radiotherapy for brain or bone             metastases for palliative purposes or radiotherapy for a condition other than NSCLC             that was ongoing at the time of randomization)               -  Patients receiving palliative radiotherapy (treatment for symptomatic metastatic                  disease) may be treated while on study      "
NCT00551733,Phase 3,CTI BioPharma,Industry,Paclitaxel Poliglumex (CT-2103)/Carboplatin vs Paclitaxel/Carboplatin for the Treatment of Chemotherapy-NaÌøve Advanced Non-Small Cell Lung Cancer (NSCLC) in Women With Estradiol >30 pg/mL,2,18,150,include,include,include,,include,include,,,,,,require,,,,,require,,exclude,1800,exclude,1800,,,"        DISEASE CHARACTERISTICS:          -  Histologically or cytologically confirmed diagnosis of non-small cell lung cancer             (NSCLC)               -  Cytologic specimens obtained by brushings, washings, or needle aspiration of a                  defined lesion or from a pleural effusion are acceptable; sputum cytology alone                  is not acceptable for determining cell type          -  Must meet one of the following criteria:               -  Recurrent disease following completion of radiation or surgery               -  Stage IIIB disease and not a candidate for combined modality therapy (primary                  radiation therapy or surgery)               -  Stage IV disease          -  Patients may have either measurable or nonmeasurable disease according to RECIST             criteria          -  Baseline estradiol > 30 pg/mL               -  Patients on hormone replacement therapy are eligible provided baseline estradiol                  > 30 pg/mL          -  Patients with known brain metastases must have received standard antitumor treatment             (e.g. whole brain radiation, stereotactic radioablation, or surgery) for their CNS             metastases as defined by the site's institutional standards               -  Neurologic function must have been stable for 2 weeks before randomization and                  patients must either be off steroid therapy for their brain metastases or on a                  tapering regimen               -  Patients must have recovered from therapy for their brain metastases with no                  evidence of significant unstable neurological symptoms within the 4 weeks before                  study randomization          -  No evidence of small cell carcinoma, carcinoid, or mixed small cell/non-small cell             histology        PATIENT CHARACTERISTICS:          -  Female          -  ECOG performance score 0-2          -  Life expectancy ‰ä´ 12 weeks          -  Absolute neutrophil count ‰ä´ 1,500/mmå_          -  Platelet count ‰ä´ 100,000/mmå_          -  Hemoglobin ‰ä´ 10 g/dL (may be achieved with transfusion)          -  Creatinine ‰ä_ 1.5 times upper limit of normal (ULN)          -  Total bilirubin ‰ä_ 1.5 times ULN (CTC grade 1) (patients with Gilbert syndrome or             other hereditary bilirubin defects may be included regardless of bilirubin levels)          -  SGOT and SGPT ‰ä_ 2.5 times ULN (CTC grade 0 or 1) (5 times ULN [CTC grade 0 to 2] if             due to liver metastases)          -  Alkaline phosphatase ‰ä_ 2.5 times ULN except for elevated alkaline phosphatase with             laboratory documentation that demonstrates bone origin          -  No pregnant women or nursing mothers          -  Negative pregnancy test          -  Fertile patients must use effective contraception during and for 6 months after study             participation          -  No known hypersensitivity to study drugs or excipients          -  Meets all of the following criteria:               -  No weight loss > 10% in previous 6 months               -  Lactate dehydrogenase (LDH) ‰ä_ 600 IU/L (central laboratory) regardless of weight                  loss               -  LDH ‰ä_ 400 IU/L (central laboratory) and no weight loss ‰ä´ 5% in previous 6 months               -  BMI ‰ä_ 35          -  No concurrent primary malignancies except for carcinoma in situ or non-melanoma skin             cancer          -  No neuropathy grade 2 or greater          -  No clinically significant active infection for which active therapy is underway          -  No unstable medical conditions including unstable angina or myocardial infarction             within the past 6 months               -  Patients with evidence of cardiac conduction abnormalities are eligible if their                  cardiac status is stable          -  No circumstance that would preclude completion of the study or the required follow-up        PRIOR CONCURRENT THERAPY:          -  See Disease Characteristics          -  Recovered from major surgery          -  At least 7 days since prior local palliative radiotherapy          -  At least 30 days since prior radiation therapy with curative intent          -  At least 4 weeks since prior investigational therapy, unless local requirements are             more stringent          -  No prior systemic chemotherapy for the treatment of lung cancer, including systemic             radiosensitizers used to treat brain metastases or any biologic agents          -  No concurrent non-protocol-specified systemic antitumor therapy          -  No concurrent amifostine, investigational agents, other cytotoxic agents for this             disease          -  No concurrent radiotherapy (with the exception of radiotherapy for brain or bone             metastases for palliative purposes or radiotherapy for a condition other than NSCLC             that was ongoing at the time of randomization)               -  Patients receiving palliative radiotherapy (treatment for symptomatic metastatic                  disease) may be treated while on study      "
NCT00551733,Phase 3,CTI BioPharma,Industry,Paclitaxel Poliglumex (CT-2103)/Carboplatin vs Paclitaxel/Carboplatin for the Treatment of Chemotherapy-NaÌøve Advanced Non-Small Cell Lung Cancer (NSCLC) in Women With Estradiol >30 pg/mL,3,18,150,include,include,include,,include,include,,,,,,require,,,,,exclude,1800,exclude,1800,require,,,,"        DISEASE CHARACTERISTICS:          -  Histologically or cytologically confirmed diagnosis of non-small cell lung cancer             (NSCLC)               -  Cytologic specimens obtained by brushings, washings, or needle aspiration of a                  defined lesion or from a pleural effusion are acceptable; sputum cytology alone                  is not acceptable for determining cell type          -  Must meet one of the following criteria:               -  Recurrent disease following completion of radiation or surgery               -  Stage IIIB disease and not a candidate for combined modality therapy (primary                  radiation therapy or surgery)               -  Stage IV disease          -  Patients may have either measurable or nonmeasurable disease according to RECIST             criteria          -  Baseline estradiol > 30 pg/mL               -  Patients on hormone replacement therapy are eligible provided baseline estradiol                  > 30 pg/mL          -  Patients with known brain metastases must have received standard antitumor treatment             (e.g. whole brain radiation, stereotactic radioablation, or surgery) for their CNS             metastases as defined by the site's institutional standards               -  Neurologic function must have been stable for 2 weeks before randomization and                  patients must either be off steroid therapy for their brain metastases or on a                  tapering regimen               -  Patients must have recovered from therapy for their brain metastases with no                  evidence of significant unstable neurological symptoms within the 4 weeks before                  study randomization          -  No evidence of small cell carcinoma, carcinoid, or mixed small cell/non-small cell             histology        PATIENT CHARACTERISTICS:          -  Female          -  ECOG performance score 0-2          -  Life expectancy ‰ä´ 12 weeks          -  Absolute neutrophil count ‰ä´ 1,500/mmå_          -  Platelet count ‰ä´ 100,000/mmå_          -  Hemoglobin ‰ä´ 10 g/dL (may be achieved with transfusion)          -  Creatinine ‰ä_ 1.5 times upper limit of normal (ULN)          -  Total bilirubin ‰ä_ 1.5 times ULN (CTC grade 1) (patients with Gilbert syndrome or             other hereditary bilirubin defects may be included regardless of bilirubin levels)          -  SGOT and SGPT ‰ä_ 2.5 times ULN (CTC grade 0 or 1) (5 times ULN [CTC grade 0 to 2] if             due to liver metastases)          -  Alkaline phosphatase ‰ä_ 2.5 times ULN except for elevated alkaline phosphatase with             laboratory documentation that demonstrates bone origin          -  No pregnant women or nursing mothers          -  Negative pregnancy test          -  Fertile patients must use effective contraception during and for 6 months after study             participation          -  No known hypersensitivity to study drugs or excipients          -  Meets all of the following criteria:               -  No weight loss > 10% in previous 6 months               -  Lactate dehydrogenase (LDH) ‰ä_ 600 IU/L (central laboratory) regardless of weight                  loss               -  LDH ‰ä_ 400 IU/L (central laboratory) and no weight loss ‰ä´ 5% in previous 6 months               -  BMI ‰ä_ 35          -  No concurrent primary malignancies except for carcinoma in situ or non-melanoma skin             cancer          -  No neuropathy grade 2 or greater          -  No clinically significant active infection for which active therapy is underway          -  No unstable medical conditions including unstable angina or myocardial infarction             within the past 6 months               -  Patients with evidence of cardiac conduction abnormalities are eligible if their                  cardiac status is stable          -  No circumstance that would preclude completion of the study or the required follow-up        PRIOR CONCURRENT THERAPY:          -  See Disease Characteristics          -  Recovered from major surgery          -  At least 7 days since prior local palliative radiotherapy          -  At least 30 days since prior radiation therapy with curative intent          -  At least 4 weeks since prior investigational therapy, unless local requirements are             more stringent          -  No prior systemic chemotherapy for the treatment of lung cancer, including systemic             radiosensitizers used to treat brain metastases or any biologic agents          -  No concurrent non-protocol-specified systemic antitumor therapy          -  No concurrent amifostine, investigational agents, other cytotoxic agents for this             disease          -  No concurrent radiotherapy (with the exception of radiotherapy for brain or bone             metastases for palliative purposes or radiotherapy for a condition other than NSCLC             that was ongoing at the time of randomization)               -  Patients receiving palliative radiotherapy (treatment for symptomatic metastatic                  disease) may be treated while on study      "
NCT00551733,Phase 3,CTI BioPharma,Industry,Paclitaxel Poliglumex (CT-2103)/Carboplatin vs Paclitaxel/Carboplatin for the Treatment of Chemotherapy-NaÌøve Advanced Non-Small Cell Lung Cancer (NSCLC) in Women With Estradiol >30 pg/mL,4,18,150,include,include,include,,include,include,,,,,,require,,,,,require,,exclude,1800,require,,,,"        DISEASE CHARACTERISTICS:          -  Histologically or cytologically confirmed diagnosis of non-small cell lung cancer             (NSCLC)               -  Cytologic specimens obtained by brushings, washings, or needle aspiration of a                  defined lesion or from a pleural effusion are acceptable; sputum cytology alone                  is not acceptable for determining cell type          -  Must meet one of the following criteria:               -  Recurrent disease following completion of radiation or surgery               -  Stage IIIB disease and not a candidate for combined modality therapy (primary                  radiation therapy or surgery)               -  Stage IV disease          -  Patients may have either measurable or nonmeasurable disease according to RECIST             criteria          -  Baseline estradiol > 30 pg/mL               -  Patients on hormone replacement therapy are eligible provided baseline estradiol                  > 30 pg/mL          -  Patients with known brain metastases must have received standard antitumor treatment             (e.g. whole brain radiation, stereotactic radioablation, or surgery) for their CNS             metastases as defined by the site's institutional standards               -  Neurologic function must have been stable for 2 weeks before randomization and                  patients must either be off steroid therapy for their brain metastases or on a                  tapering regimen               -  Patients must have recovered from therapy for their brain metastases with no                  evidence of significant unstable neurological symptoms within the 4 weeks before                  study randomization          -  No evidence of small cell carcinoma, carcinoid, or mixed small cell/non-small cell             histology        PATIENT CHARACTERISTICS:          -  Female          -  ECOG performance score 0-2          -  Life expectancy ‰ä´ 12 weeks          -  Absolute neutrophil count ‰ä´ 1,500/mmå_          -  Platelet count ‰ä´ 100,000/mmå_          -  Hemoglobin ‰ä´ 10 g/dL (may be achieved with transfusion)          -  Creatinine ‰ä_ 1.5 times upper limit of normal (ULN)          -  Total bilirubin ‰ä_ 1.5 times ULN (CTC grade 1) (patients with Gilbert syndrome or             other hereditary bilirubin defects may be included regardless of bilirubin levels)          -  SGOT and SGPT ‰ä_ 2.5 times ULN (CTC grade 0 or 1) (5 times ULN [CTC grade 0 to 2] if             due to liver metastases)          -  Alkaline phosphatase ‰ä_ 2.5 times ULN except for elevated alkaline phosphatase with             laboratory documentation that demonstrates bone origin          -  No pregnant women or nursing mothers          -  Negative pregnancy test          -  Fertile patients must use effective contraception during and for 6 months after study             participation          -  No known hypersensitivity to study drugs or excipients          -  Meets all of the following criteria:               -  No weight loss > 10% in previous 6 months               -  Lactate dehydrogenase (LDH) ‰ä_ 600 IU/L (central laboratory) regardless of weight                  loss               -  LDH ‰ä_ 400 IU/L (central laboratory) and no weight loss ‰ä´ 5% in previous 6 months               -  BMI ‰ä_ 35          -  No concurrent primary malignancies except for carcinoma in situ or non-melanoma skin             cancer          -  No neuropathy grade 2 or greater          -  No clinically significant active infection for which active therapy is underway          -  No unstable medical conditions including unstable angina or myocardial infarction             within the past 6 months               -  Patients with evidence of cardiac conduction abnormalities are eligible if their                  cardiac status is stable          -  No circumstance that would preclude completion of the study or the required follow-up        PRIOR CONCURRENT THERAPY:          -  See Disease Characteristics          -  Recovered from major surgery          -  At least 7 days since prior local palliative radiotherapy          -  At least 30 days since prior radiation therapy with curative intent          -  At least 4 weeks since prior investigational therapy, unless local requirements are             more stringent          -  No prior systemic chemotherapy for the treatment of lung cancer, including systemic             radiosensitizers used to treat brain metastases or any biologic agents          -  No concurrent non-protocol-specified systemic antitumor therapy          -  No concurrent amifostine, investigational agents, other cytotoxic agents for this             disease          -  No concurrent radiotherapy (with the exception of radiotherapy for brain or bone             metastases for palliative purposes or radiotherapy for a condition other than NSCLC             that was ongoing at the time of randomization)               -  Patients receiving palliative radiotherapy (treatment for symptomatic metastatic                  disease) may be treated while on study      "
NCT02654587,Phase 3,OSE Immunotherapeutics,Industry,"A Randomized Parallel Group Phase III Trial of OSE 2101 as 2nd Line After Prior Platinum-based Chemotherapy Failure or as 3rd Line After Platinum-failure and Checkpoint Inhibitor-failure, Compared With Standard Treatment (Docetaxel or Pemetrexed) in HLA-A2 Positive Patients With Locally Advanced (IIIB) Unsuitable for Radiotherapy or Metastatic Non-Small-Cell Lung Cancer",1,18,150,include,include,include,,,,include,include,,,,,,exclude,exclude,,,,,,,,,,"        Inclusion Criteria:          1. Signed and dated informed consent document indicating that the patient (or legally             acceptable representative) has been informed of all the pertinent aspects of the             trial prior to enrollment.          2. Willingness and ability to comply with scheduled visits, treatment plans, laboratory             tests, and other study procedures.          3. Female or male, 18 years of age or older.          4. Histologically or cytologically proven diagnosis of NSCLC that is locally advanced             (stage IIIB) unsuitable for radiotherapy or metastatic (stage IV) according to the             7th edition of tumor, node, metastasis (TNM) in Lung Cancer published by the             International Union Against Cancer and the American Joint Committee on Cancer.          5. Subjects with disease recurrence or progression               1. Patients must have had progressive disease after only one prior chemotherapy                  regimen: i) It includes patients who have received one prior platinum-based                  chemotherapy in the adjuvant setting following surgical resection for early                  disease and whose disease has recurred within 12 months of completion of prior                  chemotherapy, ii) It includes patients who received one prior platinum-based                  chemotherapy in combination with radiation therapy for Stage III locoregional                  disease and whose disease has recurred within 12 months of completion of prior                  chemotherapy, iii) It includes patients who received 2 prior platinum-based                  chemotherapy regimens, if the first regimen was given as adjuvant therapy or was                  given in combination with radiation therapy for locally advanced disease               2. or Patients must have had progressive disease after 2nd line therapy with an                  immune checkpoint inhibitor          6. Subjects with measurable or non-measurable lesions.          7. Subjects must express HLA-A2 phenotype as assessed serologically.          8. Subjects must be considered suitable for chemotherapy with either single-agent             pemetrexed or docetaxel.          9. Subjects with brain metastases are eligible if treated and symptoms have returned to             baseline (except for signs and symptoms related to central nervous system therapy)             for at least 2 weeks before initiation of allocated treatment and are not taking any             forbidden medications.         10. Any prior chemotherapy, immunotherapy, radiation therapy or surgeries must have been             completed at least 3 weeks prior to initiation of study medication.         11. Any toxicity from prior therapy must have recovered to ‰ä_ Grade 1 (except alopecia).         12. Eastern Cooperative Oncology Group (ECOG) performance status 0-1.         13. Adequate organ function as defined by all the following criteria:               1. Albuminemia > 25g/L               2. Serum aspartate transaminase (AST) and serum alanine transaminase (ALT) ‰ä_ 1.5 x                  upper limit of normal (ULN) with alkaline phosphatase ‰ä_ 2.5 x ULN, or AST and                  ALT ‰ä_ 5 x ULN if liver function abnormalities are due to liver metastases               3. Total serum bilirubin ‰ä_ 1.5 x ULN               4. Absolute neutrophil count (ANC) ‰ä´ 1500/L               5. Platelets ‰ä´ 100000/L               6. Hemoglobin ‰ä´ 9.0 g/dL (in the absence of transfusion within 2 weeks before                  randomization)               7. Creatinine clearance (based on modified Cockcroft-Gault formula) ‰ä´ 45 ml/min.        Exclusion Criteria:          1. Small-cell lung cancer/mixed NSCLC with small cell component or other neuroendocrine             lung cancers (typical and atypical carcinoids, large-cell neuroendocrine carcinomas).             Large-cell carcinoma.          2. NSCLC that is predominantly squamous cell carcinoma, and patient had docetaxel as             part of his prior chemotherapy.          3. Current or previous treatment with investigational therapy in another therapeutic             clinical trial interrupted less than 4 weeks before study treatment initiation.          4. Patients whose tumor harbors EGFR gene mutation that sensitizes tumors to             Tyrosine-Kinase Inhibitor (TKI) (EGFR exon 18-21) or Anaplastic Lymphoma Kinase (ALK)             rearrangement.          5. Ongoing immunotherapy (checkpoint inhibition, antigen immunotherapy).          6. Spinal cord compression (unless treated with the patient attaining good pain control             and stable or recovered neurologic function), carcinomatous meningitis, or             leptomeningeal disease          7. Patients with squamous cell histology or non-squamous cell histology previously             treated by pemetrexed and with a contraindication for docetaxel with grade ‰ä´ 2             neuropathy or hypersensitivity reaction to medications formulated with polysorbate             80) as they could be randomly assigned to Arm B.          8. Patients with a condition requiring systemic treatment with either corticosteroids or             other immunosuppressive medications.          9. Treatment with corticosteroids in the last 3-week period before inclusion, except for             topical, ocular, intra-articular, intranasal, and inhaled corticosteroids with             minimal systemic absorption (e.g. with a dose ‰ä_ 500 microgram beclomethasone             equivalent for inhaled steroids), or adrenal replacement steroid doses ‰ä_ 10 mg daily             prednisone equivalent which are permitted.         10. A recognized immunodeficiency disease including human immunodeficiency virus (HIV)             infection (and other cellular immunodeficiencies, hypogammaglobulinemia or             dysgammaglobulinemia; subjects who have hereditary, congenital or acquired             immunodeficiencies).         11. Patients with auto-immune disease, with the exception of type I diabetes or treated             hypothyroidism.         12. Patients with interstitial lung disease.         13. Patients with active B or C hepatitis.         14. Other malignancy: patients will not be eligible if they have evidence of active             malignancy (other than non-melanoma skin cancer or localized cervical cancer, or             localized and presumed cured prostate cancer).         15. Other severe acute or chronic medical or psychiatric conditions, or laboratory             abnormalities that would impart, in the judgment of the investigator and/or sponsor,             excess risk associated with study participation or study drug administration, and             which would, therefore, make the patient inappropriate for entry into this study.         16. Female patients must be surgically sterile or be postmenopausal, or must agree to use             effective contraception during the period of the trial and for at least 90 days after             completion of treatment.         17. Male patients sexually active with a woman of childbearing potential must be             surgically sterile or must agree to use effective contraception during the period of             the trial and for at least 90 days after completion of treatment. The decision of             effective contraception will be based on the judgment of the principal investigator.         18. Breastfeeding women.         19. Women with a positive pregnancy test.      "
NCT02810457,Phase 3,Centus Biotherapeutics Limited,Industry,"A Randomised, Parallel, Double Blinded Study to Compare the Efficacy and Safety of FKB238 to Avastinå¨ In 1st Line Treatment for Patients With Advanced/Recurrent Non Squamous NSCLC in Combination of Paclitaxel and Carboplatin",1,18,150,include,include,,,,,,include,,,,,,exclude,exclude,,,,exclude,1800,,,,,"        Inclusion Criteria:          -  Patients aged 18 years or older          -  Newly diagnosed advanced (stage IV) /recurrent non-squamous NSCLC for which they had             not received any systemic anti-cancer therapy for metastatic disease          -  Histologically or cytologically confirmed diagnosis of predominantly non-squamous             NSCLC          -  Existence of at least 1 measurable lesion by RECIST v1.1          -  Adequate hematological, renal and liver function          -  Eastern Collaborative Oncology Group Performance Status (ECOG PS) 0 or 1          -  Life expectancy longer than 6 months        Exclusion Criteria:          -  Small cell lung cancer (SCLC) or combination SCLC and NSCLC. Squamous-cell tumors and             mixed adenosquamous carcinomas of predominantly squamous nature          -  Any unresolved toxicities from prior systemic therapy          -  Known sensitizing EGFR mutations or EML4-ALK translocation positive mutations          -  Previous dosing with vascular endothelial growth factor (VEGF) inhibitor          -  Known hypersensitivity to any excipients of the Investigational Products (IPs) and             combination chemotherapy          -  Use of prohibited concomitant medication          -  Known Hepatitis B, Hepatitis C, or human immunodeficiency virus (HIV) infection          -  Fertile men or women of childbearing potential not using adequate contraception.        Other inclusion/exclusion criteria may apply.      "
NCT02810457,Phase 3,Centus Biotherapeutics Limited,Industry,"A Randomised, Parallel, Double Blinded Study to Compare the Efficacy and Safety of FKB238 to Avastinå¨ In 1st Line Treatment for Patients With Advanced/Recurrent Non Squamous NSCLC in Combination of Paclitaxel and Carboplatin",2,18,150,include,include,,,include,include,include,,,,,require,,exclude,exclude,,,,exclude,1800,,,,,"        Inclusion Criteria:          -  Patients aged 18 years or older          -  Newly diagnosed advanced (stage IV) /recurrent non-squamous NSCLC for which they had             not received any systemic anti-cancer therapy for metastatic disease          -  Histologically or cytologically confirmed diagnosis of predominantly non-squamous             NSCLC          -  Existence of at least 1 measurable lesion by RECIST v1.1          -  Adequate hematological, renal and liver function          -  Eastern Collaborative Oncology Group Performance Status (ECOG PS) 0 or 1          -  Life expectancy longer than 6 months        Exclusion Criteria:          -  Small cell lung cancer (SCLC) or combination SCLC and NSCLC. Squamous-cell tumors and             mixed adenosquamous carcinomas of predominantly squamous nature          -  Any unresolved toxicities from prior systemic therapy          -  Known sensitizing EGFR mutations or EML4-ALK translocation positive mutations          -  Previous dosing with vascular endothelial growth factor (VEGF) inhibitor          -  Known hypersensitivity to any excipients of the Investigational Products (IPs) and             combination chemotherapy          -  Use of prohibited concomitant medication          -  Known Hepatitis B, Hepatitis C, or human immunodeficiency virus (HIV) infection          -  Fertile men or women of childbearing potential not using adequate contraception.        Other inclusion/exclusion criteria may apply.      "
NCT02775435,Phase 3,Merck Sharp & Dohme Corp.,Industry,"A Randomized, Double-Blind, Phase III Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in First Line Metastatic Squamous Non-small Cell Lung Cancer Subjects (KEYNOTE-407)",1,18,150,,,include,,,,,include,,,,,,,,,,,exclude,1800,,,,,"        Inclusion Criteria:          -  Has a histologically or cytologically confirmed diagnosis of stage IV (M1a or             M1b-American Joint Committee on Cancer [AJCC] 7th edition) squamous NSCLC.          -  Has measurable disease based on RECIST 1.1 as determined by the local site             investigator/radiology assessment.          -  Has not received prior systemic treatment for metastatic NSCLC.          -  Has provided tumor tissue from locations not radiated prior to biopsy.          -  Has a life expectancy of at least 3 months.          -  Has a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG)             Performance Status.          -  Has adequate organ function.          -  If female of childbearing potential, is willing to use an adequate method of             contraception for the course of the study through 120 days after the last dose of             study drug.          -  If male with a female partner(s) of child-bearing potential, must agree to use an             adequate method of contraception starting with the first dose of study drug through             120 days after the last dose of study drug. Males with pregnant partners must agree             to use a condom; no additional method of contraception is required for the pregnant             partner.        Exclusion Criteria:          -  Has non-squamous histology NSCLC.          -  Is currently participating and receiving study therapy or has participated in a study             of an investigational agent and received study therapy or used an investigational             device within 4 weeks prior to administration of pembrolizumab.          -  Before the first dose of study drug: a) Has received prior systemic cytotoxic             chemotherapy for metastatic disease; b) Has received other targeted or biological             antineoplastic therapy (e.g., erlotinib, crizotinib, cetuximab) for metastatic             disease; c) Has had major surgery (<3 weeks prior to first dose).          -  Received radiation therapy to the lung that is > 30 Gy within 6 months of the first             dose of study drug.          -  Completed palliative radiotherapy within 7 days of the first dose of study drug.          -  Is expected to require any other form of antineoplastic therapy while on study.          -  Has received a live-virus vaccination within 30 days of planned treatment start.          -  Has a known history of prior malignancy except if the participant has undergone             potentially curative therapy with no evidence of that disease recurrence for 5 years             since initiation of that therapy.          -  Has known active central nervous system (CNS) metastases and/or carcinomatous             meningitis.          -  Has pre-existing peripheral neuropathy that is ‰ä´ Grade 2 by Common Terminology             Criteria for Adverse Events (CTCAE) version 4 criteria.          -  Previously had a severe hypersensitivity reaction to treatment with another             monoclonal antibody.          -  Has a known sensitivity to any component of carboplatin or paclitaxel or             nab-paclitaxel.          -  Has active autoimmune disease that has required systemic treatment in past 2 years.          -  Is on chronic systemic steroids.          -  Had prior treatment with any other anti-programmed cell death 1 (anti-PD-1), or             programmed cell death ligand 1 (PD-L1) or PD-L2 agent or an antibody or a small             molecule targeting other immuno-regulatory receptors or mechanisms.          -  Has participated in any other pembrolizumab trial and has been treated with             pembrolizumab.          -  Has an active infection requiring therapy.          -  Has known history of Human Immunodeficiency Virus (HIV).          -  Has known active Hepatitis B or C. Active Hepatitis B.          -  Is, at the time of signing informed consent, a regular user (including ""recreational             use"") of any illicit drugs or has a recent history (within the last year) of             substance abuse (including alcohol).          -  Has interstitial lung disease or a history of pneumonitis that required oral or             intravenous glucocorticoids to assist with management.          -  Is pregnant or breastfeeding, or expecting to conceive or father children while on             study drug and for the required duration of contraception after the last dose of             study drug.      "
NCT02414139,Phase 2,Novartis Pharmaceuticals,Industry,"A Phase II, Multicenter, Four-cohort Study of Oral cMET Inhibitor INC280 in Adult Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Received One or Two Prior Lines of Systemic Therapy for Advanced/Metastatic Disease",1,18,150,include,include,include,,,,include,include,,,,,,exclude,exclude,,,,require,,,,,,"        Inclusion Criteria:          -  Stage IIIB or IV NSCLC (any histology) at the time of study entry          -  Histologically or cytologically confirmed diagnosis of NSCLC that is:               1. EGFR wt as per patient standard of care by a validated test               2. AND ALK-negative rearrangement as part of the patient standard of care by a                  validated test               3. AND (by central assessment) either:                    -  Cohort 1: cMET GCN ‰ä´ 6 or                    -  Cohort 2: cMET GCN ‰ä´4 and < 6, or                    -  Cohort 3: cMET GCN < 4, or                    -  Cohort 4: Patients with cMET mutations regardless of cMET GCN          -  Patients must have received one or two prior lines of systemic therapy          -  At least one measurable lesion as defined by RECIST 1.1.          -  Patients must have recovered from all toxicities related to prior anticancer             therapies to grade ‰ä_ 1 (CTCAE v 4.03). Patients with any grade of alopecia are             allowed to enter the study.          -  Patients must have adequate organ function          -  ECOG performance status (PS) of 0 or 1. Details and other protocol-defined inclusion             criteria may apply        Exclusion Criteria:          -  Prior treatment with crizotinib, or any other cMET or HGF inhibitor          -  Patients with characterized EGFR mutations that predict sensitivity to EGFR therapy,             including, but not limited to exon 19 deletions and exon 21 mutations.          -  Patients with characterized ALK-positive rearrangement.          -  Clinically significant, uncontrolled heart diseases.          -  Patients receiving treatment with medications that cannot be discontinued at least 1             week prior to first INC280 treatment and for the duration of the study:               -  Strong and moderate inhibitors of CYP3A4               -  Strong inducers of CYP3A4          -  Impairment of GI function or GI disease that may significantly alter the absorption             of INC280          -  Patients receiving treatment with any enzyme-inducing anticonvulsant.          -  Previous anti-cancer and investigational agents.          -  Pregnant or nursing women          -  Women of child-bearing potential, unless they are using highly effective methods of             contraception          -  Sexually active males unless they use a condom during intercourse        Other protocol-defined exclusion criteria may apply      "
NCT02544633,Phase 2,Mirati Therapeutics Inc.,Industry,"Phase 2, Parallel-Arm Study of MGCD265 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor",1,18,150,include,include,include,,,include,include,include,,,,,,exclude,exclude,,,,require,,,,,,"        Inclusion Criteria:          -  Diagnosis of non-small cell lung cancer          -  Metastatic or locally advanced disease          -  Prior platinum chemotherapy          -  Test result showing genetic change in MET tumor gene          -  At least one tumor that can be measured on a radiographic scan        Exclusion Criteria:          -  Prior treatment with inhibitor of MET or HGF          -  Prior positive test for EGFR mutation or ALK gene rearrangement          -  Uncontrolled tumor in the brain      "
NCT02674568,Phase 2,Stemcentrx,Industry,"An Open-label, Single-Arm, Phase 2 Study Evaluating the Efficacy, Safety and Pharmacokinetics of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY)",1,18,150,,,,include,,,,,,include,,,,,,,,,require,,,,,,"        Inclusion Criteria:          1. Adult aged 18 years or older          2. Histologically confirmed small-cell lung cancer (SCLC) with documented disease             progression after at least 2 prior systemic regimens, including at least one             platinum-based regimen          3. DLL3-expressing SCLC based on central immunohistochemistry (IHC) assessment of banked             or otherwise representative tumor tissue. Positive is defined as staining in ‰ä´ 1% of             tumor cells.          4. Measurable disease as defined by RECIST 1.1          5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1          6. Minimum life expectancy of at least 12 weeks          7. Subjects with a history of central nervous system (CNS) metastases must have             documentation of stable or improved status based on brain imaging for at least 2             weeks after completion of definitive treatment and within 2 weeks prior to first dose             of Study Drug, off or on a stable dose of corticosteroids.          8. Recovery to Grade 1 of any clinically significant toxicity (excluding alopecia) prior             to initiation of study drug administration          9. Adequate hematologic and organ function as confirmed by laboratory values         10. Last dose of any prior therapy administered by the following time intervals before             the first dose of study drug:               -  Chemotherapy, small molecule inhibitors, radiation, and/or other investigational                  anticancer agents (excluding investigational monoclonal antibodies): 2 weeks               -  Immune-checkpoint inhibitors (i.e., anti-PD-1, anti-PD-L1, or anti-CTLA-4): 4                  weeks               -  Other monoclonal antibodies, antibody-drug conjugates, radioimmunoconjugates, or                  T-cell or other cell-based therapies: 4 weeks (2 weeks with documented disease                  progression)         11. Females of childbearing potential must have a negative beta human chorionic             gonadotropin (ë_-hCG) pregnancy test result within 7 days prior to the first dose of             study drug. Females of non-childbearing potential are those who are postmenopausal             greater than 1 year or who have had a bilateral tubal ligation or hysterectomy.        Exclusion Criteria:          1. Any significant medical condition, including any suggested by screening laboratory             findings that, in the opinion of the investigator or sponsor, may place the subject             at undue risk from the study, including but not necessarily limited to uncontrolled             hypertension and/or diabetes, clinically significant pulmonary disease (e.g., chronic             obstructive pulmonary disease requiring hospitalization within 6 months) or             neurological disorder (e.g., seizure disorder active within 6 months)          2. Documented history of a cerebral vascular event (stroke or transient ischemic             attack), unstable angina, myocardial infarction, or cardiac symptoms consistent with             New York Heart Association (NYHA) Class III-IV within 6 months prior to their first             dose of study drug          3. Recent or ongoing serious infection, including:               -  Any active grade 3 or higher (per NCI CTCAE version 4.03) viral, bacterial, or                  fungal infection within 2 weeks of the first dose of the study drug. Routine                  antimicrobial prophylaxis is permitted.               -  Known seropositivity for or active infection by human immunodeficiency virus                  (HIV)               -  Active Hepatitis B (by surface antigen expression or polymerase chain reaction)                  or C (by polymerase chain reaction) infection or on hepatitis-related antiviral                  therapy within 6 months of first dose of study drug.          4. Women who are breastfeeding          5. Systemic therapy with corticosteroids at >20 mg/day prednisone or equivalent within 1             week prior to the first dose of study drug          6. History of another invasive malignancy that has not been in remission for at least 3             years. Exceptions to the 3 year limit include nonmelanoma skin cancer, curatively             treated localized prostate cancer, and cervical cancer in situ on biopsy or squamous             intraepithelial lesion on PAP smear          7. Prior exposure to a pyrrolobenzodiazepine (PBD)-based drug, or known hypersensitivity             to rovalpituzumab tesirine or excipient contained in the drug formulation, unless             undergoing retreatment with rovalpituzumab tesirine in the context of this protocol      "
NCT02735980,Phase 2,Eli Lilly and Company,Industry,A Phase 2 Study of LY2606368 in Patients With Extensive Stage Disease Small Cell Lung Cancer,1,18,150,,,,include,,,,,,include,,,,,,,,,,,,,,,"        Inclusion Criteria:          -  Have ED-SCLC and have received a prior platinum-based regimen          -  Participants in Cohort 1 must have had an objective response to prior platinum-based             therapy with subsequent progression ‰ä´90 days after the last dose of platinum          -  Participants in Cohort 2 must have either not had an objective response to prior             platinum based therapy or had progression <90 days after the last dose of platinum          -  Have a performance status of 0 to 1 on the Eastern Cooperative Oncology Group scale        Exclusion Criteria:          -  Have received more than 2 prior therapies for ED-SCLC (including immunotherapy,             targeted therapies, or chemotherapy)          -  Have symptomatic central nervous system (CNS) malignancy or metastasis. Asymptomatic             participants with treated CNS metastases are eligible for this study if they are not             currently receiving corticosteroids to treat CNS metastases          -  Have previously completed or withdrawn from this study or any other study             investigating prexasertib or a checkpoint kinase I (CHK1) inhibitor or have shown             hypersensitivity to any of the components of the prexasertib formulation          -  Have a serious cardiac condition      "
NCT02336451,Phase 2,Novartis Pharmaceuticals,Industry,"A Phase II, Multi-center, Open-label, Five-arm Study to Evaluate the Efficacy and Safety of Oral Ceritinib Treatment for Patients With ALK-positive Non-small Cell Lung Cancer (NSCLC) Metastatic to the Brain and/or to Leptomeninges",1,18,150,include,include,include,,,,,include,,,,,,require,,,,,,,,,,,"        Inclusion Criteria:          -  Histologically or cytologically confirmed diagnosis of metastatic NSCLC according to             the 7th edition of the AJCC Cancer Staging Manual. In addition, the NSCLC must harbor             an ALK rearrangement, as assessed using the FDA approved Vysis ALK Break Apart FISH             Probe Kit (Abbott Molecular Inc.) test and scoring algorithm (including positivity             criteria). If documentation of ALK rearrangement as described above is not locally             available, a test to confirm ALK rearrangement must be performed by a Novartis             designated central laboratory. Patients must wait for the central laboratory result             of the ALK rearrangement status before initiating treatment with ceritinib          -  At least one extracranial measurable lesion as defined by RECIST 1.1. A previously             irradiated site lesion may only be counted as a target lesion if there is clear sign             of progression since the irradiation.          -  Patients may or may not have neurological symptoms but must be able to swallow and             retain oral medication. Be neurologically stable within at least 1 week prior to the             first dose of study drug.          -  Patients may have received prior chemotherapy, crizotinib (other ALK inhibitors are             not allowed), biologic therapy or other investigational agents. Patients must have             recovered from all toxicities related to prior anticancer therapies to grade ‰ä_ 1             (CTCAE v 4.03). Patients with any grade of alopecia are allowed to enter the study.          -  Patient has life expectancy ‰ä´ 6 weeks.          -  Patient has a WHO performance status 0-2.        Patients in Arm 1 to 4 must also meet the following inclusion criteria:        - Patients must have active brain metastases from NSCLC, confirmed by Gadolinium-enhanced        MRI without concomitant leptomeningeal carcinomatosis. Dose of steroids must be stable for        5 days before the baseline brain MRI.        Patients in Arm 5 must also meet the following inclusion criteria:        - Patients must be diagnosed with leptomeningeal carcinomatosis.        Exclusion Criteria:          -  Patients who need whole brain radiation to control the brain metastases. Patients             will not be eligible unless treated brain lesions are progressive or new brain             lesions are observed since the post whole brain radiation therapy MRI.          -  Planning of any brain local treatment (including but not limited to surgery,             stereotactic radiosurgery, whole brain radiation, intrathecal chemotherapy) following             the administration of the first dose of study drug.          -  Patient with a concurrent malignancy or history of a malignant disease other than             NSCLC that has been diagnosed and/or required therapy within the past 3 years.             Exceptions to this exclusion include the following: completely resected basal cell             and squamous cell skin cancers, and completely resected carcinoma in situ of any             type.          -  Patient has impairment of GI function or GI disease that may significantly alter the             absorption of ceritinib (e.g., ulcerative diseases, uncontrolled nausea, vomiting,             diarrhea, or malabsorption syndrome).          -  Patient is receiving unstable or increasing doses of corticosteroids.          -  Patient has other severe, acute, or chronic medical conditions including uncontrolled             diabetes mellitus or psychiatric conditions or laboratory abnormalities that in the             opinion of the investigator may increase the risk associated with study             participation, or that may interfere with the interpretation of study results.        Other protocol-defined inclusion/exclusion criteria may apply.      "
NCT02450539,Phase 2,Eli Lilly and Company,Industry,A Randomized Phase 2 Study of Abemaciclib (LY2835219) Versus Docetaxel in Patients With Stage IV Squamous Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy,1,18,150,include,include,include,,,,,include,,,,,,,,,,,require,,,,,,"        Inclusion Criteria:          -  Confirmed diagnosis of stage IV NSCLC.          -  Have progressed during or after platinum-based chemotherapy for advanced disease.          -  Have not received prior treatment with docetaxel.          -  Have availability of adequate formalin-fixed paraffin-embedded (FFPE) tumor derived             material.          -  Have adequate organ function including hematology, renal, and liver.          -  Have good performance score (0-1).          -  Have measureable disease per RECIST 1.1.          -  Agree to use a reliable medically approved method of birth control.        Exclusion Criteria:          -  Have received prior treatment with any cyclin dependent kinase (CDK) 4 and 6             inhibitor or participated in a clinical trial with a CDK 4 and 6 inhibitor and the             treatment administered is not known.          -  Are currently receiving treatment in a clinical trial involving an investigational             product or non-approved use of a drug or device.          -  Have the presence of unstable central nervous system (CNS) metastasis.          -  Have had major surgery (excluding biopsy) < 28 days of the initial dose of study             drug.      "
NCT02259582,Phase 2,"OncoMed Pharmaceuticals, Inc.",Industry,"A 2-Arm Phase 2 Double-Blind Randomized Study of Carboplatin, Pemetrexed Plus Placebo Versus Carboplatin, Pemetrexed Plus Truncated Demcizumab as First-Line Treatment in Subjects With Stage IV Non-Squamous Non-Small Cell Lung Cancer",1,21,150,include,include,,,,,,include,,,,,,exclude,exclude,,exclude,1800,exclude,1800,,,,,"        Main Inclusion Criteria:          1. Signed Informed Consent Form          2. Histologically or cytologically confirmed Stage IV non-squamous NSCLC          3. Availability of FFPE tumor tissue, either fresh core-needle-biopsied or archived          4. Age > or = to 21 years          5. ECOG performance status of 0 or 1          6. Disease that is measurable per RECIST v1.1          7. Adequate organ and marrow function          8. For women of childbearing potential, agreement to use two effective forms of             contraception        Main Exclusion Criteria:          1. Histologically or cytologically documented, advanced, mixed non-small cell and small             cell tumors or mixed adenosquamous carcinomas          2. NSCLC with known EGFR mutation or anaplastic lymphoma kinase (ALK) gene translocation             (such as EML4-ALK)          3. Prior or ongoing therapy (including chemotherapy, antibody therapy, tyrosine kinase             inhibitors, radiotherapy, immunotherapy, hormonal therapy, or investigational             therapy) for the treatment of Stage IV non-squamous NSCLC          4. Evidence of tumor invading major blood vessels, cavitation of one or more pulmonary             tumor mass(es) ortracheo-esophageal fistula          5. Brain metastases, leptomeningeal disease, uncontrolled seizure disorder, or active             neurologic disease          6. Malignancies other than non-squamous NSCLC successfully treated within 3 years prior             to randomization (with the exception of certain early-stage cancers)          7. History of a significant allergic reaction attributed to humanized or human             monoclonal antibody therapy          8. Significant intercurrent illness defined as an illness that may result in the             subject's death prior to their death from non-squamous NSCLC and/or significantly             limit their ability to comply with the requirements of this study          9. Recent hemoptysis >2.5 mL or serious bleeding from another site, known bleeding             disorder or coagulopathy or therapeutic anti-coagulation         10. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days             prior to randomization, or anticipation of need for major surgical procedure during             the course of the study      "
NCT02387216,Phase 2,Merrimack Pharmaceuticals,Industry,"A Phase 2 Study of MM-121 in Combination With Docetaxel or Pemetrexed Versus Docetaxel or Pemetrexed Alone in Patients With Heregulin Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer",1,18,150,include,include,include,,,,include,include,,,,,,exclude,exclude,,,,,,,,,,"        Inclusion Criteria:          -  Patients with a diagnosis of cytologically or histologically confirmed NSCLC with             either metastatic disease (stage IV) or Stage IIIB disease not amenable to surgery             with curative intent          -  Failed an anti-PD-1 or anti-PD-L1 therapy and has not received more than 3 prior             systemic therapies for primary or recurrent disease          -  Tissue submitted for HRG-biomarker testing          -  ECOG performance status (PS) of 0 or 1        Exclusion Criteria:          -  Known ALK mutation          -  Presence of exon 19 deletion or exon 21 (L858R) substitution of the EGFR gene          -  Received >3 prior systemic anti-cancer drug regimen for locally advanced disease          -  Prior treatment with an anti-ErbB3 antibody          -  CTCAE grade 3 or higher peripheral neuropathy          -  Symptomatic CNS metastases or CNS metastases requiring steroids          -  Any other active malignancy requiring systemic therapy          -  Clinically significant cardiac disease      "
NCT02250326,Phase 2,Celgene Corporation,Industry,"A Phase 2, Open-label, Multicenter Study to Assess Safety and Efficacy of Second/Third-line Treatment With Nabå¨-Paclitaxel (ABI-007) in Combination With Epigenetic Modifying Therapy of CC-486 , or Immunotherapy of Durvalumab (MEDI4736), or as Monotherapy in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)",1,18,150,include,include,include,,,,,include,,,,,,exclude,exclude,,,,require,,,,,,"        Inclusion Criteria: 1.Age ‰ä´ 18 years the time of signing the Informed Consent Form (ICF).        2. Understand and voluntarily provide written informed consent prior to the conduct of any        study related assessments/procedures.        3. Able to adhere to the study visit schedule and other protocol requirements. 4.        Histologically or cytologically confirmed advanced NSCLC who will receive study therapy as        second- or third-line of treatment for advanced disease.        5. No other current active malignancy requiring anticancer therapy. 6. Radiographically        documented measurable disease (defined by the presence of ‰ä´ 1 radiographically documented        measurable lesion).        7. One prior platinum-containing chemotherapy for metastatic or recurrent NSCLC unless        patients are ineligible to receive it. Patients may have received no more than one line of        chemotherapy; immunotherapy in prior line of treatment (first or second line) is allowed.        Absolute neutrophil count (ANC) ‰ä´ 1500 cells/mm3.        8. Platelets ‰ä´ 100,000 cells/mm3. 9. Hemoglobin (Hgb) ‰ä´ 9 g/dL. 10. Aspartate transaminase        (AST/serum glutamic oxaloacetic transaminase [SGOT]) and alanine transaminase (ALT/serum        glutamic pyruvic transaminase [SGPT]) ‰ä_ 2.5 ÌÑ upper limit of normal range (ULN) or ‰ä_ 5.0 ÌÑ        ULN if liver metastases.        11. Total bilirubin ‰ä_ 1.5 ULN (unless there is a known history of Gilberts Syndrome).        12. Serum creatinine ‰ä_ 1.5 x ULN, or calculated creatinine clearance ‰ä´ 60 mL/min (if renal        impairment is suspected 24-hour urine collection for measurement is required).        13. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1. 14. Eastern        Cooperative Oncology Group (ECOG) performance status 0 or 1. 15. Females of childbearing        potential [defined as a sexually mature woman who (1) have not undergone hysterectomy (the        surgical removal of the uterus) or bilateral oophorectomy (the surgical removal of both        ovaries) or (2) have not been naturally postmenopausal for at least 24 consecutive months        (ie, has had menses at any time during the preceding 24 consecutive months)] must:          1. Have a negative pregnancy test (ÌÙ-hCG) as verified by the study doctor within 72             hours prior to starting study therapy. She must agree to ongoing pregnancy testing             during the course of the study, and after end of study therapy. This applies even if             the subject practices true abstinence* from heterosexual contact.          2. Either commit to true abstinence* from heterosexual contact (which must be reviewed             on a monthly basis) or agree to use, and be able to comply with, effective             contraception without interruption, 28 days prior to starting investigational product             (IP), during the study therapy (including dose interruptions), and for 3 months after             discontinuation of study therapy.        Male subjects must:          1. Practice true abstinence* or agree to use a condom during sexual contact with a             pregnant female or a female of childbearing potential while participating in the             study, during dose interruptions and for at least 6 months following IP             discontinuation, even if he has undergone a successful vasectomy.          2. Refrain from semen or sperm donation while taking durvalumab and for at least 3             months after the last dose of durvalumab.             16. Females must abstain from breastfeeding during study participation and 3 months             after IP discontinuation.             Exclusion Criteria:               -  The presence of any of the following will exclude a subject from enrollment:                    1. Refractory to prior taxane therapy for advanced disease. Prior taxane used                       in the adjuvant setting does not exclude eligibility, provided there is no                       disease recurrence within 12 months upon completion of chemotherapy in that                       setting.                    2. Evidence of active brain metastases, including leptomeningeal involvement                       (prior evidence of brain metastasis are permitted only if asymptomatic and                       clinically stable for at least 8 weeks following completion of therapy).                       MRI of the brain (or CT scan w/contrast) is preferred.                    3. Only evidence of disease is non-measurable at study entry.                    4. Known activating EGFR mutations (such as exon 19 deletions or L858R).                    5. Known activating EML4-ALK mutations.                    6. Preexisting peripheral neuropathy of Grade > 2 (per NCI CTCAE v4.0).                    7. Any unresolved toxicity NCI CTCAE Grade ‰ä´ 2 from previous anticancer                       therapy with the exception of alopecia, vitiligo, and the laboratory values                       defined in the inclusion criteria.                    8. Venous thromboembolism within 1 month prior to Cycle 1 Day 1.                    9. Current congestive heart failure (New York Heart Association Class II-IV).                   10. History of the following within 6 months prior to Cycle 1 Day 1: a                       myocardial infarction, severe/unstable angina pectoris, coronary/peripheral                       artery bypass graft, New York Heart Association (NYHA) Class III-IV heart                       failure, uncontrolled hypertension, clinically significant cardiac                       dysrhythmia or clinically significant electrocardiogram (ECG) abnormality,                       cerebrovascular accident, transient ischemic attack, or seizure disorder.                   11. Known hepatitis B or C virus (HBV/HCV) infection, known history of human                       immunodeficiency virus (HIV) infection, or receiving immunosuppressive or                       myelosuppressive medications that would in the opinion of the investigator,                       increase the risk of serious neutropenic complications, history of active                       primary immunodeficiency, active tuberculosis (clinical evaluation that                       includes clinical history, physical examination and radiographic findings,                       and TB testing in line with local practice).                   12. Active, uncontrolled bacterial, viral, or fungal infection(s) requiring                       systemic therapy, defined as ongoing signs/symptoms related to the                       infection without improvement despite appropriate antibiotics, antiviral                       therapy, and/or other treatment.                   13. History of interstitial lung disease, history of slowly progressive dyspnea                       and unproductive cough, sarcoidosis, silicosis, idiopathic pulmonary                       fibrosis, or pulmonary hypersensitivity pneumonitis or multiple allergies.                       Any lung disease that may interfere with the detection or management of                       suspected drug-related pulmonary toxicity.                   14. Subject has a clinically significant malabsorption syndrome, persistent                       diarrhea, or known sub-acute bowel obstruction > NCI CTCAE Grade 2, despite                       medical management.                   15. Treatment with any chemotherapy, investigational product, biologic or                       hormonal therapy for cancer treatment within 28 days prior to signing the                       ICF. Concurrent use of hormonal therapy for non-cancer-related conditions                       (e.g. hormone replacement therapy) is acceptable.                   16. History of or suspected allergy to any IP or their excipients.                   17. Major surgical procedure (as defined by the Investigator) within 28 days                       prior to the first dose of IP. Note: Local surgery of isolated lesions for                       palliative intent is acceptable.                   18. Currently enrolled in any other clinical protocol or investigational trial                       that involves administration of experimental therapy and/or therapeutic                       devices.                   19. Any other clinically significant medical condition, psychiatric illness,                       and/or organ dysfunction that will interfere with the administration of the                       therapy according to this protocol or which, in the views of investigator,                       preclude combination chemotherapy.                   20. Any other malignancy within 5 years prior to randomization/treatment                       assignement, or advanced malignant hepatic tumors, with the exception of                       adequately treated squamous cell carcinoma of the skin, in-situ carcinoma                       of the cervix, uteri, non-melanomatous skin cancer, carcinoma in situ of                       the breast, or incidental histological finding of prostate cancer (TNM                       Classification of Malignant Tumours (TNM) stage of T1a or T1b). (All                       treatment of which should have been completed 6 months prior to signing                       ICF).                   21. Radiotherapy ‰ä_ 4 weeks or limited field radiation for palliation ‰ä_ 2 weeks                       prior to starting IP, and/or from whom ‰ä´ 30% of the bone marrow was                       irradiated. Prior radiation therapy to a target lesion is permitted only if                       there has been clear progression of the lesion since radiation was                       completed.                   22. Any condition including the presence of laboratory abnormalities, which                       places the subject at unacceptable risk if he/she were to participate in                       the study.                   23. Any medical condition that confounds the ability to interpret data from the                       study.                   24. Female patients who are pregnant or breastfeeding or female patients of                       reproductive potential who are not willing to employ effective birth                       control from screening to 90 days after the last dose of durvalumab.                   25. Male patients of reproductive potential who are not willing to employ                       effective birth control from screenin to 90 days after the last dose of                       durvalumab and from screening to 6 months after the last dose of of                       nab-paclitaxel.                   26. History of allogenic organ transplantation.                   27. Active or prior documented autoimmune or inflammatory disorders (including                       inflammatory bowel disease [eg, colitis or Crohn's disease], diverticulitis                       [with the exception of diverticulosis], celiac disease, irritable bowel                       disease, or other serious gastrointestinal chronic conditions associated                       with diarrhea, systemic lupus erythematosus, sarcoidosis syndrome, or                       Wegener's syndrome [granulomatosis with polyangiitis, Graves' disease,                       rheumatoid arthritis, hypophysitis, uveitis, etc]) within the past 3 years                       prior to the start of treatment. The following are exceptions to this                       criterion:               -  Patients with vitiligo or alopecia               -  Patients with hypothyroidism (eg, following Hashimoto's syndrome) stable on                  hormone replacement               -  Any chronic skin condition that does not require systemic therapy               -  Patients without active disease in the last 5 years may be included but only                  after consultation with the study physician 28. Current or prior use of                  immunosuppressive medication within 14 days before the first dose of durvalumab.                  The following are exceptions to this criterion:               -  Intranasal, inhaled, topical steroids, or local steroid injections (eg, intra                  articular injection)               -  Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of                  prednisone or its equivalent               -  Steroids as premedication for hypersensitivity reactions (eg, CT scan                  premedication) 29. Receipt of live attenuated vaccine within 30 days prior to                  the first dose of IP. Note: Patients, if enrolled, should not receive live                  vaccine during the study and up to 30 days after the last dose of IP.                  30. Prior enrollment and treatment in a previous durvalumab clinical study. 31.                  Patients who have received prior anti-PD-1 or anti PD-L1:               -  Must not have experienced a toxicity that led to permanent discontinuation of                  prior immunotherapy.               -  All AEs while receiving prior immunotherapy must have completely resolved or                  resolved to baseline prior to screening for this study.               -  Must not have experienced a ‰ä´ Grade 3 immune related AE or an immune related                  neurologic or ocular AE of any grade while receiving prior immunotherapy. NOTE:                  Subjects with endocrine AE of ‰ä_ Grade 2 are permitted to enroll if they are                  stably maintained on appropriate replacement therapy and are asymptomatic.               -  Must not have required the use of additional immunosuppression other than                  corticosteroids for the management of an AE, not have experienced recurrence of                  an AE if re-challenged, and not currently require maintenance doses of > 10 mg                  prednisone or equivalent per day.      "
NCT02659059,Phase 2,Bristol-Myers Squibb,Industry,"An Open-Label, Single Arm Phase II Study of Nivolumab in Combination With Ipilimumab as First Line-therapy in Stage IV Non-Small Cell Lung Cancer (NSCLC)",1,18,150,include,include,include,,,,include,include,,,,,,,,,,,,,,,,,"        For more information regarding Bristol-Myers Squibb (BMS) Clinical Trial participation,        please visit www.BMSStudyConnect.com        Inclusion Criteria:          -  Men and Women ‰ä´ 18 years of age          -  Diagnosed with stage IV Non-Small Cell Lung Cancer          -  Diagnosed with recurrent stage IIIB non-small cell lung cancer and failed previous             concurrent chemoradiation with no further curative options.        Exclusion Criteria:          -  Subjects with untreated CNS metastases are excluded.          -  Subjects with carcinomatous meningitis          -  Subjects with an active, known or suspected autoimmune disease.          -  Subjects with a condition requiring systemic treatment with either corticosteroids (             > 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14             days of first treatment.          -  Women who are pregnant, plan to become pregnant, and/or breastfeed during the study.        Other protocol defined inclusion/exclusion criteria could apply      "
NCT02200757,Phase 2,CytRx,Industry,"A Multicenter, Randomized, Open-Label Phase 2b Study to Investigate the Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer Who Either Relapsed or Were Refractory to Prior Chemotherapy",1,18,150,,,,include,,,,,include,include,,require,,,,,,,,,,,,,"        Inclusion Criteria:          1. Age ‰ä´18 years male or female.          2. Histological confirmation of SCLC.          3. Relapsed or refractory to no more than 1 course of a systemic therapy regimen and is             incurable by either surgery or radiation.          4. Capable of providing informed consent and complying with trial procedures.          5. ECOG PS 0-2.          6. Life expectancy >8 weeks.          7. Measurable tumor lesions according to RECIST 1.1 criteria.[22]          8. Women must not be able to become pregnant (e.g. post-menopausal for at least 1 year,             surgically sterile, or practicing adequate birth control methods) for the duration of             the study. (Adequate contraception includes: oral contraception, implanted             contraception, intrauterine device implanted for at least 3 months, or barrier method             in conjunction with spermicide.)          9. Males and their female partner(s) of child-bearing potential must use 2 forms of             effective contraception (see Inclusion 8 plus condom or vasectomy for males) from the             last menstrual period of the female partner during the study treatment and for 6             months after the final dose of study treatment.         10. Women of child bearing potential must have a negative serum or urine pregnancy test             at the Screening Visit and be non-lactating.         11. Accessibility to the site that ensures the subject will be able to keep all             study-related appointments.        Exclusion Criteria:          1. Prior exposure to >375 mg/m2 of doxorubicin or liposomal doxorubicin.          2. Prior treatment with topotecan.          3. Palliative surgery and/or radiation treatment < 21 days prior to date of             randomization.          4. Exposure to any investigational agent within 30 days of date of randomization.          5. Exposure to any systemic chemotherapy within 21 days of date of randomization.          6. Active (symptomatic) central nervous system (CNS) metastasis.          7. History of other malignancies except cured basal cell carcinoma, cutaneous squamous             cell carcinoma, melanoma in situ, superficial bladder cancer or carcinoma in situ of             the cervix unless documented free of cancer for ‰ä´3 years.          8. Laboratory values: Screening serum creatinine >1.5ÌÑupper limit of normal (ULN),             alanine aminotransferase (ALT) >3ÌÑULN or >5ÌÑULN if liver metastases are present,             total bilirubin >2ÌÑULN, absolute neutrophil count (ANC) <1,500/mm3, platelet             concentration <100,000/mm3, hemoglobin <9 g/dL, albumin <2 gm/dL.          9. Anion gap > 16 meq/L or arterial blood pH < 7.30.         10. Clinically evident congestive heart failure (CHF) > class II of the New York Heart             Association (NYHA) guidelines (Appendix D).         11. Current, serious, clinically significant cardiac arrhythmias, defined as the             existence of an absolute arrhythmia or ventricular arrhythmias classified as Lown             III, IV or V (Appendix F).         12. Baseline QTc >470 msec measured by Fridericia's formula (QTcF) and/or previous             history of QT prolongation while taking other medications. Concomitant use of             medications associated with a high incidence of QT prolongation is not allowed.         13. History or signs of active coronary artery disease with angina pectoris within the             last 6 months.         14. Serious myocardial dysfunction defined by ECHO as absolute left ventricular ejection             fraction (LVEF) below the institution's lower limit of predicted normal.         15. Known history of HIV infection.         16. Active, clinically significant serious infection requiring treatment with             antibiotics, anti-virals or anti-fungals.         17. Treatment with p-glycoprotein inhibitors such as cyclosporine A, elacridar,             ketoconazole, ritonavir, saquinavir.         18. Major surgery within 30 days prior to date of randomization.         19. Substance abuse or any condition that might interfere with the subject's             participation in the study or in the evaluation of the study results.         20. Any condition that is unstable and could jeopardize the subject's participation in             the study.      "
NCT02200757,Phase 2,CytRx,Industry,"A Multicenter, Randomized, Open-Label Phase 2b Study to Investigate the Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer Who Either Relapsed or Were Refractory to Prior Chemotherapy",2,18,150,,,,include,,,,,include,include,,,require,,,,,,,,,,,,"        Inclusion Criteria:          1. Age ‰ä´18 years male or female.          2. Histological confirmation of SCLC.          3. Relapsed or refractory to no more than 1 course of a systemic therapy regimen and is             incurable by either surgery or radiation.          4. Capable of providing informed consent and complying with trial procedures.          5. ECOG PS 0-2.          6. Life expectancy >8 weeks.          7. Measurable tumor lesions according to RECIST 1.1 criteria.[22]          8. Women must not be able to become pregnant (e.g. post-menopausal for at least 1 year,             surgically sterile, or practicing adequate birth control methods) for the duration of             the study. (Adequate contraception includes: oral contraception, implanted             contraception, intrauterine device implanted for at least 3 months, or barrier method             in conjunction with spermicide.)          9. Males and their female partner(s) of child-bearing potential must use 2 forms of             effective contraception (see Inclusion 8 plus condom or vasectomy for males) from the             last menstrual period of the female partner during the study treatment and for 6             months after the final dose of study treatment.         10. Women of child bearing potential must have a negative serum or urine pregnancy test             at the Screening Visit and be non-lactating.         11. Accessibility to the site that ensures the subject will be able to keep all             study-related appointments.        Exclusion Criteria:          1. Prior exposure to >375 mg/m2 of doxorubicin or liposomal doxorubicin.          2. Prior treatment with topotecan.          3. Palliative surgery and/or radiation treatment < 21 days prior to date of             randomization.          4. Exposure to any investigational agent within 30 days of date of randomization.          5. Exposure to any systemic chemotherapy within 21 days of date of randomization.          6. Active (symptomatic) central nervous system (CNS) metastasis.          7. History of other malignancies except cured basal cell carcinoma, cutaneous squamous             cell carcinoma, melanoma in situ, superficial bladder cancer or carcinoma in situ of             the cervix unless documented free of cancer for ‰ä´3 years.          8. Laboratory values: Screening serum creatinine >1.5ÌÑupper limit of normal (ULN),             alanine aminotransferase (ALT) >3ÌÑULN or >5ÌÑULN if liver metastases are present,             total bilirubin >2ÌÑULN, absolute neutrophil count (ANC) <1,500/mm3, platelet             concentration <100,000/mm3, hemoglobin <9 g/dL, albumin <2 gm/dL.          9. Anion gap > 16 meq/L or arterial blood pH < 7.30.         10. Clinically evident congestive heart failure (CHF) > class II of the New York Heart             Association (NYHA) guidelines (Appendix D).         11. Current, serious, clinically significant cardiac arrhythmias, defined as the             existence of an absolute arrhythmia or ventricular arrhythmias classified as Lown             III, IV or V (Appendix F).         12. Baseline QTc >470 msec measured by Fridericia's formula (QTcF) and/or previous             history of QT prolongation while taking other medications. Concomitant use of             medications associated with a high incidence of QT prolongation is not allowed.         13. History or signs of active coronary artery disease with angina pectoris within the             last 6 months.         14. Serious myocardial dysfunction defined by ECHO as absolute left ventricular ejection             fraction (LVEF) below the institution's lower limit of predicted normal.         15. Known history of HIV infection.         16. Active, clinically significant serious infection requiring treatment with             antibiotics, anti-virals or anti-fungals.         17. Treatment with p-glycoprotein inhibitors such as cyclosporine A, elacridar,             ketoconazole, ritonavir, saquinavir.         18. Major surgery within 30 days prior to date of randomization.         19. Substance abuse or any condition that might interfere with the subject's             participation in the study or in the evaluation of the study results.         20. Any condition that is unstable and could jeopardize the subject's participation in             the study.      "
NCT02584634,Phase 2,Pfizer,Industry,"A Phase 1b/2, Open Label, Dose Finding Study To Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab (msb0010718c) In Combination With Either Crizotinib Or Pf 06463922 In Patients With Advanced Or Metastatic Non Small Cell Lung Cancer Javelin Lung 101",1,18,150,include,include,include,,,,include,include,,,,require,,exclude,,,,,,,,,,,"        -  Inclusion Criteria          -  Diagnosis of advanced or metastatic NSCLC. Group A must be ALK negative NSCLC and             Group B must be ALK positive NSCLC          -  Group A at least one prior regimen of therapy          -  Group B any number of prior regimens.          -  Mandatory tumor tissue available          -  At least one measurable lesion          -  ECOG Performance status 0 or 1          -  Adequate bone marrow, renal, liver and pancreatic function          -  Negative pregnancy test for females of childbearing potential        Exclusion Criteria:          -  No prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or             anti-CTLA-4 antibody.          -  No Severe or Chronic medical conditions including gastrointestinal abnormalities or             significant cardiac history          -  No active infection requiring systemic therapy      "
NCT02584634,Phase 2,Pfizer,Industry,"A Phase 1b/2, Open Label, Dose Finding Study To Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab (msb0010718c) In Combination With Either Crizotinib Or Pf 06463922 In Patients With Advanced Or Metastatic Non Small Cell Lung Cancer Javelin Lung 101",2,18,150,include,include,include,,,,include,include,,,,,require,exclude,,,,,,,,,,,"        -  Inclusion Criteria          -  Diagnosis of advanced or metastatic NSCLC. Group A must be ALK negative NSCLC and             Group B must be ALK positive NSCLC          -  Group A at least one prior regimen of therapy          -  Group B any number of prior regimens.          -  Mandatory tumor tissue available          -  At least one measurable lesion          -  ECOG Performance status 0 or 1          -  Adequate bone marrow, renal, liver and pancreatic function          -  Negative pregnancy test for females of childbearing potential        Exclusion Criteria:          -  No prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or             anti-CTLA-4 antibody.          -  No Severe or Chronic medical conditions including gastrointestinal abnormalities or             significant cardiac history          -  No active infection requiring systemic therapy      "
NCT02584634,Phase 2,Pfizer,Industry,"A Phase 1b/2, Open Label, Dose Finding Study To Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab (msb0010718c) In Combination With Either Crizotinib Or Pf 06463922 In Patients With Advanced Or Metastatic Non Small Cell Lung Cancer Javelin Lung 101",3,18,150,include,include,include,,,,include,include,,,,,,require,,,,,,,,,,,"        -  Inclusion Criteria          -  Diagnosis of advanced or metastatic NSCLC. Group A must be ALK negative NSCLC and             Group B must be ALK positive NSCLC          -  Group A at least one prior regimen of therapy          -  Group B any number of prior regimens.          -  Mandatory tumor tissue available          -  At least one measurable lesion          -  ECOG Performance status 0 or 1          -  Adequate bone marrow, renal, liver and pancreatic function          -  Negative pregnancy test for females of childbearing potential        Exclusion Criteria:          -  No prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or             anti-CTLA-4 antibody.          -  No Severe or Chronic medical conditions including gastrointestinal abnormalities or             significant cardiac history          -  No active infection requiring systemic therapy      "
NCT02323126,Phase 2,Novartis Pharmaceuticals,Industry,"A Phase II, Multicenter, Open-label Study of EGF816 in Combination With Nivolumab in Adult Patients With EGFR Mutated Non-small Cell Lung Cancer and of INC280 in Combination With Nivolumab in Adult Patients With cMet Positive Non-small Cell Lung Cancer",1,18,150,include,include,include,,,,include,include,,,,,,,require,,,,,,,,require,,"        Inclusion Criteria:          -  Written informed consent must be obtained prior to any screening procedures          -  Presence of at least one measurable lesion according to RECIST v.1.1          -  ECOG performance status ‰ä_ 2          -  Patients with histologically documented locally advanced, recurrent and/or metastatic             NSCLC          -  Tumor tissue for determination and/or confirmation of genetic pre-requisites (i.e.             cMET positivity for Group 2 at any point in treatment; or EGFR T790M positivity post             progression on EGFR TKI) must be provided for analysis        Group 1 patients:          -  Patients with EGFR T790M NSCLC (adenocarcinoma)          -  Documented progression of disease according to RECIST v1.1 following primary standard             of care (e.g. erlotinib, gefitinib)        Group 2 patients:          -  Patients with EGFR wild-type, cMET positive NSCLC          -  Documented progression of disease according to RECIST v1.1 following primary standard             of care (e.g. platinum doublet).        Exclusion Criteria:        For Group1:        - Patients who have received more than one prior line of EGFR TKI therapy1        For Group 2:          -  Previous treatment with a c-MET inhibitor or HGF-targeting therapy          -  Patients with brain metastases. However, if radiation therapy and/or surgery has been             completed and serial evaluation by CT (with contrast enhancement) or MRI over a             minimum of one month demonstrates the disease to be stable and if the patient remains             must have no need for treatment with steroids          -  Patients who require emergent use of systemic steroids, chronic use of prednisone             (greater than 10mg or an equivalent steroid dose daily) or emergent surgery and/or             radiotherapy.          -  History of allergy or hypersensitivity to nivolumab components          -  Patients with an active, known or suspected autoimmune disease. Patients with type I             diabetes mellitis, hypothyroidism only requiring hormone replacement, skin disorders             (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or             conditions not expected to recur in the absence of an external trigger are permitted             to enroll          -  Patients with a condition requiring chronic systemic treatment with either             corticosteroids(> 10 mg daily prednisone equivalent) or other immunosuppressive             medications within 14 days of treatment start. Inhaled or topical steroids, and             adrenal replacement steroid doses> 10 mg daily prednisone equivalent, are permitted             in the absence of active autoimmune disease          -  Known history of testing positive for human immunodeficiency virus (HIV) or known             acquired immunodeficiency syndrome (AIDS)          -  Any positive test for hepatitis B virus or hepatitis C virus indicating acute or             chronic infection          -  Patients with interstitial lung disease that is symptomatic or may interfere with the             detection or management of suspected drug-related pulmonary toxicity          -  Patients with interstitial lung disease that is symptomatic or may interfere with the             detection or management of suspected drug-related pulmonary toxicity        Prior therapy:          -  Patients who have been treated with prior PD-1 and PD-L1 agents          -  Patients who previously received agents targeting c-MET and/or EGFR T790M Note:             Previous treatment with afatinib may be allowable after discussions between Novartis             and Investigator.          -  Patients with the following laboratory abnormalities:               -  Absolute Neutrophil Count (ANC) <1.5 x 109/L               -  Hemoglobin (Hgb) <9 g/dL               -  Platelets <100 x 109/L               -  Total bilirubin >1.5 x upper limit of normal (ULN). For patients with Gilbert's                  syndrome total bilirubin >2.5 x upper limit of normal (ULN)               -  Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) >3 x ULN               -  Serum creatinine >1.5 x ULN and/or measured or calculated creatinine clearance                  <75% LLN        Other protocol-related inclusion/exclusion criteria may apply.      "
NCT02323126,Phase 2,Novartis Pharmaceuticals,Industry,"A Phase II, Multicenter, Open-label Study of EGF816 in Combination With Nivolumab in Adult Patients With EGFR Mutated Non-small Cell Lung Cancer and of INC280 in Combination With Nivolumab in Adult Patients With cMet Positive Non-small Cell Lung Cancer",2,18,150,include,include,include,,include,include,,,,,,require,,,require,,,,,,,,require,,"        Inclusion Criteria:          -  Written informed consent must be obtained prior to any screening procedures          -  Presence of at least one measurable lesion according to RECIST v.1.1          -  ECOG performance status ‰ä_ 2          -  Patients with histologically documented locally advanced, recurrent and/or metastatic             NSCLC          -  Tumor tissue for determination and/or confirmation of genetic pre-requisites (i.e.             cMET positivity for Group 2 at any point in treatment; or EGFR T790M positivity post             progression on EGFR TKI) must be provided for analysis        Group 1 patients:          -  Patients with EGFR T790M NSCLC (adenocarcinoma)          -  Documented progression of disease according to RECIST v1.1 following primary standard             of care (e.g. erlotinib, gefitinib)        Group 2 patients:          -  Patients with EGFR wild-type, cMET positive NSCLC          -  Documented progression of disease according to RECIST v1.1 following primary standard             of care (e.g. platinum doublet).        Exclusion Criteria:        For Group1:        - Patients who have received more than one prior line of EGFR TKI therapy1        For Group 2:          -  Previous treatment with a c-MET inhibitor or HGF-targeting therapy          -  Patients with brain metastases. However, if radiation therapy and/or surgery has been             completed and serial evaluation by CT (with contrast enhancement) or MRI over a             minimum of one month demonstrates the disease to be stable and if the patient remains             must have no need for treatment with steroids          -  Patients who require emergent use of systemic steroids, chronic use of prednisone             (greater than 10mg or an equivalent steroid dose daily) or emergent surgery and/or             radiotherapy.          -  History of allergy or hypersensitivity to nivolumab components          -  Patients with an active, known or suspected autoimmune disease. Patients with type I             diabetes mellitis, hypothyroidism only requiring hormone replacement, skin disorders             (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or             conditions not expected to recur in the absence of an external trigger are permitted             to enroll          -  Patients with a condition requiring chronic systemic treatment with either             corticosteroids(> 10 mg daily prednisone equivalent) or other immunosuppressive             medications within 14 days of treatment start. Inhaled or topical steroids, and             adrenal replacement steroid doses> 10 mg daily prednisone equivalent, are permitted             in the absence of active autoimmune disease          -  Known history of testing positive for human immunodeficiency virus (HIV) or known             acquired immunodeficiency syndrome (AIDS)          -  Any positive test for hepatitis B virus or hepatitis C virus indicating acute or             chronic infection          -  Patients with interstitial lung disease that is symptomatic or may interfere with the             detection or management of suspected drug-related pulmonary toxicity          -  Patients with interstitial lung disease that is symptomatic or may interfere with the             detection or management of suspected drug-related pulmonary toxicity        Prior therapy:          -  Patients who have been treated with prior PD-1 and PD-L1 agents          -  Patients who previously received agents targeting c-MET and/or EGFR T790M Note:             Previous treatment with afatinib may be allowable after discussions between Novartis             and Investigator.          -  Patients with the following laboratory abnormalities:               -  Absolute Neutrophil Count (ANC) <1.5 x 109/L               -  Hemoglobin (Hgb) <9 g/dL               -  Platelets <100 x 109/L               -  Total bilirubin >1.5 x upper limit of normal (ULN). For patients with Gilbert's                  syndrome total bilirubin >2.5 x upper limit of normal (ULN)               -  Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) >3 x ULN               -  Serum creatinine >1.5 x ULN and/or measured or calculated creatinine clearance                  <75% LLN        Other protocol-related inclusion/exclusion criteria may apply.      "
NCT02323126,Phase 2,Novartis Pharmaceuticals,Industry,"A Phase II, Multicenter, Open-label Study of EGF816 in Combination With Nivolumab in Adult Patients With EGFR Mutated Non-small Cell Lung Cancer and of INC280 in Combination With Nivolumab in Adult Patients With cMet Positive Non-small Cell Lung Cancer",3,18,150,include,include,include,,,,include,include,,,,,,,exclude,,,,,,,,,,"        Inclusion Criteria:          -  Written informed consent must be obtained prior to any screening procedures          -  Presence of at least one measurable lesion according to RECIST v.1.1          -  ECOG performance status ‰ä_ 2          -  Patients with histologically documented locally advanced, recurrent and/or metastatic             NSCLC          -  Tumor tissue for determination and/or confirmation of genetic pre-requisites (i.e.             cMET positivity for Group 2 at any point in treatment; or EGFR T790M positivity post             progression on EGFR TKI) must be provided for analysis        Group 1 patients:          -  Patients with EGFR T790M NSCLC (adenocarcinoma)          -  Documented progression of disease according to RECIST v1.1 following primary standard             of care (e.g. erlotinib, gefitinib)        Group 2 patients:          -  Patients with EGFR wild-type, cMET positive NSCLC          -  Documented progression of disease according to RECIST v1.1 following primary standard             of care (e.g. platinum doublet).        Exclusion Criteria:        For Group1:        - Patients who have received more than one prior line of EGFR TKI therapy1        For Group 2:          -  Previous treatment with a c-MET inhibitor or HGF-targeting therapy          -  Patients with brain metastases. However, if radiation therapy and/or surgery has been             completed and serial evaluation by CT (with contrast enhancement) or MRI over a             minimum of one month demonstrates the disease to be stable and if the patient remains             must have no need for treatment with steroids          -  Patients who require emergent use of systemic steroids, chronic use of prednisone             (greater than 10mg or an equivalent steroid dose daily) or emergent surgery and/or             radiotherapy.          -  History of allergy or hypersensitivity to nivolumab components          -  Patients with an active, known or suspected autoimmune disease. Patients with type I             diabetes mellitis, hypothyroidism only requiring hormone replacement, skin disorders             (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or             conditions not expected to recur in the absence of an external trigger are permitted             to enroll          -  Patients with a condition requiring chronic systemic treatment with either             corticosteroids(> 10 mg daily prednisone equivalent) or other immunosuppressive             medications within 14 days of treatment start. Inhaled or topical steroids, and             adrenal replacement steroid doses> 10 mg daily prednisone equivalent, are permitted             in the absence of active autoimmune disease          -  Known history of testing positive for human immunodeficiency virus (HIV) or known             acquired immunodeficiency syndrome (AIDS)          -  Any positive test for hepatitis B virus or hepatitis C virus indicating acute or             chronic infection          -  Patients with interstitial lung disease that is symptomatic or may interfere with the             detection or management of suspected drug-related pulmonary toxicity          -  Patients with interstitial lung disease that is symptomatic or may interfere with the             detection or management of suspected drug-related pulmonary toxicity        Prior therapy:          -  Patients who have been treated with prior PD-1 and PD-L1 agents          -  Patients who previously received agents targeting c-MET and/or EGFR T790M Note:             Previous treatment with afatinib may be allowable after discussions between Novartis             and Investigator.          -  Patients with the following laboratory abnormalities:               -  Absolute Neutrophil Count (ANC) <1.5 x 109/L               -  Hemoglobin (Hgb) <9 g/dL               -  Platelets <100 x 109/L               -  Total bilirubin >1.5 x upper limit of normal (ULN). For patients with Gilbert's                  syndrome total bilirubin >2.5 x upper limit of normal (ULN)               -  Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) >3 x ULN               -  Serum creatinine >1.5 x ULN and/or measured or calculated creatinine clearance                  <75% LLN        Other protocol-related inclusion/exclusion criteria may apply.      "
NCT02323126,Phase 2,Novartis Pharmaceuticals,Industry,"A Phase II, Multicenter, Open-label Study of EGF816 in Combination With Nivolumab in Adult Patients With EGFR Mutated Non-small Cell Lung Cancer and of INC280 in Combination With Nivolumab in Adult Patients With cMet Positive Non-small Cell Lung Cancer",4,18,150,include,include,include,,include,include,,,,,,require,,,exclude,,,,,,,,,,"        Inclusion Criteria:          -  Written informed consent must be obtained prior to any screening procedures          -  Presence of at least one measurable lesion according to RECIST v.1.1          -  ECOG performance status ‰ä_ 2          -  Patients with histologically documented locally advanced, recurrent and/or metastatic             NSCLC          -  Tumor tissue for determination and/or confirmation of genetic pre-requisites (i.e.             cMET positivity for Group 2 at any point in treatment; or EGFR T790M positivity post             progression on EGFR TKI) must be provided for analysis        Group 1 patients:          -  Patients with EGFR T790M NSCLC (adenocarcinoma)          -  Documented progression of disease according to RECIST v1.1 following primary standard             of care (e.g. erlotinib, gefitinib)        Group 2 patients:          -  Patients with EGFR wild-type, cMET positive NSCLC          -  Documented progression of disease according to RECIST v1.1 following primary standard             of care (e.g. platinum doublet).        Exclusion Criteria:        For Group1:        - Patients who have received more than one prior line of EGFR TKI therapy1        For Group 2:          -  Previous treatment with a c-MET inhibitor or HGF-targeting therapy          -  Patients with brain metastases. However, if radiation therapy and/or surgery has been             completed and serial evaluation by CT (with contrast enhancement) or MRI over a             minimum of one month demonstrates the disease to be stable and if the patient remains             must have no need for treatment with steroids          -  Patients who require emergent use of systemic steroids, chronic use of prednisone             (greater than 10mg or an equivalent steroid dose daily) or emergent surgery and/or             radiotherapy.          -  History of allergy or hypersensitivity to nivolumab components          -  Patients with an active, known or suspected autoimmune disease. Patients with type I             diabetes mellitis, hypothyroidism only requiring hormone replacement, skin disorders             (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or             conditions not expected to recur in the absence of an external trigger are permitted             to enroll          -  Patients with a condition requiring chronic systemic treatment with either             corticosteroids(> 10 mg daily prednisone equivalent) or other immunosuppressive             medications within 14 days of treatment start. Inhaled or topical steroids, and             adrenal replacement steroid doses> 10 mg daily prednisone equivalent, are permitted             in the absence of active autoimmune disease          -  Known history of testing positive for human immunodeficiency virus (HIV) or known             acquired immunodeficiency syndrome (AIDS)          -  Any positive test for hepatitis B virus or hepatitis C virus indicating acute or             chronic infection          -  Patients with interstitial lung disease that is symptomatic or may interfere with the             detection or management of suspected drug-related pulmonary toxicity          -  Patients with interstitial lung disease that is symptomatic or may interfere with the             detection or management of suspected drug-related pulmonary toxicity        Prior therapy:          -  Patients who have been treated with prior PD-1 and PD-L1 agents          -  Patients who previously received agents targeting c-MET and/or EGFR T790M Note:             Previous treatment with afatinib may be allowable after discussions between Novartis             and Investigator.          -  Patients with the following laboratory abnormalities:               -  Absolute Neutrophil Count (ANC) <1.5 x 109/L               -  Hemoglobin (Hgb) <9 g/dL               -  Platelets <100 x 109/L               -  Total bilirubin >1.5 x upper limit of normal (ULN). For patients with Gilbert's                  syndrome total bilirubin >2.5 x upper limit of normal (ULN)               -  Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) >3 x ULN               -  Serum creatinine >1.5 x ULN and/or measured or calculated creatinine clearance                  <75% LLN        Other protocol-related inclusion/exclusion criteria may apply.      "
NCT02864992,Phase 2,"EMD Serono Research & Development Institute, Inc.",Industry,"A Phase II Single-arm Trial to Investigate Tepotinib in Stage IIIB/IV Adenocarcinoma of the Lung With MET Exon 14 (METex14) Skipping Alterations After Failure of at Least One Prior Active Therapy, Including a Platinum-doublet-containing Regimen",1,18,150,include,,,,,,include,include,,,,,,exclude,exclude,,,,require,,,,,,"        Inclusion Criteria:          -  Histologically confirmed advanced adenocarcinoma of the lung, having failed at least             one line of systemic therapy, including a platinum-doublet-containing regimen, but             having failed a maximum of 2 lines of active therapy          -  MET Exon 14 (METex14) skipping alterations, as determined by the central laboratory.             Both, archival and fresh biopsies are acceptable; In case METex14 skipping alteration             has been observed in a subject in a pre-trial setting, it should be ensured that             sufficient tissue is available for re-testing before trial entry. Only subjects with             METex14 skipping mutation based on trial central testing will be enrolled into the             trial          -  Signed, written informed consent by subject or legal representative prior to any             trial-specific screening procedure          -  Male or female, greater than or equal to (>=) 18 years of age (or having reached the             age of majority according to local laws and regulations, if the age of majority is >             18 years of age)          -  Measurable disease in accordance with RECIST version 1.1          -  ECOG PS of 0 or 1        Exclusion Criteria:          -  Subjects with characterized Epidermal Growth Factor Receptor (EGFR) (documented             results; local testing acceptable) that predict sensitivity to EGFR-therapy,             including, but not limited to exon 19 deletions and exon 21 alterations          -  Subjects with characterized Anaplastic Lymphoma Kinase (ALK) rearrangements             (documented results; local testing acceptable)          -  Active brain metastases (defined as neurologically stable for less than (<) 4 weeks             and/or symptomatic and/or requiring treatment with steroids and/or leptomeningeal             disease) Subjects must have completed any prior treatment for brain metastases >= 4             weeks prior to start of therapy (>= 2 weeks for stereotactic radiosurgery/gamma             knife). Subjects who are neurologically stable on symptomatic therapy with             anticonvulsants with low drug interaction risk or whose steroids are being tapered             are eligible. Asymptomatic untreated brain metastases less than or equal to (<=) 1 cm             are eligible          -  Any unresolved toxicity Grade 2 or more according to National Cancer Institute Common             Terminology Criteria for Adverse Events (NCI-CTCAE) from previous anticancer therapy          -  Need for transfusion within 14 days prior to the first dose of trial treatment          -  Prior chemotherapy, biological therapy, radiation therapy, or other investigational             anticancer therapy (not including palliative radiotherapy at focal sites) within 21             days prior to the first dose of trial treatment          -  Inadequate hematological, liver, renal, cardiac function          -  Prior treatment with other agents targeting the HGF/c-Met pathway          -  Past or current history of neoplasm other than Non-small Cell Lung Cancer (NSCLC),             except for curatively treated non-melanoma skin cancer, in situ carcinoma of the             cervix, or other cancer curatively treated and with no evidence of disease for at             least 5 years      "
NCT02443337,Phase 2,Eli Lilly and Company,Industry,A Phase II Study of the Combination of LY3023414 and Necitumumab After First-Line Chemotherapy for Metastatic Squamous Non-small Cell Carcinoma of the Lung,1,18,150,,,include,,,,,include,,,,,,,,,,,require,,,,,,"        Inclusion Criteria:          -  Histologically confirmed squamous advanced NSCLC (Stage IV).          -  Participants must have progressed on one prior line of platinum-based chemotherapy in             the advanced or metastatic setting.          -  Measurable disease as measured by response evaluation criteria in solid tumors             (RECIST) criteria v 1.1.          -  Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.          -  Able to swallow the study drugs whole.          -  Adequate organ function.          -  Women of childbearing potential must have a negative serum or urine pregnancy test             performed ‰ä_ 7 days prior to start of treatment. Women of childbearing potential or             men with partners of childbearing potential must use effective birth control measures             during treatment and during the 3 months following completion of study treatment.        Exclusion Criteria:          -  Participants who have received > 1 prior line of chemotherapy in the advanced or             metastatic setting. (Immunotherapy will not be considered a line of chemotherapy.)          -  Prior treatment with a PI3K/mTOR inhibitor, epidermal growth factor receptor (EGFR)             inhibitor, and/or necitumumab.          -  History of brain metastases unless irradiated ‰ä´ 2 weeks prior to first study             treatment and stable without requirement of corticosteroids.          -  Have serious pre-existing medical conditions.          -  Have insulin-dependent diabetes mellitus. Participants with a type 2 diabetes             mellitus are eligible if adequate control of blood glucose level is obtained by oral             anti-diabetics.          -  Women who are pregnant or breast-feeding.          -  Clinically significant electrolyte imbalance ‰ä´ Grade 2.          -  Currently receiving treatment with therapeutic doses of warfarin sodium. Low             molecular weight heparin and oral Xa inhibitors are allowed.          -  Have initiated treatment with bisphosphonates or approved receptor activator of             nuclear factor kappa-B ligand (RANK-L) targeted agents (e.g. denosumab) ‰ä_ 28 days             prior to Day 1 of Cycle 1.          -  Concurrent serious infection requiring parenteral antibiotic therapy.          -  Have a second primary malignancy that in the judgment of the investigator and Medical             Monitor may affect the interpretation of results.          -  Have an active, known fungal, bacterial, and/or known viral infection.          -  History of arterial or venous embolism within 3 months prior to study enrollment. If             the embolism occurred >3 and <6 months, the participant is eligible provided             appropriate treatment according to institutional standard of care is ensured.      "
NCT02392507,Phase 2,Eli Lilly and Company,Industry,"A Single-Arm, Multicenter, Open-Label, Phase 2 Study of Nabå¨-Paclitaxel (Abraxaneå¨) and Carboplatin Chemotherapy Plus Necitumumab (LY3012211) in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)",1,18,150,,,include,,,,,include,,,,,,,,,,,exclude,1800,exclude,12,,,"        Inclusion Criteria:          -  Have histologically or cytologically confirmed squamous NSCLC.          -  Have stage IV disease at the time of study entry (American Joint Committee on Cancer             [AJCC] Staging Manual, 7th edition).          -  Have measurable disease at the time of study enrollment as defined by Response             Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1).          -  Have tumor tissue available for biomarker analysis.          -  Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.          -  Have adequate organ functions.        Exclusion Criteria:          -  Are currently enrolled in another clinical trial.          -  Have received prior anticancer therapy with monoclonal antibodies, signal             transduction inhibitors, or any therapies targeting the epidermal growth factor             receptor (EGFR), vascular endothelial growth factor (VEGF), or VEGF receptor.          -  Have received previous chemotherapy for advanced NSCLC. Participants who have             received adjuvant or neoadjuvant chemotherapy are eligible if the last administration             of the prior regimens occurred at least 1 year prior to study entry.          -  Have undergone major surgery or received any investigational therapy in the 4 weeks             prior to study entry.          -  Have undergone systemic radiotherapy within 4 weeks prior to study entry, or focal             radiotherapy within 2 weeks prior to study entry.          -  Have symptomatic central nervous system (CNS) malignancy or metastasis (screening not             required).          -  Have a history of arterial or venous embolism within 6 months prior to study entry.          -  Have clinical evidence of concomitant infectious conditions.          -  Have a known allergy / history of hypersensitivity reaction to any of the treatment             components, including any ingredient used in the formulation of necitumumab, or any             other contraindication to one of the administered treatments.          -  Are pregnant or breastfeeding.          -  Have a known history of drug abuse.          -  Have a concurrent active malignancy. Participants with a history of malignancy are             eligible provided the participant has been disease-free for ‰ä´3 years, with the             following exception: Participants with adequately treated basal or squamous cell             carcinoma of the skin, preinvasive carcinoma of the cervix, or any cancer that in the             judgment of the investigator and Lilly clinical research physician/designee may not             affect the interpretation of results (for example, prostate, bladder) are eligible.          -  Have discontinued investigational product or non approved use of a drug or device             from a clinical trial within 30 days before the first day of study treatment.      "
NCT02412371,Phase 2,AbbVie,Industry,"A Phase 1 Dose Escalation and Phase 2 Randomized, Placebo-Controlled Study of the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Subjects With Stage III Non-Small Cell Lung Cancer (NSCLC)",1,18,99,include,include,include,,,,include,,,,,exclude,,,,,exclude,1800,exclude,1800,exclude,1800,,,"        Inclusion Criteria:          1. Participants with Histologically or cytologically confirmed Stage III non-small cell             lung cancer (NSCLC).          2. Participants in the randomized portion of the study must have measurable disease per             Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1 criteria.          3. Participants must have V20 (volume of lung to receive 20 Gy radiotherapy according to             simulation) < 35%.          4. Participant must have an Eastern Cooperative Oncology Group (ECOG) performance score             of 0 - 1.          5. Participant must have adequate hematologic, renal, hepatic, and lung function.        Exclusion Criteria:          1. Participants with prior chemotherapy or radiotherapy (RT) for current NSCLC.             Participants curatively treated for past early stage NSCLC greater than 3 years ago             may be included.          2. Participants with prior exposure to poly-ADP-ribose polymerase (PARP) inhibitors.          3. Participants with known hypersensitivity to carboplatin, paclitaxel, or formulations             containing polyethoxylated castor oil (Cremophor).          4. Participants with prior mediastinal or thoracic radiotherapy. Prior tangential RT to             prior breast cancer is acceptable.          5. Participants with major surgery in the 4 weeks prior to randomization (Video-assisted             thoracoscopic surgery (VATS) and/or mediastinoscopy is not considered major surgery).          6. Participants with a previous or concurrent malignancy except for treated basal cell             or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the             patient received potentially curative treatment and has been disease-free for 3 years             or is considered cured by the investigator if has been disease-free for less than 3             years.          7. Participant is pregnant or lactating.          8. Participant with sensory peripheral neuropathy of ‰ä´ Grade 2 at baseline, unable to             swallow medication, or participants with prior history of seizure within the prior 12             months.      "
NCT02412371,Phase 2,AbbVie,Industry,"A Phase 1 Dose Escalation and Phase 2 Randomized, Placebo-Controlled Study of the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Subjects With Stage III Non-Small Cell Lung Cancer (NSCLC)",2,18,99,include,include,include,,,,include,,,,,require,,,,,exclude,36,exclude,36,exclude,36,,,"        Inclusion Criteria:          1. Participants with Histologically or cytologically confirmed Stage III non-small cell             lung cancer (NSCLC).          2. Participants in the randomized portion of the study must have measurable disease per             Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1 criteria.          3. Participants must have V20 (volume of lung to receive 20 Gy radiotherapy according to             simulation) < 35%.          4. Participant must have an Eastern Cooperative Oncology Group (ECOG) performance score             of 0 - 1.          5. Participant must have adequate hematologic, renal, hepatic, and lung function.        Exclusion Criteria:          1. Participants with prior chemotherapy or radiotherapy (RT) for current NSCLC.             Participants curatively treated for past early stage NSCLC greater than 3 years ago             may be included.          2. Participants with prior exposure to poly-ADP-ribose polymerase (PARP) inhibitors.          3. Participants with known hypersensitivity to carboplatin, paclitaxel, or formulations             containing polyethoxylated castor oil (Cremophor).          4. Participants with prior mediastinal or thoracic radiotherapy. Prior tangential RT to             prior breast cancer is acceptable.          5. Participants with major surgery in the 4 weeks prior to randomization (Video-assisted             thoracoscopic surgery (VATS) and/or mediastinoscopy is not considered major surgery).          6. Participants with a previous or concurrent malignancy except for treated basal cell             or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the             patient received potentially curative treatment and has been disease-free for 3 years             or is considered cured by the investigator if has been disease-free for less than 3             years.          7. Participant is pregnant or lactating.          8. Participant with sensory peripheral neuropathy of ‰ä´ Grade 2 at baseline, unable to             swallow medication, or participants with prior history of seizure within the prior 12             months.      "
NCT02750514,Phase 2,Bristol-Myers Squibb,Industry,"A Phase 2, Fast Real Time Assessment of Combination Therapies in Immuno-Oncology Study in Subjects With Advanced Non-Small Cell Lung Cancer (FRACTION-Lung)",1,18,150,include,include,include,,,,,include,,,,,,,,,,,,,,,,,"        Inclusion Criteria:          -  Advanced Non Small Cell Lung Cancer (NSCLC)          -  Eastern Cooperative Oncology Group (ECOG) Performance status of ‰ä_ 1          -  Life expectancy of at least 3 months from most recent chemotherapy or immunotherapy             treatment          -  Must have at least 1 lesion with measurable disease        Exclusion Criteria:          -  Subjects with certain mutations that have not been treated with a targeted therapy             prior to enrollment          -  Must not have suspected or known central nervous system metastases unless adequately             treated          -  Subjects who need daily oxygen therapy          -  People with autoimmune disease      "
NCT02616393,Phase 2,"Kadmon Corporation, LLC",Industry,"A Phase 2, Multicenter Study of Tesevatinib in Subjects With Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases",1,18,150,include,include,include,,include,include,include,include,,,,,,,require,,,,,,,,require,,"        Cohort A        Inclusion Criteria:          -  History of NSCLC with EGFR mutation or an EGFR activating mutation that has had a             clinical response to erlotinib, afatinib, or gefitinib in the patient being enrolled.          -  Occurrence or progression of BM while receiving either erlotinib or afatinib or             gefitinib. Previous systemic treatment included erlotinib or afatinib or gefitinib             for at least 14 days. Patients may have received osimertinib or rociletinib, or other             agents inhibiting the T790M EGFR mutation, but only if they then receive at least 14             days of treatment with erlotinib, afatinib, or gefitinib and have CNS but not             peripheral progression          -  At least one measurable BM by RECIST 1.1 criteria (‰ä´ 10mm in longest diameter).             Target lesions must not have received stereotactic radiotherapy (SRS). If subject had             prior whole brain radiotherapy (WBRT), progression in any measurable BM lesion must             have occurred at least 3 months after the end of WBRT. Subjects with asymptomatic             brain metastases may be enrolled without prior radiation therapy to the brain.             Subjects with minimally symptomatic brain metastases may be enrolled without prior             radiation therapy to the brain if they do not require immediate surgical or radiation             therapy in the opinion of the treating investigator and in the opinion of a radiation             therapy or neurosurgical consultant          -  Subjects in Cohort A may have asymptomatic LM detected by MRI. (Subjects with             symptoms or signs attributed to LM will be enrolled in Cohort B whether or not they             have brain metastases)          -  No clinically significant progression outside of the CNS on most recent EGFR             inhibitor therapy          -  ECOG Score ‰ä_2          -  No history of another malignancy in the 5 years prior to study entry, except treated             non-melanoma skin cancer or superficial bladder cancer or carcinoma-in-situ of the             cervix or Stage 1 or 2 cancers of other sites that have been treated surgically and             have not recurred          -  Adequate organ and bone marrow functions          -  Serum potassium and magnesium levels above the lower limit of normal          -  No coexisting medical problems of sufficient severity to limit compliance with the             study          -  Willing and able to sign written informed consent and be able to comply with the             study protocol for the duration of the study          -  Women of childbearing potential (i.e., menstruating women) must have a negative urine             pregnancy test (positive urine tests are to be confirmed by serum test)        Exclusion Criteria:          -  First day of dosing with tesevatinib is less than 2 weeks from the last treatment of             cytotoxic chemotherapy, biological therapy, or immunotherapy, and less than 6 weeks             for nitrosoureas and mitomycin C. Surgical procedures must have been performed at             least 2 weeks prior to the start of study treatment. Subjects must have recovered             from the reversible effects of prior lung cancer treatments, including surgery and             radiation therapy (excluding alopecia)          -  First day of dosing with tesevatinib is less than 4 weeks from the last radiotherapy             of the brain or spinal cord/cauda equina          -  First day of dosing with tesevatinib is less than 2 weeks from treatment with another             investigational agent          -  Treatment with erlotinib must be discontinued at least 3 days prior to first dose of             tesevatinib and treatment with afatinib or other tyrosine kinase inhibitor must be             discontinued at least 3 days prior to first dose of tesevatinib          -  Any concurrent therapy for BM other than the specified treatment in this study          -  Taking any medication known to moderately or severely inhibit the CYP3A4 isozyme or             any drugs that are CYP3A4 inducers (including anti-epileptic agents such as             phenytoin). A stable regimen (‰ä´ 4 weeks) of antidepressants of the SSRI class is             allowed (common SSRIs include escitalopram oxalate, citalopram, fluvoxamine,             paroxetine, sertraline, and fluoxetine)          -  Taking any drugs associated with torsades de pointes or known to moderately or             severely prolong the QTc(F) interval          -  Has evidence of active heart disease such as myocardial infarction within the 3             months prior to study entry; symptomatic coronary insufficiency congestive heart             failure; moderate or severe pulmonary dysfunction          -  History of torsades de pointes, ventricular tachycardia or fibrillation, pathologic             sinus bradycardia (< 50 bpm), heart block (excluding first degree block, being PR             interval only), or congenital long QT syndrome. Subjects with a history of atrial             arrhythmias should be discussed with the medical monitor          -  Has an active infectious process          -  Female subject who is pregnant or lactating          -  Known contraindication to MRI, such as cardiac pacemaker, shrapnel, or ocular foreign             body          -  Has marked prolongation of QTc(F) interval at screening or baseline (QTc[F] interval             > 470 msec) using the Fridericia method of correction for heart rate          -  Gastrointestinal (GI) condition that interferes with drug absorption          -  Non-malignant neurological disease that would interfere with evaluation of symptoms             or signs of brain metastases        Cohort B        Inclusion Criteria:          -  History of NSCLC with EGFR mutation (either exon 19 deletion or L858R mutation) or,             if previously treated, history of an activating EGFR mutation that has had a clinical             response to erlotinib, afatinib, or gefitinib in the patient being enrolled).          -  Presentation with LM at initial presentation with no prior systemic treatment, or             occurrence or progression of LM while receiving either erlotinib or afatinib or             gefitinib. Previous systemic treatment included erlotinib or afatinib or gefitinib             for at least 14 days. Patients may have received osimertinib or rociletinib, or other             agents inhibiting the T790M EGFR mutation, but only if they then receive at least 14             days of treatment with erlotinib, afatinib, or gefitinib and have CNS but not             peripheral progression          -  Presence of at least one CTCAE 4.03 symptom/sign of at least Grade 1 attributed by             the investigator to leptomeningeal metastases          -  Diagnosis of LM by:               1. Cytological evidence in CSF sample of LM due to NSCLC, and/or               2. Findings on gadolinium-enhanced MRI          -  No clinically significant progression outside of the CNS on most recent EGFR             inhibitor therapy          -  Concomitant brain metastases and brain metastases previously treated with radiation             therapy are allowed. (Subjects with symptoms or signs attributed to LM will be             enrolled in Cohort B whether or not they have brain metastases)          -  ECOG Score ‰ä_2          -  No history of another malignancy in the 5 years prior to study entry, except treated             non-melanoma skin cancer or superficial bladder cancer or carcinoma-in-situ of the             cervix or Stage 1 or 2 cancers of other sites that have been treated surgically and             have not recurred.          -  Adequate organ and bone marrow functions          -  Serum potassium and magnesium levels above the lower limit of normal          -  No coexisting medical problems of sufficient severity to limit compliance with the             study          -  Willing and able to sign written informed consent and be able to comply with the             study protocol for the duration of the study          -  Women of childbearing potential (i.e., menstruating women) must have a negative urine             pregnancy test (positive urine tests are to be confirmed by serum test)        Exclusion Criteria:          -  First day of dosing with tesevatinib is less than 2 weeks from the last treatment of             cytotoxic chemotherapy, biological therapy, or immunotherapy, and less than 6 weeks             for nitrosoureas and mitomycin C. Surgical procedures must have been performed at             least 2 weeks prior to the start of study treatment. Subjects must have recovered             from the reversible effects of prior lung cancer treatments, including surgery and             radiation therapy (excluding alopecia)          -  First day of dosing with tesevatinib is less than 4 weeks from the last radiotherapy             of the brain or spinal cord/cauda equina          -  First day of dosing with tesevatinib is less than 2 weeks from treatment with another             investigational agent          -  Treatment with erlotinib must be discontinued at least 3 days prior to first dose of             tesevatinib and treatment with afatinib or other tyrosine kinase inhibitor must be             discontinued at least 3 days prior to first dose of tesevatinib          -  Any concurrent therapy for LM other than the specified treatment in this study          -  Taking any medication known to moderately or severely inhibit the CYP3A4 isozyme or             any drugs that are CYP3A4 inducers (including anti-epileptic agents such as             phenytoin). A stable regimen (‰ä´ 4 weeks) of antidepressants of the SSRI class is             allowed (common SSRIs include escitalopram oxalate, citalopram, fluvoxamine,             paroxetine, sertraline, and fluoxetine)          -  Taking any drugs associated with torsades de pointes or known to moderately or             severely prolong the QTc(F) interval          -  Has evidence of active heart disease such as myocardial infarction within the 3             months prior to study entry; symptomatic coronary insufficiency congestive heart             failure; moderate or severe pulmonary dysfunction          -  History of torsades de pointes, ventricular tachycardia or fibrillation, pathologic             sinus bradycardia (< 50 bpm), heart block (excluding first degree block, being PR             interval only), or congenital long QT syndrome. Subjects with a history of atrial             arrhythmias should be discussed with the medical monitor          -  Has an active infectious process          -  Female subject who is pregnant or lactating          -  Known contraindication to MRI, such as cardiac pacemaker, shrapnel, or ocular foreign             body          -  Has marked prolongation of QTc(F) interval at screening or baseline (QTc[F] interval             > 470 msec) using the Fridericia method of correction for heart rate          -  Gastrointestinal (GI) condition that interferes with drug absorption          -  Non-malignant neurological disease that would interfere with evaluation of symptoms             or signs of leptomeningeal metastases          -  Contraindications to lumbar puncture:               1. INR > 1.5               2. Platelets < 50 ÌÑ 109/L (Note that platelets are required to be ‰ä´100ÌÑ 109/L at                  screening)               3. Therapeutic anticoagulant treatment that can't be held for 24 hours. Low dose                  low molecular weight heparin given for deep vein thrombosis (DVT) prophylaxis is                  allowed.               4. CNS lesions considered to be at risk for cerebral herniation, myelocompression,                  or conus/cauda compression        Cohort C        Inclusion Criteria:          -  NSCLC with EGFR activating mutation          -  No prior systemic treatment for NSCLC. Treatment with systemic steroids is not             considered systemic treatment for NSCLC          -  No prior radiation therapy to the CNS (brain or spinal cord)          -  At least one measurable BM by RECIST 1.1 criteria (‰ä´ 10mm in longest diameter) in a             subject with asymptomatic or minimally symptomatic brain metastases who does not             require immediate surgical or radiation therapy in the opinion of the treating             investigator and in the opinion of a radiation therapy or neurosurgical consultant.          -  Subjects in Cohort C may have asymptomatic LM detected by MRI          -  ECOG Score ‰ä_2          -  No history of another malignancy in the 5 years prior to study entry, except treated             non-melanoma skin cancer or superficial bladder cancer or carcinoma-in-situ of the             cervix or Stage 1 or 2 cancers of other sites that have been treated surgically and             have not recurred          -  Adequate organ and bone marrow functions          -  Serum potassium and magnesium levels above the LLN          -  No coexisting medical problems of sufficient severity to limit compliance with the             study.          -  Willing and able to sign written informed consent and be able to comply with the             study protocol for the duration of the study          -  Women of childbearing potential (i.e., menstruating women) must have a negative urine             pregnancy test (positive urine tests are to be confirmed by serum test)        Exclusion Criteria:          -  Surgical procedures that were performed less than 2 weeks prior to the start of study             treatment          -  Any concurrent therapy for BM other than the specified treatment in this study          -  Taking any medication known to moderately or severely inhibit the CYP3A4 isozyme or             any drugs that are CYP3A4 inducers (including anti-epileptic agents such as             phenytoin). A stable regimen (‰ä´ 4 weeks) of antidepressants of the SSRI class is             allowed (common SSRIs include escitalopram oxalate, citalopram, fluvoxamine,             paroxetine, sertraline, and fluoxetine)          -  Taking any drugs associated with torsades de pointes or known to moderately or             severely prolong the QTc(F) interval          -  Has evidence of active heart disease such as myocardial infarction within the 3             months prior to study entry; symptomatic coronary insufficiency congestive heart             failure; moderate or severe pulmonary dysfunction          -  History of torsades de pointes, ventricular tachycardia or fibrillation, pathologic             sinus bradycardia (< 50 bpm), heart block (excluding first degree block, being PR             interval only), or congenital long QT syndrome. Subjects with a history of atrial             arrhythmias should be discussed with the medical monitor          -  Has an active infectious process          -  Female subject who is pregnant or lactating          -  Known contraindication to MRI, such as cardiac pacemaker, shrapnel, or ocular foreign             body          -  Has marked prolongation of QTc(F) interval at screening or Cycle 1 Day 1 (QTc[F]             interval > 470 msec) using the Fridericia method of correction for heart rate          -  GI condition that interferes with drug absorption          -  Non-malignant neurological disease that would interfere with evaluation of symptoms             or signs of brain metastases      "
NCT02616393,Phase 2,"Kadmon Corporation, LLC",Industry,"A Phase 2, Multicenter Study of Tesevatinib in Subjects With Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases",2,18,150,include,include,include,,include,include,include,include,,,require,,,,require,,exclude,1800,exclude,1800,,,,,"        Cohort A        Inclusion Criteria:          -  History of NSCLC with EGFR mutation or an EGFR activating mutation that has had a             clinical response to erlotinib, afatinib, or gefitinib in the patient being enrolled.          -  Occurrence or progression of BM while receiving either erlotinib or afatinib or             gefitinib. Previous systemic treatment included erlotinib or afatinib or gefitinib             for at least 14 days. Patients may have received osimertinib or rociletinib, or other             agents inhibiting the T790M EGFR mutation, but only if they then receive at least 14             days of treatment with erlotinib, afatinib, or gefitinib and have CNS but not             peripheral progression          -  At least one measurable BM by RECIST 1.1 criteria (‰ä´ 10mm in longest diameter).             Target lesions must not have received stereotactic radiotherapy (SRS). If subject had             prior whole brain radiotherapy (WBRT), progression in any measurable BM lesion must             have occurred at least 3 months after the end of WBRT. Subjects with asymptomatic             brain metastases may be enrolled without prior radiation therapy to the brain.             Subjects with minimally symptomatic brain metastases may be enrolled without prior             radiation therapy to the brain if they do not require immediate surgical or radiation             therapy in the opinion of the treating investigator and in the opinion of a radiation             therapy or neurosurgical consultant          -  Subjects in Cohort A may have asymptomatic LM detected by MRI. (Subjects with             symptoms or signs attributed to LM will be enrolled in Cohort B whether or not they             have brain metastases)          -  No clinically significant progression outside of the CNS on most recent EGFR             inhibitor therapy          -  ECOG Score ‰ä_2          -  No history of another malignancy in the 5 years prior to study entry, except treated             non-melanoma skin cancer or superficial bladder cancer or carcinoma-in-situ of the             cervix or Stage 1 or 2 cancers of other sites that have been treated surgically and             have not recurred          -  Adequate organ and bone marrow functions          -  Serum potassium and magnesium levels above the lower limit of normal          -  No coexisting medical problems of sufficient severity to limit compliance with the             study          -  Willing and able to sign written informed consent and be able to comply with the             study protocol for the duration of the study          -  Women of childbearing potential (i.e., menstruating women) must have a negative urine             pregnancy test (positive urine tests are to be confirmed by serum test)        Exclusion Criteria:          -  First day of dosing with tesevatinib is less than 2 weeks from the last treatment of             cytotoxic chemotherapy, biological therapy, or immunotherapy, and less than 6 weeks             for nitrosoureas and mitomycin C. Surgical procedures must have been performed at             least 2 weeks prior to the start of study treatment. Subjects must have recovered             from the reversible effects of prior lung cancer treatments, including surgery and             radiation therapy (excluding alopecia)          -  First day of dosing with tesevatinib is less than 4 weeks from the last radiotherapy             of the brain or spinal cord/cauda equina          -  First day of dosing with tesevatinib is less than 2 weeks from treatment with another             investigational agent          -  Treatment with erlotinib must be discontinued at least 3 days prior to first dose of             tesevatinib and treatment with afatinib or other tyrosine kinase inhibitor must be             discontinued at least 3 days prior to first dose of tesevatinib          -  Any concurrent therapy for BM other than the specified treatment in this study          -  Taking any medication known to moderately or severely inhibit the CYP3A4 isozyme or             any drugs that are CYP3A4 inducers (including anti-epileptic agents such as             phenytoin). A stable regimen (‰ä´ 4 weeks) of antidepressants of the SSRI class is             allowed (common SSRIs include escitalopram oxalate, citalopram, fluvoxamine,             paroxetine, sertraline, and fluoxetine)          -  Taking any drugs associated with torsades de pointes or known to moderately or             severely prolong the QTc(F) interval          -  Has evidence of active heart disease such as myocardial infarction within the 3             months prior to study entry; symptomatic coronary insufficiency congestive heart             failure; moderate or severe pulmonary dysfunction          -  History of torsades de pointes, ventricular tachycardia or fibrillation, pathologic             sinus bradycardia (< 50 bpm), heart block (excluding first degree block, being PR             interval only), or congenital long QT syndrome. Subjects with a history of atrial             arrhythmias should be discussed with the medical monitor          -  Has an active infectious process          -  Female subject who is pregnant or lactating          -  Known contraindication to MRI, such as cardiac pacemaker, shrapnel, or ocular foreign             body          -  Has marked prolongation of QTc(F) interval at screening or baseline (QTc[F] interval             > 470 msec) using the Fridericia method of correction for heart rate          -  Gastrointestinal (GI) condition that interferes with drug absorption          -  Non-malignant neurological disease that would interfere with evaluation of symptoms             or signs of brain metastases        Cohort B        Inclusion Criteria:          -  History of NSCLC with EGFR mutation (either exon 19 deletion or L858R mutation) or,             if previously treated, history of an activating EGFR mutation that has had a clinical             response to erlotinib, afatinib, or gefitinib in the patient being enrolled).          -  Presentation with LM at initial presentation with no prior systemic treatment, or             occurrence or progression of LM while receiving either erlotinib or afatinib or             gefitinib. Previous systemic treatment included erlotinib or afatinib or gefitinib             for at least 14 days. Patients may have received osimertinib or rociletinib, or other             agents inhibiting the T790M EGFR mutation, but only if they then receive at least 14             days of treatment with erlotinib, afatinib, or gefitinib and have CNS but not             peripheral progression          -  Presence of at least one CTCAE 4.03 symptom/sign of at least Grade 1 attributed by             the investigator to leptomeningeal metastases          -  Diagnosis of LM by:               1. Cytological evidence in CSF sample of LM due to NSCLC, and/or               2. Findings on gadolinium-enhanced MRI          -  No clinically significant progression outside of the CNS on most recent EGFR             inhibitor therapy          -  Concomitant brain metastases and brain metastases previously treated with radiation             therapy are allowed. (Subjects with symptoms or signs attributed to LM will be             enrolled in Cohort B whether or not they have brain metastases)          -  ECOG Score ‰ä_2          -  No history of another malignancy in the 5 years prior to study entry, except treated             non-melanoma skin cancer or superficial bladder cancer or carcinoma-in-situ of the             cervix or Stage 1 or 2 cancers of other sites that have been treated surgically and             have not recurred.          -  Adequate organ and bone marrow functions          -  Serum potassium and magnesium levels above the lower limit of normal          -  No coexisting medical problems of sufficient severity to limit compliance with the             study          -  Willing and able to sign written informed consent and be able to comply with the             study protocol for the duration of the study          -  Women of childbearing potential (i.e., menstruating women) must have a negative urine             pregnancy test (positive urine tests are to be confirmed by serum test)        Exclusion Criteria:          -  First day of dosing with tesevatinib is less than 2 weeks from the last treatment of             cytotoxic chemotherapy, biological therapy, or immunotherapy, and less than 6 weeks             for nitrosoureas and mitomycin C. Surgical procedures must have been performed at             least 2 weeks prior to the start of study treatment. Subjects must have recovered             from the reversible effects of prior lung cancer treatments, including surgery and             radiation therapy (excluding alopecia)          -  First day of dosing with tesevatinib is less than 4 weeks from the last radiotherapy             of the brain or spinal cord/cauda equina          -  First day of dosing with tesevatinib is less than 2 weeks from treatment with another             investigational agent          -  Treatment with erlotinib must be discontinued at least 3 days prior to first dose of             tesevatinib and treatment with afatinib or other tyrosine kinase inhibitor must be             discontinued at least 3 days prior to first dose of tesevatinib          -  Any concurrent therapy for LM other than the specified treatment in this study          -  Taking any medication known to moderately or severely inhibit the CYP3A4 isozyme or             any drugs that are CYP3A4 inducers (including anti-epileptic agents such as             phenytoin). A stable regimen (‰ä´ 4 weeks) of antidepressants of the SSRI class is             allowed (common SSRIs include escitalopram oxalate, citalopram, fluvoxamine,             paroxetine, sertraline, and fluoxetine)          -  Taking any drugs associated with torsades de pointes or known to moderately or             severely prolong the QTc(F) interval          -  Has evidence of active heart disease such as myocardial infarction within the 3             months prior to study entry; symptomatic coronary insufficiency congestive heart             failure; moderate or severe pulmonary dysfunction          -  History of torsades de pointes, ventricular tachycardia or fibrillation, pathologic             sinus bradycardia (< 50 bpm), heart block (excluding first degree block, being PR             interval only), or congenital long QT syndrome. Subjects with a history of atrial             arrhythmias should be discussed with the medical monitor          -  Has an active infectious process          -  Female subject who is pregnant or lactating          -  Known contraindication to MRI, such as cardiac pacemaker, shrapnel, or ocular foreign             body          -  Has marked prolongation of QTc(F) interval at screening or baseline (QTc[F] interval             > 470 msec) using the Fridericia method of correction for heart rate          -  Gastrointestinal (GI) condition that interferes with drug absorption          -  Non-malignant neurological disease that would interfere with evaluation of symptoms             or signs of leptomeningeal metastases          -  Contraindications to lumbar puncture:               1. INR > 1.5               2. Platelets < 50 ÌÑ 109/L (Note that platelets are required to be ‰ä´100ÌÑ 109/L at                  screening)               3. Therapeutic anticoagulant treatment that can't be held for 24 hours. Low dose                  low molecular weight heparin given for deep vein thrombosis (DVT) prophylaxis is                  allowed.               4. CNS lesions considered to be at risk for cerebral herniation, myelocompression,                  or conus/cauda compression        Cohort C        Inclusion Criteria:          -  NSCLC with EGFR activating mutation          -  No prior systemic treatment for NSCLC. Treatment with systemic steroids is not             considered systemic treatment for NSCLC          -  No prior radiation therapy to the CNS (brain or spinal cord)          -  At least one measurable BM by RECIST 1.1 criteria (‰ä´ 10mm in longest diameter) in a             subject with asymptomatic or minimally symptomatic brain metastases who does not             require immediate surgical or radiation therapy in the opinion of the treating             investigator and in the opinion of a radiation therapy or neurosurgical consultant.          -  Subjects in Cohort C may have asymptomatic LM detected by MRI          -  ECOG Score ‰ä_2          -  No history of another malignancy in the 5 years prior to study entry, except treated             non-melanoma skin cancer or superficial bladder cancer or carcinoma-in-situ of the             cervix or Stage 1 or 2 cancers of other sites that have been treated surgically and             have not recurred          -  Adequate organ and bone marrow functions          -  Serum potassium and magnesium levels above the LLN          -  No coexisting medical problems of sufficient severity to limit compliance with the             study.          -  Willing and able to sign written informed consent and be able to comply with the             study protocol for the duration of the study          -  Women of childbearing potential (i.e., menstruating women) must have a negative urine             pregnancy test (positive urine tests are to be confirmed by serum test)        Exclusion Criteria:          -  Surgical procedures that were performed less than 2 weeks prior to the start of study             treatment          -  Any concurrent therapy for BM other than the specified treatment in this study          -  Taking any medication known to moderately or severely inhibit the CYP3A4 isozyme or             any drugs that are CYP3A4 inducers (including anti-epileptic agents such as             phenytoin). A stable regimen (‰ä´ 4 weeks) of antidepressants of the SSRI class is             allowed (common SSRIs include escitalopram oxalate, citalopram, fluvoxamine,             paroxetine, sertraline, and fluoxetine)          -  Taking any drugs associated with torsades de pointes or known to moderately or             severely prolong the QTc(F) interval          -  Has evidence of active heart disease such as myocardial infarction within the 3             months prior to study entry; symptomatic coronary insufficiency congestive heart             failure; moderate or severe pulmonary dysfunction          -  History of torsades de pointes, ventricular tachycardia or fibrillation, pathologic             sinus bradycardia (< 50 bpm), heart block (excluding first degree block, being PR             interval only), or congenital long QT syndrome. Subjects with a history of atrial             arrhythmias should be discussed with the medical monitor          -  Has an active infectious process          -  Female subject who is pregnant or lactating          -  Known contraindication to MRI, such as cardiac pacemaker, shrapnel, or ocular foreign             body          -  Has marked prolongation of QTc(F) interval at screening or Cycle 1 Day 1 (QTc[F]             interval > 470 msec) using the Fridericia method of correction for heart rate          -  GI condition that interferes with drug absorption          -  Non-malignant neurological disease that would interfere with evaluation of symptoms             or signs of brain metastases      "
NCT02574078,Phase 1/Phase 2,Bristol-Myers Squibb,Industry,A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370),1,18,150,include,include,include,,,,,include,,,,,,,,,,,,,,,,,"        For more information regarding BMS clinical trial participation, please visit        www.BMSStudyConnect.com        Inclusion Criteria:          -  Histologically confirmed locally advanced or stage IV NSCLC          -  Eastern Cooperative Oncology Group (ECOG) Performance status (PS) 0-2          -  Tumor tissue sections must be available for biomarker evaluation        Exclusion Criteria:          -  Untreated or active/progressing Central Nervous system (CNS) metastases          -  Active, known or suspected autoimmune disease          -  Known history of testing positive for HIV or AIDS          -  Active or chronic infection of hepatitis B virus or hepatitis C      "
NCT01970865,Phase 1/Phase 2,Pfizer,Industry,Phase 1/2 Study Of PF-06463922 (An ALK/ROS1 Tyrosine Kinase Inhibitor) In Patients With Advanced Non-Small Cell Lung Cancer Harboring Specific Molecular Alterations,1,18,150,include,include,include,,,,,include,,,require,,,require,,,,,,,,,,,"        Inclusion Criteria          -  Evidence of histologically or cytologically confirmed diagnosis of metastatic NSCLC             (Stage IV, AJCC v7.0) that carries an ALK rearrangement, as determined by the Food             and Drug Administration (FDA) approved FISH assay (Abbott Molecular Inc) or by             Immunohistochemistry (IHC) (Ventana Inc), or a ROS1 rearrangement as determined by             FISH or RT PCR or Next Generation Sequencing (NGS) via a local diagnostic test (LDT).             All patients (ALK positive and ROS1 positive) must have archival tissue sample             available and collected prior to enrollment.          -  Disease Status Requirements:        Phase 1: ALK-positive NSCLC and ROS1-positive patients must either be treatment naÌøve in        the advanced setting or have had disease progression after at least 1 previous ALK/ROS1        inhibitor therapy(ies).        Phase 2:        ALK-positive NSCLC patients must either be or have had:          -  Treatment naÌøve (ie, no prior chemotherapy in the metastatic disease setting and no             prior ALK inhibitor therapy allowed).          -  Disease progression after crizotinib only. No prior chemotherapy is allowed in the             metastatic disease setting.          -  Disease progression after crizotinib and 1 or 2 prior regimens of chemotherapy in the             metastatic disease setting.          -  Disease progression after 1 prior ALK inhibitor therapy other than crizotinib.             Patients may have had any number of prior chemotherapy regimens in any disease             setting.          -  Disease progression after 2 prior ALK inhibitor therapies. Patients may have had any             number of prior chemotherapy regimens in any disease setting.          -  Disease progression after 3 prior ALK inhibitor therapies. Patients may have had any             number of prior chemotherapy regimens in any disease setting.        ROS1-positive NSCLC patients may be:          -  Treatment naÌøve (ie, no prior chemotherapy in the metastatic disease setting and no             prior ROS inhibitor therapy).          -  Any number of prior therapies (ie, chemotherapy and/or ROS inhibitor therapies).               -  Tumor Requirements:        All Patients must have at least one measurable target extracranial lesion according to        RECIST v1.1. In addition patients with asymptomatic CNS metastases (including patients        asymptomatic by means of stable or decreasing doses of steroids within the last 2 weeks        prior to study entry) will be eligible. Patients who have leptomeningeal disease (LM) or        carcinomatous meningitis (CM) are eligible.          -  Adequate Bone Marrow, Pancreatic Function, Renal Function and Liver Function.          -  Negative Serum pregnancy test for females of childbearing potential Exclusion             Criteria          -  Radiation therapy (except palliative to relieve bone pain) within 2 weeks of study             entry. Whole brain radiation must have completed at least 4 weeks prior to study             entry.          -  Systemic anti cancer therapy completed within a minimum of 5 half lives of study             entry.          -  Prior therapy with an antibody or drug specifically targeting T-cell co-stimulation             or immune checkpoint pathways, including, but not limited to, anti-PD-1, anti-PD-L1,             anti-PD-L2, anti-CD137, or anti-cytotoxic T lymphocyte associated antigen 4             (anti-CTLA-4) antibody.          -  Active and clinically significant bacterial, fungal, or viral infection including             hepatitis B (HBV), hepatitis C (HCV), known human immunodeficiency virus (HIV), or             acquired immunodeficiency syndrome (AIDS) related illness.          -  Clinically significant cardiovascular disease (that is, active or <3 months prior to             enrollment): cerebral vascular accident/stroke, myocardial infarction, unstable             angina, congestive heart failure (New York Heart Association Classification Class ‰ä´             II), second-degree or third-degree AV block (unless paced) or any AV block with PR             >220 msec. Ongoing cardiac dysrhythmias of NCI CTCAE Grade ‰ä´2, uncontrolled atrial             fibrillation of any grade, bradycardia defined as <50 bpm (unless patient is             otherwise healthy such as long-distance runners, etc.), machine-read ECG with QTc             >470 msec, or congenital long QT syndrome.          -  History of extensive, disseminated, bilateral or presence of Grade 3 or 4             interstitial fibrosis or interstitial lung disease including a history of             pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, interstitial lung             disease, obliterative bronchiolitis and pulmonary fibrosis.          -  Current use or anticipated need for food or drugs that are known strong or moderate             CYP3A4 inhibitors, inducers and substrates; drugs that are CYP2C9 substrates; drugs             that are sensitive CYP2B6 substrates; drugs that are strong CYP2C19 inhibitors; drugs             that are strong CYP2C8 inhibitors; and drugs that are P-gp substrates.      "
NCT01970865,Phase 1/Phase 2,Pfizer,Industry,Phase 1/2 Study Of PF-06463922 (An ALK/ROS1 Tyrosine Kinase Inhibitor) In Patients With Advanced Non-Small Cell Lung Cancer Harboring Specific Molecular Alterations,2,18,150,include,include,include,,,,,include,,,,,require,require,,,,,,,,,,,"        Inclusion Criteria          -  Evidence of histologically or cytologically confirmed diagnosis of metastatic NSCLC             (Stage IV, AJCC v7.0) that carries an ALK rearrangement, as determined by the Food             and Drug Administration (FDA) approved FISH assay (Abbott Molecular Inc) or by             Immunohistochemistry (IHC) (Ventana Inc), or a ROS1 rearrangement as determined by             FISH or RT PCR or Next Generation Sequencing (NGS) via a local diagnostic test (LDT).             All patients (ALK positive and ROS1 positive) must have archival tissue sample             available and collected prior to enrollment.          -  Disease Status Requirements:        Phase 1: ALK-positive NSCLC and ROS1-positive patients must either be treatment naÌøve in        the advanced setting or have had disease progression after at least 1 previous ALK/ROS1        inhibitor therapy(ies).        Phase 2:        ALK-positive NSCLC patients must either be or have had:          -  Treatment naÌøve (ie, no prior chemotherapy in the metastatic disease setting and no             prior ALK inhibitor therapy allowed).          -  Disease progression after crizotinib only. No prior chemotherapy is allowed in the             metastatic disease setting.          -  Disease progression after crizotinib and 1 or 2 prior regimens of chemotherapy in the             metastatic disease setting.          -  Disease progression after 1 prior ALK inhibitor therapy other than crizotinib.             Patients may have had any number of prior chemotherapy regimens in any disease             setting.          -  Disease progression after 2 prior ALK inhibitor therapies. Patients may have had any             number of prior chemotherapy regimens in any disease setting.          -  Disease progression after 3 prior ALK inhibitor therapies. Patients may have had any             number of prior chemotherapy regimens in any disease setting.        ROS1-positive NSCLC patients may be:          -  Treatment naÌøve (ie, no prior chemotherapy in the metastatic disease setting and no             prior ROS inhibitor therapy).          -  Any number of prior therapies (ie, chemotherapy and/or ROS inhibitor therapies).               -  Tumor Requirements:        All Patients must have at least one measurable target extracranial lesion according to        RECIST v1.1. In addition patients with asymptomatic CNS metastases (including patients        asymptomatic by means of stable or decreasing doses of steroids within the last 2 weeks        prior to study entry) will be eligible. Patients who have leptomeningeal disease (LM) or        carcinomatous meningitis (CM) are eligible.          -  Adequate Bone Marrow, Pancreatic Function, Renal Function and Liver Function.          -  Negative Serum pregnancy test for females of childbearing potential Exclusion             Criteria          -  Radiation therapy (except palliative to relieve bone pain) within 2 weeks of study             entry. Whole brain radiation must have completed at least 4 weeks prior to study             entry.          -  Systemic anti cancer therapy completed within a minimum of 5 half lives of study             entry.          -  Prior therapy with an antibody or drug specifically targeting T-cell co-stimulation             or immune checkpoint pathways, including, but not limited to, anti-PD-1, anti-PD-L1,             anti-PD-L2, anti-CD137, or anti-cytotoxic T lymphocyte associated antigen 4             (anti-CTLA-4) antibody.          -  Active and clinically significant bacterial, fungal, or viral infection including             hepatitis B (HBV), hepatitis C (HCV), known human immunodeficiency virus (HIV), or             acquired immunodeficiency syndrome (AIDS) related illness.          -  Clinically significant cardiovascular disease (that is, active or <3 months prior to             enrollment): cerebral vascular accident/stroke, myocardial infarction, unstable             angina, congestive heart failure (New York Heart Association Classification Class ‰ä´             II), second-degree or third-degree AV block (unless paced) or any AV block with PR             >220 msec. Ongoing cardiac dysrhythmias of NCI CTCAE Grade ‰ä´2, uncontrolled atrial             fibrillation of any grade, bradycardia defined as <50 bpm (unless patient is             otherwise healthy such as long-distance runners, etc.), machine-read ECG with QTc             >470 msec, or congenital long QT syndrome.          -  History of extensive, disseminated, bilateral or presence of Grade 3 or 4             interstitial fibrosis or interstitial lung disease including a history of             pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, interstitial lung             disease, obliterative bronchiolitis and pulmonary fibrosis.          -  Current use or anticipated need for food or drugs that are known strong or moderate             CYP3A4 inhibitors, inducers and substrates; drugs that are CYP2C9 substrates; drugs             that are sensitive CYP2B6 substrates; drugs that are strong CYP2C19 inhibitors; drugs             that are strong CYP2C8 inhibitors; and drugs that are P-gp substrates.      "
NCT02499770,Phase 1/Phase 2,"G1 Therapeutics, Inc.",Industry,Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Etoposide and Carboplatin,1,18,150,,,,include,,,,,include,include,,,,,,,,,exclude,1800,,,,,"        Inclusion Criteria:          -  Male or female subjects aged ‰ä´18 years          -  Unequivocally confirmed diagnosis of SCLC by histology or cytology, preferably             including the presence of neuroendocrine features by immunohistochemistry          -  At least 1 target lesion that is unirradiated and measurable by RECIST, Version 1.1          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2          -  Adequate organ function        Exclusion Criteria:          -  Prior chemotherapy for extensive-stage SCLC          -  Presence of symptomatic brain metastases requiring immediate treatment with radiation             therapy or steroids.          -  Uncontrolled ischemic heart disease or uncontrolled symptomatic congestive heart             failure          -  Known history of stroke or cerebrovascular accident within 6 months prior to             enrollment          -  Other uncontrolled serious chronic disease or conditions that in the investigator's             opinion could affect compliance or follow-up in the protocol          -  Concurrent radiotherapy to any site or radiotherapy within 2 weeks prior to             enrollment or previous radiotherapy to the target lesion sites (the sites that are to             be followed for determination of a response)          -  Receipt of any investigational medication within 4 weeks prior to enrollment      "
NCT02468661,Phase 1/Phase 2,Novartis Pharmaceuticals,Industry,"A Phase Ib/II, Open-label, Multicenter Trial With Oral cMET Inhibitor INC280 Alone and in Combination With Erlotinib Versus Platinum With Pemetrexed in Adult Patients With EGFR Mutated, cMET-amplified, Locally Advanced/Metastatic Non-small Cell Lung Cancer (NSCLC) With Acquired Resistance to Prior EGFR Tyrosine Kinase Inhibitor (EGFR TKI)",1,18,150,include,include,include,,,,include,include,,,,,,,require,,,,,,,,require,,"        Inclusion Criteria:          -  Locally advanced or metastatic NSCLC          -  EGFR mutation (L858R and /or ex19del)          -  cMET amplification by FISH (GCN ‰ä´ 6),          -  Acquired resistance to EGFR TKI (1st or 2nd gÌ©nÌ©ration)          -  ECOG performance status (PS) ‰ä_ 1.        Exclusion Criteria:          -  Prior treatment with 3rd generation TKI          -  PhaseII : Prior treatment with any of the following agents:               -  Crizotinib, or any other cMET inhibitor or HGF-targeting inhibitor.               -  Concomitant EGFR TKI and platinum based chemotherapy as first line regimen.               -  Platinum-based chemotherapy as first line treatment      "
NCT01625234,Phase 1/Phase 2,"Xcovery Holding Company, LLC",Industry,"Phase 1/2, First-in-Human, Dose-Escalation Study of X-396 (Ensartinib) in Patients With Advanced Solid Tumors and Expansion Phase in Patients With ALK-positive Non-Small Cell Lung Cancer",1,18,150,include,include,include,,,,include,include,,,,,,require,,,,,,,,,,,"        Inclusion Criteria:          1. Histologically or cytologically confirmed diagnosis of advanced solid tumor             malignancy. Patients may have received prior crizotinib and/or second generation ALK             TKIs (patient must have progressed on alectinib).             -For the expanded cohort portion of the study, patients must have NSCLC with ALK             genomic alterations positive by FISH or IHC testing done centrally; however, patients             will be allowed to enroll based on local ALK FISH or IHC results.          2. Eastern Cooperative Group ECOG) Performance Status score of 0 or 1.          3. Ability to swallow and retain oral medication.          4. Adequate organ system function.          5. Patients with treated or untreated asymptomatic CNS metastases may be allowed to             enroll.          6. Male patients willing to use adequate contraceptive measures.          7. Female patients who are not of child-bearing potential, and female patients of             child-bearing potential who agree to use adequate contraceptive measures.          8. Patients must be ‰ä´ 18 years of age.          9. Patients must have measurable or evaluable disease for the dose escalation portion of             the study and measurable disease for the expanded cohort portion of the study (except             for patients in the CNS metastases and leptomeningeal cohorts).         10. Patients entering this study will be asked to provide tissue for correlative testing             (if available).         11. Willingness and ability to comply with the trial and follow-up procedures.         12. Ability to understand the nature of this trial and give written informed consent.        Exclusion Criteria:          1. Patients currently receiving cancer therapy.          2. Use of an investigational drug within 21 days or 5 half-lives (whichever is shorter)             prior to the first dose of X-396.          3. Any major surgery, radiotherapy, or immunotherapy within the last 21 days.             Chemotherapy regimens with delayed toxicity within the last 4 weeks. Chemotherapy             regimens given continuously or on a weekly basis with limited potential for delayed             toxicity within the last 2 weeks.          4. Prior stem cell transplant.          5. Patients with a known allergy or delayed hypersensitivity reaction to drugs             chemically related to X-396 (e.g., crizotinib) or to the active ingredient of X-396.          6. Patients with primary CNS tumors are ineligible.          7. Concomitant use of herbal medications at least 7 days prior to the first dose of             study drug and throughout participation in the trial.          8. Females who are pregnant or breastfeeding.          9. Presence of active gastrointestinal (GI) disease or other condition that will             interfere significantly with the absorption, distribution, metabolism, or excretion             of X-396.         10. Clinically significant cardiovascular disease.         11. Patients who are immunosuppressed (including known HIV infection), have a serious             active infection at the time of treatment, have known hepatitis C, or have any             serious underlying medical condition that would impair the ability of the patient to             receive protocol treatment.         12. Psychological, familial, sociological, or geographical conditions that do not permit             compliance with the protocol.         13. Concurrent condition that in the investigator's opinion would jeopardize compliance             with the protocol or would impart excessive risk associated with study participation             that would make it inappropriate for the patient to be enrolled.         14. Inability or unwillingness to comply with study and/or follow-up procedures outlined             in the protocol.      "
NCT02039674,Phase 1/Phase 2,Merck Sharp & Dohme Corp.,Industry,A Phase I/II Study of MK-3475 (SCH900475) in Combination With Chemotherapy or Immunotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma,1,18,150,include,include,include,,,,include,include,,,,,,,,,exclude,6,exclude,12,exclude,12,,,"        Inclusion Criteria:          -  Stage IIIb/IV NSCLC          -  Disease progression >1 year after completing adjuvant therapy for Stage I-IIIA             disease and no systemic therapy for the recurrent disease          -  Resolution of any toxic effects (excepting alopecia) of the most recent therapy          -  At least one radiographically measurable lesion          -  Performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG)             Performance Status scale          -  Female participants of reproductive potential must not be pregnant (negative urine or             serum human chorionic gonadotropin test within 72 hours of study start)          -  Female and male participants of reproductive potential must agree to use adequate             contraception throughout the study period and for up to 120 days after the last dose             of study therapy and for up to 180 days after the last dose of chemotherapeutic             agents or tyrosine kinase inhibitors        Exclusion Criteria:          -  Currently participating or has participated in a study of an investigational agent or             using an investigational device within 4 weeks of administration of pembrolizumab          -  Expected to require any other form of antineoplastic therapy while on study          -  Is on chronic systemic steroid therapy or on any other form of immunosuppressive             medication          -  Has received a live-virus vaccination within 30 days of planned treatment start          -  Clinically active diverticulitis, intra-abdominal abscess, gastrointestinal (GI)             obstruction, or abdominal carcinomatosis (known risks factors for bowel perforation)          -  History of a hematologic malignancy, primary brain tumor or sarcoma, or of another             primary solid tumor, unless the participant has undergone potentially curative             therapy with no evidence of that disease for 5 years          -  Active central nervous system (CNS) metastases and/or carcinomatous meningitis          -  Severe hypersensitivity reaction to treatment with another monoclonal antibody (mAb)          -  Active autoimmune disease that has required systemic treatment in the past 2 years             (replacement therapies for hormone deficiencies are allowed)          -  Prior treatment with any other anti-programmed cell death protein-1 (anti-PD-1), or             PD Ligand-1 (PD-L1) or PD Ligand-2 (PD-L2) agent or an antibody targeting other             immuno-regulatory receptors or mechanisms          -  Systemic cytotoxic chemotherapy, antineoplastic biologic therapy, or major surgery             within 3 weeks of the first dose of study medication          -  Radiation therapy to lung >30 Gy within 6 months of first dose of study medication          -  Prior tyrosine kinase inhibitor therapy or palliative radiation within 7 days of             first dose of study medication          -  Active infection requiring therapy          -  History of Human Immunodeficiency Virus (HIV)          -  Active Hepatitis B or C          -  Symptomatic ascites or pleural effusion          -  Interstitial lung disease or pneumonitis requiring oral or IV glucocorticoids          -  Pregnant or breastfeeding, or expecting to conceive or father children within the             projected duration of the study          -  Psychiatric disorders and substance (drug/alcohol) abuse      "
NCT02403271,Phase 1/Phase 2,Pharmacyclics,Industry,"A Multi-Center Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With Durvalumab (MEDI4736), in Subjects With Relapsed or Refractory Solid Tumors",1,18,150,include,include,include,,,,include,include,,,,require,,,,,,,,,,,,,"        Inclusion Criteria:          1. Pathologically confirmed Non-small cell lung cancer (NSCLC, adenocarcinoma or             squamous-cell carcinoma)          2. Relapsed or refractory disease (Stage III or IV): NSCLC must have failed at least 1             prior treatment.          3. Measurable lesion by RECIST 1.1          4. Adequate hematologic function:               -  ANC >1500 cells/mm3               -  Platelet count >100,000 cells/mm3               -  HGB >9.0 g/dL          5. Adequate hepatic and renal function:               -  AST and ALT ‰ä_2.5 x ULN for subjects without liver metastases and ‰ä_3.5 x ULN for                  subjects with liver metastases               -  Bilirubin ‰ä_1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of                  non-hepatic origin)               -  Creatinine ‰ä_2.0 x ULN or Creatinine Clearance ‰ä´40 mL/min          6. PT/INR <1.5 x ULN and PTT/ aPTT <1.5 x ULN        Exclusion Criteria:          1. Mixed small cell and NSCLC histology          2. A history of CNS involvement except as follows: Subjects with previously treated CNS             metastases that are adequately treated with whole brain radiotherapy, that are             neurologically stable, and do not require corticosteroids for symptomatic management             for at least 14 days prior to first dose of study drug. There must be no clear             evidence of radiographically active disease for at least 90 days prior to enrollment.          3. Anti-tumor therapy within 21 days of study Day 1          4. Prior treatment with ibrutinib or other BTK inhibitor anti-CD137 or CTLA-4 antibody.             The following are exceptions to this criterion: Subjects previously treated with an             anti-PD1, anti-PD-L1, or anti-PD-L2 antibody.          5. History of allogeneic organ transplant          6. Treatment with a strong cytochrome P450 (CYP) 3A inhibitor      "
NCT02403271,Phase 1/Phase 2,Pharmacyclics,Industry,"A Multi-Center Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With Durvalumab (MEDI4736), in Subjects With Relapsed or Refractory Solid Tumors",2,18,150,include,include,include,,,,include,include,,,,,require,,,,,,,,,,,,"        Inclusion Criteria:          1. Pathologically confirmed Non-small cell lung cancer (NSCLC, adenocarcinoma or             squamous-cell carcinoma)          2. Relapsed or refractory disease (Stage III or IV): NSCLC must have failed at least 1             prior treatment.          3. Measurable lesion by RECIST 1.1          4. Adequate hematologic function:               -  ANC >1500 cells/mm3               -  Platelet count >100,000 cells/mm3               -  HGB >9.0 g/dL          5. Adequate hepatic and renal function:               -  AST and ALT ‰ä_2.5 x ULN for subjects without liver metastases and ‰ä_3.5 x ULN for                  subjects with liver metastases               -  Bilirubin ‰ä_1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of                  non-hepatic origin)               -  Creatinine ‰ä_2.0 x ULN or Creatinine Clearance ‰ä´40 mL/min          6. PT/INR <1.5 x ULN and PTT/ aPTT <1.5 x ULN        Exclusion Criteria:          1. Mixed small cell and NSCLC histology          2. A history of CNS involvement except as follows: Subjects with previously treated CNS             metastases that are adequately treated with whole brain radiotherapy, that are             neurologically stable, and do not require corticosteroids for symptomatic management             for at least 14 days prior to first dose of study drug. There must be no clear             evidence of radiographically active disease for at least 90 days prior to enrollment.          3. Anti-tumor therapy within 21 days of study Day 1          4. Prior treatment with ibrutinib or other BTK inhibitor anti-CD137 or CTLA-4 antibody.             The following are exceptions to this criterion: Subjects previously treated with an             anti-PD1, anti-PD-L1, or anti-PD-L2 antibody.          5. History of allogeneic organ transplant          6. Treatment with a strong cytochrome P450 (CYP) 3A inhibitor      "
NCT02514447,Phase 1/Phase 2,"G1 Therapeutics, Inc.",Industry,Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients With Previously Treated Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Topotecan Chemotherapy,1,18,150,,,,include,,,,,include,include,,,,,,,,,require,,,,,,"        Inclusion Criteria:          -  Male or female subjects aged ‰ä´18 years          -  Unequivocally confirmed diagnosis of SCLC by histology or cytology, preferably             including the presence of neuroendocrine features by immunohistochemistry          -  Progression during or after prior first- or second-line chemotherapy and eligible to             receive topotecan therapy          -  At least 1 target lesion that is measurable by RECIST, Version 1.1          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2          -  Adequate organ function        Exclusion Criteria:          -  Presence of symptomatic brain metastases requiring immediate treatment with radiation             therapy or steroids.          -  Uncontrolled ischemic heart disease or uncontrolled symptomatic congestive heart             failure          -  Known history of stroke or cerebrovascular accident within 6 months prior to             enrollment          -  Other uncontrolled serious chronic disease or conditions that in the investigator's             opinion could affect compliance or follow-up in the protocol          -  Concurrent radiotherapy to any site or radiotherapy within 2 weeks prior to             enrollment or previous radiotherapy to the target lesion sites (the sites that are to             be followed for determination of a response)          -  Receipt of any investigational medication within 2 weeks prior to enrollment          -  History of topotecan treatment for SCLC      "
NCT02247349,Phase 1/Phase 2,Bristol-Myers Squibb,Industry,A Phase 1/2 Multicenter Study of BMS-986012 in Subjects With Relapsed/Refractory Small Cell Lung Cancer,1,18,150,,,,include,,,,,include,include,,,,,,,,,,,,,,,"        For more information regarding BMS clinical trial participation, please visit        www.BMSStudyConnect.com        Inclusion Criteria:          -  Histological or cytological confirmed small cell lung cancer (SCLC)          -  Performance Status 0-1          -  Adequate organ function          -  Measurable disease        Exclusion Criteria:          -  Known or suspected brain metastasis          -  Small cell cancer not lung in origin          -  Significant or acute medical illness          -  Uncontrolled or significant cardiac disease          -  Infection          -  ‰ä´ Grade 2 peripheral neuropathy          -  Concomitant malignancies          -  HIV related disease or known or suspected HIV+          -  Hepatitis B or C infection          -  ECG abnormalities as defined by the protocol          -  Allergies or hypersensitivities to monoclonal antibodies, BMS-986012 or related             compounds, including fucosyl-GM1 vaccine and Nivolumab        Other protocol defined inclusion/exclusion criteria could apply      "
NCT02346370,Phase 1/Phase 2,Halozyme Therapeutics,Industry,"PRIMAL STUDY: A Phase 1b/2, Randomized, Multicenter, Multinational Study of Pegylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Docetaxel (PDoc) Compared With Docetaxel (Doc) Alone in Subjects With Recurrent Previously Treated Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)",1,18,150,include,include,include,,,,include,include,,,,require,,,,,,,,,,,,,"        Inclusion Criteria:          -  Signed, approved Informed Consent          -  Histologically confirmed and previously treated Stage IIIB/IV NSCLC, having failed no             more than 1 platinum chemo regimen          -  Available archival tumor tissue block - 10 unstained, core biopsy slides that meet             specific tissue requirements          -  Phase 1b Schedule finding/Phase 2 - one or more tumors measureable on CT scan (RECIST             1.1)          -  Life expectancy - =/> 3 months, ECOG (Eastern Cooperative Oncology Group) status = 0             or 1          -  Negative pregnancy test          -  Men and women agreement to use effective contraceptive method          -  Specific ranges/levels of Screening labs that are acceptable        Exclusion Criteria:          -  Previous treatment with docetaxel          -  New York Heart Assoc Class III or IV cardiac disease, myocardial infarction within             the past 12 - months          -  Prior history of cerebrovascular accident or transient ischemic attack or preexisting             - carotid artery disease          -  History of pulmonary embolism or pulmonary embolism found on screening exam          -  Active, uncontrolled bacterial, viral or fungal infection at time of screening          -  Known infection with HIV, Hepatitis B or C          -  Known allergy to hyaluronidase or any constituents of docetaxel formulation          -  Current use (within 10 days of day 1) of megestrol acetate          -  Women currently pregnant or breast feeding          -  Intolerance to dexamethasone as determined by Investigator          -  History of another primary cancer within the last 3 years          -  Any other disease, metabolic dysfunction, physical exam finding or clinical lab             finding that leads to reasonable suspicion of disease that contraindicates the use of             an investigational drug that might affect interpretation of results or render subject             at high risk for treatment complications          -  In opinion of Investigator, make subject unsuitable for study. Subject's inability to             comply with study and follow-up procedures, as judged by the Investigator      "
NCT02349633,Phase 1/Phase 2,Pfizer,Industry,Phase 1/2 Open‰ÛÔLabel Study Of PF-06747775 (Epidermal Growth Factor Receptor T790M Inhibitor) In Patients With Advanced Epidermal Growth Factor Receptor Mutant (Ddel 19 or L858R å± t790M) Non‰ÛÔSmall Cell Lung Cancer,1,18,150,include,include,include,,,,include,include,,,,,,,require,,,,,,,,require,,"        Inclusion criteria (partial list):          -  Evidence of histologically or cytologically confirmed diagnosis of locally advanced             or metastatic EGFRm (del19 or L858R) NSCLC that has progressed after at least 1 prior             line of therapy.        Patients must have at least on measurable lesion as defined by RECIST V1.1 that has not        been previously irradiated          -  Patients must have had disease progression on treatment with an approved EGFR TKI.               -  In Phase 1, patients may have also received other lines of therapy before or                  after the EGFR TKI.               -  In Phase 2, while patients may have had multiple lines of therapy, the last                  therapy prior to study treatment must have been an approved EGFR TKI and                  received within 6 weeks prior to study registration.          -  In the Phase 1 portion:               -  In the dose escalation and MTD expansion portions patients must be T790M                  positive or unknown status.               -  In the PK sub-studies, patients with EGFRm (del 19 or L858R) with any T790M                  status are eligible to enroll.          -  In the Phase 2 portion:             ‰Û¢ Patients must have EGFRm (del 19 and T790M or L858R and T790M) NSCLC tumors          -  Patients must have at least one measurable lesion as defined by RECIST version 1.1          -  Tumor tissue available (ie, formalin fixed paraffin embedded (FFPE) block or 15             unstained sections (5 micron). If lesser amount of tissue is available, contact the             sponsor. An archival specimen is acceptable for Phase 1; a de novo specimen is             required for Phase 2.          -  Patients must have adequate bone marrow, hepatic and renal functions          -  Negative serum pregnancy test        Exclusion Criteria (partial list)          -  Previously diagnosed brain metastases, unless the patient has completed their             treatment that is clinically indicated, if any, and has recovered from the acute             effects of radiation therapy or surgery prior to study registration, have             discontinued corticosteroid treatment for these metastases for at least 2 weeks, and             are neurologically stable.          -  Major surgery within 2 weeks prior to registration          -  Radiation therapy, excluding steriotactic radiosurgery, within 1 week prior to             registration.          -  Systemic anti cancer therapy within 2 weeks or 5 half-lives (whichever is longer) of             registration excluding EGFR TKIs. Patients on EGFR TKIs must discontinue the agent             for a minimum of :               -  2 days prior to registration for erlotinib or afatinib, or 3 days for gefitinib                  if they will be part of the lead-in single dose PF-06747775 PK study (Phase 1                  Dose Escalation Single and Multiple dose PK and ECG Assessments; Phase 1                  Sildenafil at MTD and Japan PK sub-studies). Please contact the Sponsor for                  direction for any other EGFR TKI.               -  5 half-lives or 5 days (whichever is longer) prior to registration if they will                  be starting on continuous PF-06747775 dosing directly (Phase 1 PK sub-studies at                  RP2D except Japan).          -  Concurrent use of drugs that are strong P-glycoprotein (P-gp) inhibitors (such as but             not limited to: dronedarone, erythromycin, indinavir, indinavir/ritonavir,             itraconazole, ketoconazole, lapatinib, lopinavir/ritonavir, quinidine, rifampin,             ritonavir, valspodar, verapamil, vorapaxar). Patients must avoid the use of drugs             that are known strong P-gp inhibitors for the duration of the study. therapy with a             T790M directed agent      "
NCT02108964,Phase 1/Phase 2,Novartis Pharmaceuticals,Industry,"A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies",1,18,150,include,include,include,,,,,include,,,,,,require,,,,,,,,,,,"        Inclusion Criteria: (For all patients unless otherwise specified)          1. Written informed consent must be obtained prior to any screening procedures          2. Patient (male or female) ‰ä´ 18 years of age [For Japan only: written consent is             necessary both from the patient and his/her legal representative if he/she is under             the age of 20 years.]          3. Patients must have histologically or cytologically confirmed locally advanced (stage             IIIB not amenable to definitive multi-modality therapy including surgery) or             metastatic (stage IV) EGFR mutant NSCLC.          4. Patients with controlled brain metastases may participate in the trial. They must             complete any planned radiation therapy and/or surgery >2 weeks prior to the first             dose of study treatment and remain asymptomatic. Patients on steroids must have been             on a stable low dose for 2 weeks prior to initiating study treatment.          5. ECOG performance status: Phase I part: 0, 1, or 2; Phase II part: 0 or 1          6. Presence of at least one measurable lesion according to RECIST 1.1 per Investigator             assessment. A previously irradiated site lesion may be counted as a target lesion             only if there is clear sign of progression since the irradiation. (see Section 14.1             Appendix 1)          7. Patients must be screened for HBV. Patients who are either HBsAg positive or HBV-DNA             positive must be willing and able to take antiviral therapy 1-2 weeks prior to 1st             dose of EGF816 treatment and continue on antiviral therapy for at least 4 weeks after             the last dose of EGF816. Additional management of the patients would be provided by a             physician with expertise in management of HBV, if needed.          8. Patients must be screened for HCV. Patients must have negative hepatitis C antibody             (HCV-Ab) or positive HCV-Ab but undetectable level of HCV-RNA. Note: patients with             detectable HCV-RNA are not eligible for the study.          9. Willingness and ability to comply with scheduled visits, treatment plans, laboratory             tests and other study procedures        Exclusion criteria: (Applies to all patients unless otherwise specified)          1. Patients with a history or presence of interstitial lung disease or interstitial             pneumonitis, including clinically significant radiation pneumonitis (i.e. affecting             activities of daily living or requiring therapeutic intervention)          2. Patients with unstable brain metastases          3. History of another malignancy Exception: Patients who have been disease-free for 3             years, or patients with a history of adequately treated in-situ carcinoma of the             uterine cervix, basal or squamous cell carcinoma, non-melanomatous cancer of skin,             history of stage IA melanoma that has been cured, are eligible.          4. Undergone a bone marrow or solid organ transplant          5. Known history of human immunodeficiency virus (HIV) seropositivity (HIV testing is             not mandatory)          6. Patients receiving concomitant immunosuppressive agents or chronic corticosteroids             use at the time of study entry except for control of brain metastases, topical             applications, inhaled sprays, eye drops or local injections          7. Patients with clinically significant, uncontrolled heart disease, such as:               -  Unstable angina within 6 months prior to screening               -  Myocardial infarction within 6 months prior to screening               -  Patients with a history of documented congestive heart failure (New York Heart                  Association functional classification III-IV)               -  Patients with uncontrolled hypertension defined as a Systolic Blood Pressure                  (SBP) ‰ä´ 160 mm Hg and/or Diastolic Blood Pressure (DBP) ‰ä´ 100 mm Hg, with or                  without anti-hypertensive medication. Initiation or adjustment of                  antihypertensive medication(s) is allowed prior to screening               -  Ventricular arrhythmias               -  Supraventricular and nodal arrhythmias not controlled with medication               -  Other cardiac arrhythmia not controlled with medication               -  Patients with a history of congenital long QT syndrome, history of Torsade de                  Pointes or patients with corrected QT (QTc) >480 msec using Fridericia                  correction (QTcF) on the screening ECG (using triplicate ECGs)          8. Patients who have received thoracic radiotherapy to lung fields ‰ä_ 4 weeks prior to             starting the study treatment or patients who have not recovered from             radiotherapy-related toxicities. For all other anatomic sites (including radiotherapy             to thoracic vertebrae and ribs), radiotherapy ‰ä_ 2 weeks prior to starting the study             treatment or patients who have not recovered from radiotherapy-related toxicities.             Palliative radiotherapy for bone lesions ‰ä_ 2 weeks prior to starting study treatment          9. Patients who have had major surgery (e.g., intra-thoracic, intra-abdominal or             intra-pelvic) within 4 weeks prior (2 weeks for resection of brain metastases) to             starting study drug or who have not recovered from side effects of such procedure.             Video-assisted thoracic surgery (VATS) and mediastinoscopy will not be counted as             major surgery and patients can be enrolled in the study ‰ä´1 week after the procedure.         10. Any medical condition that would, in the investigator's judgment, prevent the             patient's participation in the clinical study due to safety concerns or compliance             with clinical study procedures. Any severe, acute, or chronic medical or psychiatric             condition or laboratory abnormality that may increase the risk associated with study             participation or study treatment administration or that may interfere with the             interpretation of study results and, in the judgment of the investigator, would make             the patient inappropriate for the study         11. Prior therapies               -  Patients who have been treated with chemotherapy or biologic therapy or other                  investigational agent ‰ä_ 1 week prior to the first dose of study treatment               -  Unresolved toxicity greater than CTCAE grade 1 from prior anticancer therapy or                  radiotherapy (excluding neurotoxicity, alopecia, lymphopenia)               -  Note: exceptions to the above are possible, on a case by case basis, following                  discussion and mutual agreement between investigator and Novartis (applicable to                  the Phase I part only).         12. Patients who have out of range laboratory values defined as               -  Absolute Neutrophil Count (ANC) <1.5 x 109/L               -  Hemoglobin (Hgb) <9 g/dL               -  Platelets <75 x 109/L               -  Total bilirubin >1.5 x upper limit of normal (ULN). For patients with Gilbert's                  syndrome total bilirubin >3.0 x ULN               -  Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) >3 x ULN                  for patients without hepatic metastasis               -  AST and/or ALT >5 x ULN for patients with hepatic metastasis               -  Alkaline phosphatase (ALP) >5 x ULN               -  Fasting plasma glucose >175 mg/dL (>9.8 mmol/L)               -  Measured or calculated creatinine clearance <45 ml/min using Cockcroft-Gault                  formula         13. Patients who have the following laboratory values outside of the laboratory normal             limits or cannot be corrected to within normal limits with supplements during             screening:               -  Potassium               -  Magnesium               -  Phosphorus               -  Total calcium (corrected for serum albumin)         14. Patients who are receiving treatment with medications that are known to be strong             inhibitors or inducers of CYP3A4/5 and cannot be discontinued 1 week prior to the             start of EGF816 treatment and for the duration of the study.         15. Participation in a prior investigational study within 1 week or within 5 half-lives             of the investigational product, whichever is longer, prior to first dose of study             treatment Note: exceptions to the above are possible, on a case by case basis,             following discussion and mutual agreement between investigator and Novartis             (applicable to the Phase I part only).         16. Patients who have impairment of GI function or GI disease that may significantly             alter the absorption of EGF816 (e.g., ulcerative diseases, uncontrolled nausea,             vomiting, diarrhea, or malabsorption syndrome)         17. Patients who are receiving treatment with any enzyme-inducing anticonvulsant that             cannot be discontinued at least 1 week before first dose of study treatment, and for             the duration of the study. Patients on non-enzyme-inducing anticonvulsants are             eligible         18. Pregnant or nursing (lactating) women         19. Women of child-bearing potential, defined as all women physiologically capable of             becoming pregnant, unless they are using highly effective methods of contraception             during the study and for 3 months after stopping the study treatment. Highly             effective contraception methods include:               -  Total abstinence (when this is in line with the preferred and usual lifestyle of                  the subject. Periodic abstinence (e.g., calendar, ovulation, symptomthermal,                  post-ovulation methods) and withdrawal are not acceptable methods of                  contraception               -  Female sterilization (have had surgical bilateral oophorectomy with or without                  hysterectomy) or tubal ligation at least six weeks before taking study                  treatment. In case of oophorectomy alone, only when the reproductive status of                  the woman has been confirmed by follow up hormone level assessment               -  Male Partner: male sterilization (at least 6 months prior to screening). For                  female subjects on the study the vasectomized male partner should be the sole                  partner for that subject.               -  Combination of any two of the following (a+b or a+c, or b+c):                    1. Use of oral, injected or implanted hormonal methods of contraception or                       other forms of hormonal contraception that have comparable efficacy                       (failure rate < 1%), for example hormone vaginal ring or transdermal                       hormone contraception.                    2. Placement of an intrauterine device (IUD) or intrauterine system (IUS)                    3. Barrier methods of contraception: Condom or Occlusive cap (diaphragm or                       cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal                       suppository In case of use of oral contraception women should have been                       stable on the same pill for a minimum of 30 days before taking study                       treatment.             Women are considered post-menopausal and not of childbearing potential if they have             had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical             profile (e.g. age appropriate, history of vasomotor symptoms) or have had surgical             bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six             weeks ago. In the case of oophorectomy alone, only when the reproductive status of             the woman has been confirmed by follow up hormone level assessment is she considered             not of childbearing potential.         20. Sexually active males unless they use a condom during intercourse while taking drug             and for 3 months after stopping treatment; men should not father a child in this             period. A condom is required to be used also by vasectomized men in order to prevent             delivery of the drug via seminal fluid.        Other protocol-defined exclusion criteria may apply.      "
NCT02642042,Phase 2,National Cancer Institute (NCI),NIH,A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies,1,0,150,include,include,include,,,,,include,,,,,,,,require,,,require,,,,,,"        Inclusion Criteria:          -  DISEASE RELATED CRITERIA: Patients must have pathologically confirmed KRAS mutation             positive non-small cell lung cancer (NSCLC) that is stage IV or recurrent; the             specific subtype of KRAS mutation must be known; KRAS mutation testing must have been             performed in a Clinical Laboratory Improvement Amendments (CLIA) certified             laboratory; CLIA certified commercially available tests are acceptable          -  DISEASE RELATED CRITERIA: Patients must have measurable disease documented by             computed tomography (CT) or magnetic resonance imaging (MRI) within 28 days prior to             registration; the CT from a combined positron emission tomography (PET)/CT may be             used only if it is of diagnostic quality; non-measurable disease must be assessed             within 42 days prior to registration; all known sites of disease must be assessed and             documented on the baseline tumor assessment form (Response Evaluation Criteria in             Solid Tumors [RECIST 1.1])          -  DISEASE RELATED CRITERIA: Patients must not have known brain metastases unless: (1)             metastases have been locally treated (including stereotactic body radiation therapy             [SBRT], whole brain radiotherapy [WBRT], and surgical resection) and have remained             clinically controlled and asymptomatic for at least 14 days following treatment and             prior to registration, AND (2) patient has no residual neurological dysfunction and             has been off corticosteroids for at least 24 hours prior to registration          -  PRIOR/CONCURRENT THERAPY CRITERIA: Patients must have documented progressive cancer             following at least one but no more than two prior regimens of systemic therapy for             lung cancer, one of which must have been platinum based combination chemotherapy.             Patients must not have received any chemotherapy drug within three weeks prior to             registration. Patients must not have received any biologic agent within two weeks             prior to registration          -  PRIOR/CONCURRENT THERAPY CRITERIA: Adjuvant chemotherapy or chemotherapy administered             as part of concurrent chemotherapy and radiation therapy for the treatment of lung             cancer will not count as a prior regimen of systemic therapy as long as recurrent of             patient's lung cancer occurred more than 12 months after the last day of chemotherapy          -  PRIOR/CONCURRENT THERAPY CRITERIA: Patients must not have received prior docetaxel;             patients must not have received therapy with a drug known to be either a             mitogen-activated protein kinase (MEK) inhibitor or a phosphatidylinositol 3 kinase             (PI3K)/v-akt murine thymoma viral oncogene homolog 1 (AKT)/mammalian target of             rapamycin (mTOR) pathway inhibitor          -  PRIOR/CONCURRENT THERAPY CRITERIA: Patients must have recovered from any adverse             effects from prior therapy (except alopecia) to =< grade 1 prior to registration          -  PRIOR/CONCURRENT THERAPY CRITERIA: Patients may have had prior radiation therapy as             long as it has not affected greater than 25% of the bone marrow and at least one             measurable lesion is outside the area of prior radiation; at least one week must have             elapsed since last radiation treatment; patients must have recovered from any adverse             events from prior radiation therapy to =< Common Terminology Criteria For Adverse             Events (CTCAE) grade 1          -  PRIOR/CONCURRENT THERAPY CRITERIA: Patients must not have had a major surgery within             28 days prior to registration; patients must have recovered from any adverse effects             of prior surgery to the satisfaction of the treating physician          -  CLINICAL/LABORATORY CRITERIA: Patients must have Zubrod performance status of 0-2          -  CLINICAL/LABORATORY CRITERIA: Absolute neutrophil count (ANC) >= 1500/mcL; these             results must be obtained within 28 days prior to registration          -  CLINICAL/LABORATORY CRITERIA: Platelet count >= 100,000/mcL; these results must be             obtained within 28 days prior to registration          -  CLINICAL/LABORATORY CRITERIA: Hemoglobin >= 9 grams/dl; these results must be             obtained within 28 days prior to registration          -  CLINICAL/LABORATORY CRITERIA: Total bilirubin =< 1.5 x institutional upper limit of             normal (IULN); these results must be obtained within 28 days prior to registration          -  CLINICAL/LABORATORY CRITERIA: Aspartate aminotransferase (AST) and alanine             aminotransferase (ALT) =< 2.5 x IULN (or =< 5 x IULN for patients with known liver             metastases); these results must be obtained within 28 days prior to registration          -  CLINICAL/LABORATORY CRITERIA: Serum creatinine =< 1.5 x IULN OR measured or             calculated creatinine clearance >= 40 mL/min; this result must have been obtained             within 28 days prior to registration          -  CLINICAL/LABORATORY CRITERIA: Patients must be able to swallow oral medications and             must not have a gastro-intestinal disorder with diarrhea as a major symptom          -  CLINICAL/LABORATORY CRITERIA: Patients must not have history of significant co-morbid             illness inclusive of but not restricted to uncontrolled congestive cardiac failure,             uncontrolled hypertension, history of myocardial infarction or cerebrovascular             accident within 6 months prior to registration or any other illness that in the             assessment of the treating physician would compromise the ability of the patient to             participate in this study          -  CLINICAL/LABORATORY CRITERIA: Patients must have corrected QT (QTc) interval =< 480             msec on electrocardiogram performed within 42 days prior to registration          -  CLINICAL/LABORATORY CRITERIA: Patients must not have untreated or unresolved             retinopathy          -  CLINICAL/LABORATORY CRITERIA: Patients must not have a known history of active             hepatitis B infection (defined as presence of hepatitis [Hep] B surface antigen [sAg]             and/or Hep B deoxyribonucleic acid [DNA]), active hepatitis C infection (defined as             presence of Hep C ribonucleic acid [RNA]), or human immunodeficiency virus (HIV)             seropositivity          -  CLINICAL/LABORATORY CRITERIA: No other prior malignancy is allowed except for the             following: adequately treated basal cell or squamous cell skin cancer, in situ             cervical cancer, adequately treated stage I or II cancer from which the patient is             currently in complete remission, or any other cancer from which the patient has been             disease free for three years; patients with localized prostate cancer who are being             followed by an active surveillance program are also eligible          -  CLINICAL/LABORATORY CRITERIA: Patients must not be pregnant or nursing; women/men of             reproductive potential must have agreed to use an effective contraceptive method; a             woman is considered to be of ""reproductive potential"" if she has had menses at any             time in the preceding 12 consecutive months; in addition to routine contraceptive             methods, ""effective contraception"" also includes heterosexual celibacy and surgery             intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined             as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation; however, if at             any point a previously celibate patient chooses to become heterosexually active             during the time period for use of contraceptive measures outlined in the protocol,             he/she is responsible for beginning contraceptive measures          -  SPECIMEN SUBMISSION CRITERIA: Patients must be offered participation in translational             medicine studies and banking          -  REGULATORY CRITERIA: Patients must be informed of the investigational nature of this             study and must sign and give written informed consent in accordance with             institutional and federal guidelines          -  REGULATORY CRITERIA: As a part of the Oncology Patient Enrollment Network (OPEN)             registration process the treating institution's identity is provided in order to             ensure that the current (within 365 days) date of institutional review board approval             for this study has been entered in the system      "
NCT02642042,Phase 2,National Cancer Institute (NCI),NIH,A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies,2,0,150,include,include,include,,include,include,include,,,,,require,,,,require,,,require,,,,,,"        Inclusion Criteria:          -  DISEASE RELATED CRITERIA: Patients must have pathologically confirmed KRAS mutation             positive non-small cell lung cancer (NSCLC) that is stage IV or recurrent; the             specific subtype of KRAS mutation must be known; KRAS mutation testing must have been             performed in a Clinical Laboratory Improvement Amendments (CLIA) certified             laboratory; CLIA certified commercially available tests are acceptable          -  DISEASE RELATED CRITERIA: Patients must have measurable disease documented by             computed tomography (CT) or magnetic resonance imaging (MRI) within 28 days prior to             registration; the CT from a combined positron emission tomography (PET)/CT may be             used only if it is of diagnostic quality; non-measurable disease must be assessed             within 42 days prior to registration; all known sites of disease must be assessed and             documented on the baseline tumor assessment form (Response Evaluation Criteria in             Solid Tumors [RECIST 1.1])          -  DISEASE RELATED CRITERIA: Patients must not have known brain metastases unless: (1)             metastases have been locally treated (including stereotactic body radiation therapy             [SBRT], whole brain radiotherapy [WBRT], and surgical resection) and have remained             clinically controlled and asymptomatic for at least 14 days following treatment and             prior to registration, AND (2) patient has no residual neurological dysfunction and             has been off corticosteroids for at least 24 hours prior to registration          -  PRIOR/CONCURRENT THERAPY CRITERIA: Patients must have documented progressive cancer             following at least one but no more than two prior regimens of systemic therapy for             lung cancer, one of which must have been platinum based combination chemotherapy.             Patients must not have received any chemotherapy drug within three weeks prior to             registration. Patients must not have received any biologic agent within two weeks             prior to registration          -  PRIOR/CONCURRENT THERAPY CRITERIA: Adjuvant chemotherapy or chemotherapy administered             as part of concurrent chemotherapy and radiation therapy for the treatment of lung             cancer will not count as a prior regimen of systemic therapy as long as recurrent of             patient's lung cancer occurred more than 12 months after the last day of chemotherapy          -  PRIOR/CONCURRENT THERAPY CRITERIA: Patients must not have received prior docetaxel;             patients must not have received therapy with a drug known to be either a             mitogen-activated protein kinase (MEK) inhibitor or a phosphatidylinositol 3 kinase             (PI3K)/v-akt murine thymoma viral oncogene homolog 1 (AKT)/mammalian target of             rapamycin (mTOR) pathway inhibitor          -  PRIOR/CONCURRENT THERAPY CRITERIA: Patients must have recovered from any adverse             effects from prior therapy (except alopecia) to =< grade 1 prior to registration          -  PRIOR/CONCURRENT THERAPY CRITERIA: Patients may have had prior radiation therapy as             long as it has not affected greater than 25% of the bone marrow and at least one             measurable lesion is outside the area of prior radiation; at least one week must have             elapsed since last radiation treatment; patients must have recovered from any adverse             events from prior radiation therapy to =< Common Terminology Criteria For Adverse             Events (CTCAE) grade 1          -  PRIOR/CONCURRENT THERAPY CRITERIA: Patients must not have had a major surgery within             28 days prior to registration; patients must have recovered from any adverse effects             of prior surgery to the satisfaction of the treating physician          -  CLINICAL/LABORATORY CRITERIA: Patients must have Zubrod performance status of 0-2          -  CLINICAL/LABORATORY CRITERIA: Absolute neutrophil count (ANC) >= 1500/mcL; these             results must be obtained within 28 days prior to registration          -  CLINICAL/LABORATORY CRITERIA: Platelet count >= 100,000/mcL; these results must be             obtained within 28 days prior to registration          -  CLINICAL/LABORATORY CRITERIA: Hemoglobin >= 9 grams/dl; these results must be             obtained within 28 days prior to registration          -  CLINICAL/LABORATORY CRITERIA: Total bilirubin =< 1.5 x institutional upper limit of             normal (IULN); these results must be obtained within 28 days prior to registration          -  CLINICAL/LABORATORY CRITERIA: Aspartate aminotransferase (AST) and alanine             aminotransferase (ALT) =< 2.5 x IULN (or =< 5 x IULN for patients with known liver             metastases); these results must be obtained within 28 days prior to registration          -  CLINICAL/LABORATORY CRITERIA: Serum creatinine =< 1.5 x IULN OR measured or             calculated creatinine clearance >= 40 mL/min; this result must have been obtained             within 28 days prior to registration          -  CLINICAL/LABORATORY CRITERIA: Patients must be able to swallow oral medications and             must not have a gastro-intestinal disorder with diarrhea as a major symptom          -  CLINICAL/LABORATORY CRITERIA: Patients must not have history of significant co-morbid             illness inclusive of but not restricted to uncontrolled congestive cardiac failure,             uncontrolled hypertension, history of myocardial infarction or cerebrovascular             accident within 6 months prior to registration or any other illness that in the             assessment of the treating physician would compromise the ability of the patient to             participate in this study          -  CLINICAL/LABORATORY CRITERIA: Patients must have corrected QT (QTc) interval =< 480             msec on electrocardiogram performed within 42 days prior to registration          -  CLINICAL/LABORATORY CRITERIA: Patients must not have untreated or unresolved             retinopathy          -  CLINICAL/LABORATORY CRITERIA: Patients must not have a known history of active             hepatitis B infection (defined as presence of hepatitis [Hep] B surface antigen [sAg]             and/or Hep B deoxyribonucleic acid [DNA]), active hepatitis C infection (defined as             presence of Hep C ribonucleic acid [RNA]), or human immunodeficiency virus (HIV)             seropositivity          -  CLINICAL/LABORATORY CRITERIA: No other prior malignancy is allowed except for the             following: adequately treated basal cell or squamous cell skin cancer, in situ             cervical cancer, adequately treated stage I or II cancer from which the patient is             currently in complete remission, or any other cancer from which the patient has been             disease free for three years; patients with localized prostate cancer who are being             followed by an active surveillance program are also eligible          -  CLINICAL/LABORATORY CRITERIA: Patients must not be pregnant or nursing; women/men of             reproductive potential must have agreed to use an effective contraceptive method; a             woman is considered to be of ""reproductive potential"" if she has had menses at any             time in the preceding 12 consecutive months; in addition to routine contraceptive             methods, ""effective contraception"" also includes heterosexual celibacy and surgery             intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined             as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation; however, if at             any point a previously celibate patient chooses to become heterosexually active             during the time period for use of contraceptive measures outlined in the protocol,             he/she is responsible for beginning contraceptive measures          -  SPECIMEN SUBMISSION CRITERIA: Patients must be offered participation in translational             medicine studies and banking          -  REGULATORY CRITERIA: Patients must be informed of the investigational nature of this             study and must sign and give written informed consent in accordance with             institutional and federal guidelines          -  REGULATORY CRITERIA: As a part of the Oncology Patient Enrollment Network (OPEN)             registration process the treating institution's identity is provided in order to             ensure that the current (within 365 days) date of institutional review board approval             for this study has been entered in the system      "
NCT01822496,Phase 2,National Cancer Institute (NCI),NIH,A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer (NSCLC),1,18,150,include,include,,,,,include,,,,require,exclude,,,,,,,exclude,1800,,,,,"        Inclusion Criteria:          -  Histologically or cytologically confirmed, newly diagnosed non-squamous NSCLC          -  Unresectable stage IIIA or IIIB disease; patients must be surgically staged to             confirm N2 or N3 disease; patients may have invasive mediastinal staging by             mediastinoscopy, mediastinotomy, endobronchial ultrasound transbronchial aspiration             (EBUS-TBNA), endoscopic ultrasound (EUS), or video-assisted thoracoscopic surgery             (VATS)          -  Patients with any tumor (T) with node (N)2 or N3 are eligible; patients with T3,             N1-N3 disease are eligible if deemed unresectable; patients with T4, any N are             eligible          -  Patients must have measurable disease, i.e., lesions that can be accurately measured             in at least 1 dimension (longest dimension in the plane of measurement is to be             recorded) with a minimum size of 10 mm by computed tomography (CT) scan (CT scan             slice thickness no greater than 5 mm)          -  Patients with a pleural effusion, which is a transudate, cytologically negative and             non-bloody, are eligible if the radiation oncologist feels the tumor can be             encompassed within a reasonable field of radiotherapy          -  If a pleural effusion can be seen on the chest CT but not on chest x-ray and is too             small to tap, the patient will be eligible; patients who develop a new pleural             effusion after thoracotomy or other invasive thoracic procedure will be eligible          -  The institution's pre-enrollment biomarker screening at a Clinical Laboratory             Improvement Amendments (CLIA) certified lab documents presence of known ""sensitive""             mutations in epidermal growth factor receptor tyrosine kinase (EGFR TK) domain (exon             19 deletion, L858) and/or EML4-anaplastic lymphoma kinase (ALK) fusion arrangement;             either the primary tumor or the metastatic lymph node tissue may be used for testing             of mutations          -  The institution's pre-enrollment biomarker screening at a CLIA certified lab             documents absence of T790M mutation in the EGFR TK domain          -  Appropriate stage for protocol entry, including no distant metastases, based upon the             following minimum diagnostic workup:               -  History/physical examination, including recording of pulse, blood pressure (BP),                  weight, and body surface area, within 45 days prior to registration               -  Whole body fludeoxyglucose-positron emission tomography (FDG-PET)/CT (orbits to                  mid-thighs) within 30 days prior to registration; PET/CT must be negative for                  distant metastasis               -  CT scan with contrast of the chest and upper abdomen to include liver and                  adrenals (unless medically contraindicated) within 30 days prior to registration               -  Magnetic resonance imaging (MRI) of the brain with contrast (or CT scan with                  contrast, if MRI medically contraindicated) within 30 days prior to registration          -  Zubrod performance status 0-1 within 14 days prior to registration          -  Absolute neutrophil count (ANC) >= 1,000 cells/mm^3          -  Platelets >= 100,000 cells/mm^3          -  Hemoglobin >= 8.0 g/dl (Note: the use of transfusion or other intervention to achieve             hemoglobin [Hgb] >= 8.0 g/dl is acceptable)          -  Serum creatinine < 1.5 mg/dL or calculated creatinine clearance >= 50 ml/min (by             Cockcroft-Gault formula) within 14 days prior to registration          -  Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x upper limit             of normal (ULN) within 14 days prior to registration          -  Bilirubin within normal institutional limits within 14 days prior to registration          -  Negative serum pregnancy test within 14 days prior to registration for women of             childbearing potential          -  Patient must provide study specific informed consent prior to study entry, including             consent for mandatory screening of tissue        Exclusion Criteria:          -  Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free             for a minimum of 730 days (2 years) (for example, carcinoma in situ of the breast,             oral cavity, or cervix are all permissible)          -  Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a             different cancer is allowable          -  Prior radiotherapy to the region of the study cancer that would result in overlap of             radiation therapy fields          -  Atelectasis of the entire lung          -  Contralateral hilar node involvement          -  Exudative, bloody, or cytologically malignant effusions          -  Severe, active co-morbidity, defined as follows:               -  Unstable angina and/or congestive heart failure requiring hospitalization within                  the last 6 months               -  Transmural myocardial infarction within the last 6 months               -  Acute bacterial or fungal infection requiring intravenous antibiotics at the                  time of registration               -  Chronic obstructive pulmonary disease exacerbation or other respiratory illness                  requiring hospitalization or precluding study therapy at the time of                  registration; hepatic insufficiency resulting in clinical jaundice and/or                  coagulation defects               -  Acquired immune deficiency syndrome (AIDS) based upon current Centers for                  Disease Control and Prevention (CDC) definition; note, however, that human                  immunodeficiency virus (HIV) testing is not required for entry into this                  protocol; protocol-specific requirements may also exclude immuno-compromised                  patients          -  Pregnancy or women of childbearing potential and men who are sexually active and not             willing/able to use medically acceptable forms of contraception          -  Prior allergic reaction to the study drug(s) involved in this protocol      "
NCT01507428,Phase 2,National Cancer Institute (NCI),NIH,Randomized Phase II Trial of Individualized Adaptive Radiotherapy Using During-Treatment FDG-PET/CT and Modern Technology in Locally Advanced Non-small Cell Lung Cancer (NSCLC),1,18,150,include,include,include,,,,include,,,,,,,,,,,,exclude,1800,,,,,"        Inclusion Criteria:          -  Patients must have FDG-avid (maximum SUV >= 4.0) (from PET scan of any date, any             scanner) and histologically or cytologically proven non-small cell lung cancer          -  Patients must be clinical American Joint Committee on Cancer (AJCC) stage IIIA or             IIIB (AJCC, 7th ed.) with non-operable disease; non-operable disease will be             determined by a multi-disciplinary treatment team, involving evaluation by at least 1             thoracic surgeon within 8 weeks prior to registration; Note: For patients who are             clearly nonresectable, the case can be determined by the treating radiation             oncologist and a medical oncologist, or pulmonologist          -  Patients with multiple, ipsilateral pulmonary nodules (T3 or T4) are eligible if a             definitive course of daily fractionated radiation therapy (RT) is planned          -  History/physical examination, including documentation of weight, within 2 weeks prior             to registration          -  FDG-PET/CT scan for staging and RT plan within 4 weeks prior to registration          -  CT scan or sim CT of chest and upper abdomen (IV contrast is recommended unless             medically contraindicated) within 6 weeks prior to registration          -  CT scan of the brain (contrast is recommended unless medically contraindicated) or             MRI of the brain within 6 weeks prior to registration          -  Pulmonary function tests, including diffusion capacity of carbon monoxide (DLCO),             within 6 weeks prior to registration; patients must have forced expiratory volume in             1 second (FEV1) >= 1.2 Liter or >= 50% predicted without bronchodilator          -  Zubrod performance status 0-1          -  Able to tolerate PET/CT imaging required to be performed at an American College of             Radiology (ACR) Imaging Core Laboratory (Lab) qualified facility          -  Absolute neutrophil count (ANC) >= 1,500 cells/mm^3          -  Platelets >= 100,000 cells/mm^3          -  Hemoglobin (Hgb) >= 10.0 g/dL (note: the use of transfusion or other intervention to             achieve Hgb >= 10.0 g/dL is acceptable)          -  Serum creatinine within normal institutional limits or a creatinine clearance >= 60             ml/min within 2 weeks prior to registration          -  Negative serum or urine pregnancy test within 3 days prior to registration for women             of childbearing potential          -  Women of childbearing potential and male participants must agree to use a medically             effective means of birth control throughout their participation in the treatment             phase of the study          -  The patient must provide study-specific informed consent prior to study entry        Exclusion Criteria:          -  Patients with any component of small cell lung carcinoma are excluded          -  Patients with evidence of a malignant pleural or pericardial effusion are excluded          -  Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free             for a minimum of 3 years (for example, carcinoma in situ of the breast, oral cavity,             or cervix are all permissible)          -  Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a             different cancer is allowable          -  Prior radiotherapy to the region of the study cancer that would result in overlap of             radiation therapy fields          -  Severe, active co-morbidity, defined as follows:               -  Unstable angina and/or congestive heart failure requiring hospitalization within                  the last 6 months               -  Transmural myocardial infarction within the last 6 months               -  Acute bacterial or fungal infection requiring intravenous antibiotics at the                  time of registration               -  Chronic obstructive pulmonary disease exacerbation or other respiratory illness                  requiring hospitalization or precluding study therapy at the time of                  registration               -  Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects;                  note, however, that laboratory tests for liver function and coagulation                  parameters are not required for entry into this protocol               -  Acquired immune deficiency syndrome (AIDS) based upon current Centers for                  Disease Control (CDC) definition; note, however, that human immunodeficiency                  virus (HIV) testing is not required for entry into this protocol          -  Pregnancy or women of childbearing potential and men who are sexually active and not             willing/able to use medically acceptable forms of contraception          -  Poorly controlled diabetes (defined as fasting glucose level > 200 mg/dL) despite             attempts to improve glucose control by fasting duration and adjustment of medications          -  For 18F-fluoromisonidazole (FMISO)-PET/CT: patient is unable to undergo this imaging          -  Patients with T4 disease with radiographic evidence of massage invasion of a large             pulmonary artery and tumor causing significant narrowing and destruction of that             artery are excluded      "
NCT01386385,Phase 1/Phase 2,National Cancer Institute (NCI),NIH,"A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811)",1,18,150,include,include,include,,,,include,,,,require,,,,,,exclude,1800,exclude,1800,,,,,"        Inclusion Criteria:          -  Patients must have histologically or cytologically-proven new diagnosis of             unresectable stage IIIA/IIIB*, non-small cell lung cancer (adenocarcinoma,             bronchioloalveolar cell carcinoma, large cell carcinoma, squamous cell carcinoma, or             mixed)               -  Per the American Joint Committee on Cancer (AJCC) 7th edition, pleural and                  pericardial are now considered stage M1a disease; when pleural fluid is visible                  on the computed tomography (CT) scan or on a chest x-ray, a thoracentesis is                  required to confirm that the pleural fluid is cytologically negative; patients                  with exudative pleural effusions are excluded, regardless of cytology; patients                  with effusions that are minimal (i.e. not visible on chest x-ray) that are too                  small to safely tap are eligible; a small effusion that has positive                  fludeoxyglucose F 18 (FDG) uptake on positron emission tomography (PET) has to                  be proven to be malignant per standard of care diagnostic procedures for the                  patient to be excluded          -  Patients must have measurable or non-measurable disease documented by CT, magnetic             resonance imaging (MRI) or PET/CT; the CT from a combined PET/CT may be used to             document only non-measurable disease unless the scan is of diagnostic quality;             measurable disease must be assessed by CT within 28 days prior to registration;             pleural effusions, ascites and laboratory parameters are not acceptable as the only             evidence of disease; non-measurable disease must be assessed within 42 days prior to             registration; all disease must be assessed and documented on the Baseline Tumor             Assessment Form          -  Patients with brain metastases are ineligible; all patients must have a pretreatment             CT or MRI scan of the brain to evaluate for central nervous system (CNS) disease             within 42 days prior to registration          -  Patients must not have received any prior systemic therapy (chemotherapy or other             biologic therapy) for lung cancer          -  Patients must not have received prior chest radiation therapy for NSCLC          -  Patients must not have had a previous surgical resection; however, patients may have             undergone exploratory thoracotomy, mediastinoscopy, excisional biopsy or similar             surgery for the purpose of determining the diagnosis, stage or potential             resectability of newly diagnosed lung tumor; at least 28 days must have elapsed since             thoracic surgery (excluding mediastinoscopy or other minor surgeries) and patients             should have recovered from all associated toxicities at the time of registration;             patients must not be planning to undergo a minor surgical procedure while on this             study          -  Patients must have Zubrod performance status 0-1          -  Patients must have tumor tissue available for submission to assess gene expression of             ERCC1 and XRCC1; patients must also be offered participation in banking for future             use of specimens          -  Absolute neutrophil count >= 1,500/mcl          -  Platelets >= 100,000/mcl          -  Hemoglobin >= 9.0 g/dl          -  Total bilirubin within institutional upper limit of normal (IULN)          -  Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) or             serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 2.5             x IULN          -  Patients must not be pregnant or nursing; women/men of reproductive potential must             have agreed to use an effective contraceptive method; a woman is considered to be of             ""reproductive potential"" if she has had menses at any time in the preceding 12             consecutive months; in addition to routine contraceptive methods, ""effective             contraception"" also includes heterosexual celibacy and surgery intended to prevent             pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy,             bilateral oophorectomy or bilateral tubal ligation; however, if at any point a             previously celibate patient chooses to become heterosexually active during the time             period for use of contraceptive measures outlined in the protocol, he/she is             responsible for beginning contraceptive measures          -  Patients must have a serum creatinine =< the IULN AND measured or calculated             creatinine clearance >= 60 cc/min          -  Patients must have pulmonary function tests (PFTs) including forced expiratory volume             in 1 second (FEV1) within 84 days prior to registration; for FEV1, the best value             obtained pre- or post-bronchodilator must be >= 1.2 liters/second and/or >= 50%             predicted          -  Patients may not be planning to receive any other investigational agents          -  Patients must not have more than 10% weight loss in the past 6 months          -  Patients must not have a history of allergic reactions attributed to compounds of             similar chemical or biologic composition to ABT-888, carboplatin, paclitaxel or other             agents used in study          -  No other prior malignancy is allowed except for the following: adequately treated             basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated             stage I or II cancer from which the patient is currently in complete remission, or             any other cancer from which the patient has been disease free for five years          -  Patient must not have any uncontrolled intercurrent illness including, but not             limited to ongoing or active infection, symptomatic congestive heart failure,             unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social             situations that would limit compliance with study requirements          -  Patients must not currently have a >= grade 1 symptomatic neuropathy-sensory             (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events             [CTCAE] version 4.0)          -  Patients must not have a history of seizures          -  Patients must not have any known immune deficiencies; patients with immune deficiency             are at increased risk of lethal infections when treated with marrow-suppressive             therapy; therefore, known human immunodeficiency virus (HIV) positive patients             receiving combination anti-retroviral therapy are excluded from the study          -  Patients must be able to swallow whole capsules          -  Prestudy history and physical must be obtained within 28 days prior to registration          -  All patients must be informed of the investigational nature of this study and must             sign and give written informed consent in accordance with institutional and federal             guidelines          -  As a part of the Oncology Patient Enrollment Network (OPEN) registration process the             treating institution's identity is provided in order to ensure that the current             (within 365 days) date of institutional review board approval for this study has been             entered in the system          -  REGISTRATION #2 - PRIOR TO CONSOLIDATION CHEMOTHERAPY:          -  REGISTRATION #2 - PRIOR TO CONSOLIDATION CHEMOTHERAPY: Patients must have completed             chemoradiotherapy per protocol and at least four weeks but no more than six weeks             must have elapsed from the last day of induction therapy (the last day of radiation)          -  REGISTRATION #2 - PRIOR TO CONSOLIDATION CHEMOTHERAPY: Patients must have undergone             restaging tests according to the study calendar and determined to have no evidence of             disease progression          -  REGISTRATION #2 - PRIOR TO CONSOLIDATION CHEMOTHERAPY: Patients must have a serum             creatinine =< (IULN) AND measured of calculated creatinine clearance >= 60 cc/min             using the Cockroft-Gault formula          -  REGISTRATION #2 - PRIOR TO CONSOLIDATION CHEMOTHERAPY: Absolute neutrophil count >=             1,500 mcl          -  REGISTRATION #2 - PRIOR TO CONSOLIDATION CHEMOTHERAPY: Platelets >= 100,000/ml          -  REGISTRATION #2 - PRIOR TO CONSOLIDATION CHEMOTHERAPY: Hemoglobin >= 9.0 g/dl          -  REGISTRATION #2 - PRIOR TO CONSOLIDATION CHEMOTHERAPY: Total bilirubin =< IULN          -  REGISTRATION #2 - PRIOR TO CONSOLIDATION CHEMOTHERAPY: SGOT (AST) or SGPT (ALT) =<             2.5 x IULN          -  REGISTRATION #2 - PRIOR TO CONSOLIDATION CHEMOTHERAPY: Patients must have Zubrod             performance status 0-1      "
NCT01107626,Phase 3,Eastern Cooperative Oncology Group,Other,"Randomized Phase III Study of Maintenance Therapy With Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC",1,18,150,include,include,,,,,include,include,,,,,,,,,,,exclude,1800,exclude,12,,,"        DISEASE CHARACTERISTICS:          -  Cytologically or histologically confirmed non-small cell lung cancer (NSCLC)               -  Predominant non-squamous histology                    -  NSCLC not otherwise specified allowed                    -  Mixed tumors are categorized by the predominant cell type          -  Must meet 1 of the following criteria:               -  Stage IV disease including M1a or M1b stages or recurrent disease               -  Stage IIIB (T4NX) disease with ipsilateral lung lobe allowed provided patients                  are not candidates for combined chemotherapy or radiotherapy          -  Measurable or non-measurable disease as defined by RECIST criteria          -  Patient must have an overall stable or better response after 4 courses of induction             therapy          -  No cavitary lesions in the lungs          -  Patients with brain metastasis must have received local therapy to the brain and have             no evidence of progression in the brain for at least 2 weeks from the time of             completion of local therapy, prior to registration        PATIENT CHARACTERISTICS:          -  ECOG performance status 0-1          -  Leukocytes ‰ä´ 3,000/mm^3          -  ANC ‰ä´ 1,500/mm^3          -  Platelet count ‰ä´ 100,000/mm^3          -  Total bilirubin ‰ä_ institutional upper limit of normal (ULN)          -  AST and ALT ‰ä_ 3 times ULN          -  Creatinine ‰ä_ institutional ULN OR creatinine clearance ‰ä´ 60 mL/min          -  Urine protein:urine dipstick ‰ä_ 0-1+ (if > 1+, urine protein creatinine ratio must be             < 1)          -  Not pregnant or nursing          -  Negative pregnancy test          -  Fertile patients must agree to abstain from sexual intercourse or to use adequate             contraceptive methods during and for at least 6 months after completion of study             therapy          -  No prior malignancy within the past 3 years except superficial melanoma, basal cell             carcinoma, or carcinoma in situ          -  No major hemoptysis within the past 4 weeks          -  No uncontrolled intercurrent illness including, but not limited to, any of the             following:               -  Ongoing or active infection               -  Symptomatic congestive heart failure               -  Unstable angina pectoris               -  Serious cardiac arrhythmia               -  Psychiatric illness and/or social situations that would limit compliance with                  study requirements          -  Patients with hypertension must be adequately controlled (BP < 150/100 mm Hg) with             appropriate anti-hypertensive therapy or diet          -  No history of arterial thrombotic events or major bleeding within the past 12 months          -  No significant vascular disease (e.g., aortic aneurysm requiring surgical repair or             recent peripheral arterial thrombosis) within the past 6 months          -  No significant traumatic injury in the past 3 months          -  No clinically significant cardiovascular disease          -  No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within             the past 6 months          -  No history of serious non-healing wounds, ulcers, or bone fractures        PRIOR CONCURRENT THERAPY:          -  See Disease Characteristics          -  At least 12 months since prior adjuvant chemotherapy          -  At least 2 weeks since prior radiotherapy          -  Patients must not have had any major surgery such as thoracotomy, laparotomy,             craniotomy, or significant traumatic injury within 6 weeks prior to registration               -  Biopsy procedures and chest tube insertion are not considered major surgery for                  the purpose of this protocol          -  More than 7 days since a core biopsy          -  Concurrent therapeutic anti-coagulation allowed          -  No prior systemic chemotherapy for advanced stage lung cancer          -  No prior paclitaxel, pemetrexed disodium, or bevacizumab               -  Prior carboplatin allowed provided it was given as part of adjuvant chemotherapy          -  No concurrent anti-retroviral therapy in patients with HIV infection      "
NCT01107626,Phase 3,Eastern Cooperative Oncology Group,Other,"Randomized Phase III Study of Maintenance Therapy With Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC",2,18,150,include,include,,,include,include,,,,,,require,,,,,,,exclude,1800,exclude,12,,,"        DISEASE CHARACTERISTICS:          -  Cytologically or histologically confirmed non-small cell lung cancer (NSCLC)               -  Predominant non-squamous histology                    -  NSCLC not otherwise specified allowed                    -  Mixed tumors are categorized by the predominant cell type          -  Must meet 1 of the following criteria:               -  Stage IV disease including M1a or M1b stages or recurrent disease               -  Stage IIIB (T4NX) disease with ipsilateral lung lobe allowed provided patients                  are not candidates for combined chemotherapy or radiotherapy          -  Measurable or non-measurable disease as defined by RECIST criteria          -  Patient must have an overall stable or better response after 4 courses of induction             therapy          -  No cavitary lesions in the lungs          -  Patients with brain metastasis must have received local therapy to the brain and have             no evidence of progression in the brain for at least 2 weeks from the time of             completion of local therapy, prior to registration        PATIENT CHARACTERISTICS:          -  ECOG performance status 0-1          -  Leukocytes ‰ä´ 3,000/mm^3          -  ANC ‰ä´ 1,500/mm^3          -  Platelet count ‰ä´ 100,000/mm^3          -  Total bilirubin ‰ä_ institutional upper limit of normal (ULN)          -  AST and ALT ‰ä_ 3 times ULN          -  Creatinine ‰ä_ institutional ULN OR creatinine clearance ‰ä´ 60 mL/min          -  Urine protein:urine dipstick ‰ä_ 0-1+ (if > 1+, urine protein creatinine ratio must be             < 1)          -  Not pregnant or nursing          -  Negative pregnancy test          -  Fertile patients must agree to abstain from sexual intercourse or to use adequate             contraceptive methods during and for at least 6 months after completion of study             therapy          -  No prior malignancy within the past 3 years except superficial melanoma, basal cell             carcinoma, or carcinoma in situ          -  No major hemoptysis within the past 4 weeks          -  No uncontrolled intercurrent illness including, but not limited to, any of the             following:               -  Ongoing or active infection               -  Symptomatic congestive heart failure               -  Unstable angina pectoris               -  Serious cardiac arrhythmia               -  Psychiatric illness and/or social situations that would limit compliance with                  study requirements          -  Patients with hypertension must be adequately controlled (BP < 150/100 mm Hg) with             appropriate anti-hypertensive therapy or diet          -  No history of arterial thrombotic events or major bleeding within the past 12 months          -  No significant vascular disease (e.g., aortic aneurysm requiring surgical repair or             recent peripheral arterial thrombosis) within the past 6 months          -  No significant traumatic injury in the past 3 months          -  No clinically significant cardiovascular disease          -  No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within             the past 6 months          -  No history of serious non-healing wounds, ulcers, or bone fractures        PRIOR CONCURRENT THERAPY:          -  See Disease Characteristics          -  At least 12 months since prior adjuvant chemotherapy          -  At least 2 weeks since prior radiotherapy          -  Patients must not have had any major surgery such as thoracotomy, laparotomy,             craniotomy, or significant traumatic injury within 6 weeks prior to registration               -  Biopsy procedures and chest tube insertion are not considered major surgery for                  the purpose of this protocol          -  More than 7 days since a core biopsy          -  Concurrent therapeutic anti-coagulation allowed          -  No prior systemic chemotherapy for advanced stage lung cancer          -  No prior paclitaxel, pemetrexed disodium, or bevacizumab               -  Prior carboplatin allowed provided it was given as part of adjuvant chemotherapy          -  No concurrent anti-retroviral therapy in patients with HIV infection      "
NCT00632853,Phase 3,Alliance for Clinical Trials in Oncology,Other,Phase III Comparison of Thoracic Radiotherapy Regimens in Patients With Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide,1,18,150,,,,include,,,,,include,,,,,,,,exclude,1800,,,,,,,"        1. Documentation of Disease               1. Histologically or cytologically documented small cell lung cancer (SCLC)               2. Limited-stage disease patients with disease restricted to one hemithorax with                  regional lymph node metastases, including ipsilateral hilar, ipsilateral and                  contralateral mediastinal, and ipsilateral supraclavicular lymph nodes                    -  Patients with disease involvement of the contralateral hilar or                       supraclavicular lymph nodes are not eligible                    -  Patients with pleural effusions that are visible on plain chest                       radiographs, whether cytologically positive or not are not eligible unless                       they have a negative thoracentesis                    -  Patients with cytologically positive pleural or pericardial fluid,                       regardless of the appearance on plain x-ray are not eligible          2. Measurable disease - Patients must have measurable disease, which includes lesions             that can be accurately measured in at least one dimension (longest diameter to be             recorded) as ‰ä´ 2 cm with conventional techniques OR ‰ä´ 1 cm by spiral CT scan          3. Prior Treatment               1. Patients may have received one and only one cycle of chemotherapy prior to                  enrolling on CALGB 30610, which must have included carboplatin or cisplatin and                  etoposide.               2. If a patient has had one cycle of cisplatin or carboplatin/etoposide prior to                  registration, the patient must have had all of it prior to registration tests as                  outlined in the protocol and prior to starting their first cycle of                  chemotherapy.               3. Additionally, these patients also must have met all of the eligibility criteria                  in the protocol prior to receiving the first cycle of chemotherapy.               4. Registration to CALGB 30610 must take place within 14-21 days after the start of                  the non-protocol therapy.               5. Failing to do all of the above will make the patient NOT eligible for CALGB                  30610.               6. No prior radiotherapy or chemotherapy (except for the chemotherapy described in                  the bullet above) for SCLC               7. No prior mediastinal or thoracic radiotherapy               8. Patients with complete surgical resection of disease are not eligible          4. Age Requirement ‰ä´ 18 years of age          5. ECOG Performance Status 0-2          6. Non-pregnant and non-nursing - No patients that are known to be pregnant or nursing          7. Required Initial Laboratory Values               1. Granulocytes ‰ä´ 1,500/åµl               2. Platelet count ‰ä´ 100,000/åµl               3. Total bilirubin ‰ä_ 1.5 times upper limit of normal (ULN)               4. AST (SGOT) ‰ä_ 2.0 times ULN               5. Serum creatinine ‰ä_ 1.5 times ULN OR Calculated creatinine clearance ‰ä´ 70 mL/min      "
NCT02273375,Phase 3,Canadian Cancer Trials Group,Other,A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 In Completely Resected Non-Small Cell Lung Cancer,1,18,150,include,include,include,,include,include,include,,,,,,,,,,exclude,1800,exclude,1800,,,,,"        Inclusion Criteria:          -  Histologically confirmed diagnosis of primary non-small cell carcinoma of the lung.          -  Patients must be classified post-operatively as Stage IB (‰ä´ 4cm in the longest             diameter), II or IIIA on the basis of pathologic criteria               -  Complete surgical resection of the primary NSCLC is also mandatory. All gross                  disease must have been removed at the end of surgery. All surgical margins of                  resection must be negative for tumour. Resection may be accomplished by open or                  VATS techniques        Note: Patients with synchronous primary tumours will not be eligible due to the potential        uncertainty regarding their appropriate PD-L1 status.        Prior Systemic Therapy:          -  Pre-operative (neo-adjuvant) platinum based or other chemotherapy is not permissible.          -  Patients may have received prior post-operative platinum based chemotherapy as per             standard of care.          -  No prior anticancer therapy for treatment of NSCLC other than standard post-operative             adjuvant chemotherapy is permissible.        Radiation:        ‰Û¢ Pre-operative or post-operative or planned radiation therapy is not permissible.          -  The patient must have an ECOG performance status of 0, 1.          -  Hematology: . Absolute neutrophil count ‰ä´ 1.5 x 109/L or ‰ä´ 1,500/åµl Platelets ‰ä´ 100 x             109/L or ‰ä´ 100,000/åµl          -  Biochemistry:        Total bilirubin* within normal institutional limits Alkaline phosphatase ‰ä_ 2.5 x        institutional upper limit of normal AST(SGOT) and ALT(SGPT) ‰ä_ 2.5 x institutional upper        limit of normal Creatinine Clearance ‰ä´ 50 ml/min        * excluding Gilbert's syndrome        Creatinine clearance to be measured directly by 24 hour urine sampling or as calculated by        Cockcroft Formula:        Females: GFR = 1.04 x (140-age) x weight in kg serum creatinine in ë_mol/L Males: GFR =        1.23 x (140-age) x weight in kg serum creatinine in ë_mol/L          -  Patient able and willing to complete the QoL, economics and other questionnaires. The             baseline assessment must already have been completed within required timelines prior             to randomization. Inability (illiteracy, loss of sight, or other equivalent reason)             to complete the questionnaires will not make the patient ineligible for the study.             However, ability but unwillingness to complete the questionnaires will make the             patient ineligible          -  Patient consent must be appropriately obtained in accordance with applicable local             and regulatory requirements. Each patient must sign a consent form prior to enrolment             in the trial to document their willingness to participate          -  Patients must be accessible for treatment and follow-up. Investigators must assure             themselves the patients randomized on this trial will be available for complete             documentation of the treatment, adverse events, and follow-up          -  Protocol treatment is to begin within 2 working days of patient randomization        Exclusion Criteria:          -  Patients with a history of other malignancies, except: adequately treated             non-melanoma skin cancer, curatively treated in-situ cancer, or other solid tumours             curatively treated with no evidence of disease for ‰ä´ 5 years following the end of             treatment and which, in the opinion of the treating physician, do not have a             substantial risk of recurrence of the prior malignancy.          -  A combination of small cell and non-small cell lung cancer or pulmonary carcinoid             tumour.          -  History of autoimmune disease, including but not limited to myasthenia gravis,             myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis,             inflammatory bowel disease, vascular thrombosis associated with antiphospholipid             syndrome, Wegener's granulomatosis, SjÌ¦gren's syndrome, Guillain-BarrÌ© syndrome,             multiple sclerosis, vasculitis, or glomerulonephritis.          -  History of primary immunodeficiency, history of allogenic organ transplant that             requires therapeutic immunosuppression and the use of immunosuppressive agents within             28 days of randomization* or a prior history of severe (grade 3 or 4) immune mediated             toxicity from other immune therapy.          -  Live attenuated vaccination administered within 30 days prior to randomization.          -  History of hypersensitivity to MEDI4736 or any excipient.          -  Mean QTc correction > 470msec in screening ECG measured using standard institutional             method or history of familial long QT syndrome.          -  Patients who have experienced untreated and/or uncontrolled cardiovascular conditions             and/or have symptomatic cardiac dysfunction (unstable angina, congestive heart             failure, myocardial infarction within the previous year or cardiac ventricular             arrhythmias requiring medication, history of 2nd or 3rd degree atrioventricular             conduction defects). Patients with a significant cardiac history, even if controlled,             should have a LVEF > 50%.          -  Concurrent treatment with other investigational drugs or anti-cancer therapy.          -  Patients with active or uncontrolled infections or with serious illnesses or medical             conditions which would not permit the patient to be managed according to the             protocol. This includes but is not limited to:               -  known prior history of tuberculosis;               -  known acute hepatitis B or C by serological evaluation;               -  known Human immunodeficiency virus infection.          -  Pregnant or lactating women. Women of childbearing potential must have a urine             pregnancy test proven negative within 14 days prior to randomization. Men and women             of child-bearing potential must agree to use adequate contraception.      "
NCT00499330,Phase 3,Alliance for Clinical Trials in Oncology,Other,A Phase III Randomized Trial of Lobectomy Versus Sublobar Resection for Small (‰ä_ 2 cm) Peripheral Non-Small Cell Lung Cancer,1,18,150,include,include,include,,include,include,,,,,require,,,,,,exclude,1800,exclude,1800,exclude,1800,,,"        Pre-registration Eligibility Criteria:          1. Peripheral lung nodule ‰ä_ 2 cm on preoperative CT scan and presumed to be lung cancer.             The center of the tumor, as seen on CT, must be located in the outer third of the             lung in either the transverse, coronal or sagittal plane. Patients with pure ground             glass opacities or pathologically confirmed N1 or N2 disease are not eligible.          2. The tumor location must be suitable for either lobar or sublobar resection (wedge or             segment).          3. ECOG performance status of 0-2.          4. No prior malignancy within 3 years other than non-melanoma skin cancer, superficial             bladder cancer, or CIS of the cervix.          5. No prior chemotherapy or radiation therapy for this malignancy.          6. No evidence of locally advanced or metastatic disease.          7. Age ‰ä´ 18 years        Intra-operative Randomization Eligibility Criteria:          1. Histologic confirmation of NSCLC (if not already obtained)          2. Confirmation of N0 status by frozen section examination. Right sided tumors require             that node levels 4, 7, and 10 be sampled and diagnosed as negative on frozen section.             Left sided tumors require that node levels 5 or 6, 7 and 10 be sampled and diagnosed             as negative on frozen section. Levels 4 and 7 nodes may be sampled by             mediastinoscopy, endobronchial ultrasound (EBUS) and/or endoscopic ultrasound (EUS),             or at the time of thoracotomy or VATS exploration. Nodes previously sampled by             mediastinoscopy (or EBUS and/or EUS) either immediately prior to or within 6 weeks of             the definitive surgical procedure (thoracotomy or VATS) do not need to be resampled.      "
NCT01993810,Phase 3,Radiation Therapy Oncology Group,Other,Phase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Chemoradiotherapy for Inoperable Stage II-IIIB NSCLC,1,18,150,include,include,include,,,include,include,,,,,,,,,,,,exclude,1800,,,,,"        Inclusion Criteria:          -  Histologically or cytologically proven diagnosis of non-small cell lung cancer          -  Clinical American Joint Committee on Cancer (AJCC) (AJCC, 7th ed.) II, IIIA or IIIB             (with non-operable disease; non-operable disease will be determined by a             multi-disciplinary treatment team within 60 days prior to registration; note: for             patients who are clearly nonresectable, the case can be determined by the treating             radiation oncologist and/or a medical oncologist or pulmonologist               -  Patients who present with N2 or N3 disease and an undetectable NSCLC primary                  tumor are eligible               -  Patients who refuse surgery are eligible          -  Appropriate stage for protocol entry, including no distant metastases, based upon the             following minimum diagnostic workup:               -  History/physical examination within 30 days prior to registration;               -  Fludeoxyglucose F 18 (FDG)-positron emission tomography (PET)/computed                  tomography (CT) scan for staging within 60 days prior to registration               -  Magnetic resonance imaging (MRI) scan with contrast of the brain (preferred) or                  CT scan of the brain with contrast within 60 days prior to registration;               -  Forced expiratory volume in one second (FEV1) >= 1.0 Liter or >= 40% predicted                  with or without bronchodilator within 90 days prior to registration;                    -  Patients who meet the criterion above without oxygen (O2), but who need                       acute (started within 10 days prior to registration) supplemental oxygen                       due to tumor-caused obstruction/hypoxia are eligible, provided the amount                       of the O2 needed has been stable          -  Zubrod performance status 0-1 within 30 days prior to registration          -  Absolute neutrophil count (ANC) >= 1,500 cells/mm^3          -  Platelets >= 100,000 cells/mm^3          -  Hemoglobin >= 9.0 g/dl (note: the use of transfusion or other intervention to achieve             hemoglobin [Hgb] >= 9.0 g/dl is acceptable)          -  Serum glutamic oxaloacetic transaminase (SGOT) or serum glutamate pyruvate             transaminase (SGPT) =< 1.5 upper limit of normal          -  Total bilirubin =< 1.5 upper limit of normal          -  Serum creatinine < 1.5 mg/dL or calculated creatinine clearance >= 50 mL/min             estimated by the Cockcroft-Gault formula          -  Peripheral neuropathy =< grade 1 at the time of registration          -  Patients with non-malignant pleural effusion are eligible               -  If a pleural effusion is present, the following criteria must be met to exclude                  malignant involvement:                    -  When pleural fluid is visible on both the CT scan and on a chest x-ray, a                       pleuracentesis is required to confirm that the pleural fluid is                       cytologically negative;                    -  Exudative pleural effusions are excluded, regardless of cytology;                    -  Effusions that are minimal (ie, not visible on chest x-ray) that are too                       small to safely tap are eligible          -  Patients must have measurable or evaluable disease          -  Women of childbearing potential must have a negative serum pregnancy test within 14             days prior to registration          -  Women of childbearing potential and male participants must practice adequate             contraception          -  Patient must provide study-specific informed consent prior to study entry        Exclusion Criteria:          -  Prior invasive malignancy unless disease free for a minimum of 3 years; however, skin             cancer and in situ carcinomas of the breast, oral cavity, cervix, and other organs             and are permissible          -  Patients with prior history of either small cell lung cancer or NSCLC regardless of             the treatment received          -  Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a             different cancer is allowable          -  Prior radiotherapy to the region of the study cancer that would result in overlap of             radiation therapy fields          -  Severe, active co-morbidity, defined as follows:               -  Unstable angina and/or congestive heart failure requiring hospitalization within                  the last 6 months;               -  Transmural myocardial infarction within the last 6 months;               -  Chronic obstructive pulmonary disease exacerbation or other respiratory illness                  other than the diagnosed lung cancer requiring hospitalization or precluding                  study therapy within 30 days before registration;               -  Acquired immune deficiency syndrome (AIDS) based upon current Centers for                  Disease Control and Prevention (CDC) definition; note, however, that human                  immunodeficiency virus (HIV) testing is not required for entry into this                  protocol          -  Unintentional weight loss > 10% within 90 days prior to registration          -  Pregnancy or women of childbearing potential and men who are sexually active and not             willing/able to use medically acceptable forms of contraception      "
NCT02468024,Phase 3,University of Texas Southwestern Medical Center,Other,"JoLT-Ca A Randomized Phase III Study of Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) in High Risk Patients With Stage I Non-Small Cell Lung Cancer (NSCLC), The STABLE-MATES Trial",1,18,99,include,include,include,,include,,,,,,,,,,,,,,exclude,1800,exclude,1800,,,"        Inclusion Criteria:          -  Age > 18 years.          -  ECOG performance status (PS) 0, 1, or 2.          -  Radiographic findings consistent with non-small cell lung cancer, including lesions             with ground glass opacities with a solid component of 50% or greater. Those with             ground glass opacities and <50% solid component will be excluded.          -  Biopsy confirmed non-small cell lung cancer.          -  Tumor ‰ä_ 4 cm maximum diameter, including clinical stage IA and selected IB by PET/CT             scan of the chest and upper abdomen performed within 60 days prior to registration.          -  All clinically suspicious mediastinal N1, N2, or N3 lymph nodes (> 1 cm short-axis             dimension on CT scan and/or positive on PET scan) confirmed negative for involvement             with NSCLC by one of the following methods: mediastinoscopy, anterior mediastinotomy             EUS/EBUS guided needle aspiration, CT-guided, video-assisted thoracoscopic or open             lymph node biopsy.          -  Tumor verified by a thoracic surgeon to be in a location that will permit sublobar             resection.          -  Tumor located peripherally within the lung. NOTE: Peripheral is defined as not             touching any surface within 2 cm of the proximal bronchial tree in all directions.             See below. Patients with non-peripheral (central) tumors are NOT eligible.          -  No evidence of distant metastases.          -  Availability of pulmonary function tests (PFTs - spirometry, DLCO, +/- arterial blood             gases) within 90 days prior to registration. Patients with tracheotomy, etc, who are             physically unable to perform PFTs (and therefore cannot be tested for the Major             criteria in 3.1.10 below) are potentially still eligible if a study credentialed             thoracic surgeon documents that the patient's health characteristics would otherwise             have been acceptable for eligibility as a high risk but nonetheless operable patient             (in particular be eligible for sublobar resection).          -  Patient at high-risk for surgery by meeting a minimum of one major criteria or two             minor criteria          -  No prior intra-thoracic radiation therapy. NOTE: Previous radiotherapy as part of             treatment for head and neck, breast, or other non-thoracic cancer is permitted so             long as possible radiation fields would not overlap. Previous chemotherapy or             surgical resection specifically for the lung cancer being treated on this protocol is             NOT permitted. No prior lung resection on the ipsilateral side.          -  Non-pregnant and non-lactating. Women of child-bearing potential must have a negative             urine or serum pregnancy test within 60 days prior to registration. Peri-menopausal             women must be amenorrheic > 12 months prior to registration to be considered not of             childbearing potential.          -  No prior invasive malignancy, unless disease-free for ‰ä´ 3 years prior to registration             (exceptions: non-melanoma skin cancer, in-situ cancers).          -  Ability to understand and the willingness to sign a written informed consent.        Exclusion Criteria:          -  evidence of distant metastases          -  prior intra-thoracic radiation therapy. NOTE: Previous radiotherapy as part of             treatment for head and neck, breast, or other non-thoracic cancer is permitted so             long as possible radiation fields would not overlap. Previous chemotherapy or             surgical resection specifically for the lung cancer being treated on this protocol is             NOT permitted. No prior lung resection on the ipsilateral side.          -  pregnant and lactating women          -  prior invasive malignancy, unless disease-free for ‰ä´ 3 years prior to registration             (exceptions: non-melanoma skin cancer, in-situ cancers).      "
NCT02154490,Phase 2/Phase 3,Southwest Oncology Group,Other,A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-MAP),1,18,150,,,include,,,,,include,,,,,,exclude,exclude,,,,require,,,,,,"        Inclusion Criteria:          -  SCREENING/PRE-SCREENING REGISTRATION:          -  Patients must have pathologically proven squamous cell carcinoma (SCCA) cancer of the             lung confirmed by tumor biopsy and/or fine-needle aspiration; disease must be stage             IV SCCA, or recurrent; the primary diagnosis of SCCA should be established using the             current World Health Organization (WHO)/International Association for the Study of             Lung Cancer (IASLC)-classification of Thoracic Malignancies; the diagnosis is based             on hematoxylin and eosin (H&E) stained slides with or without specific defined             immunohistochemistry (IHC) characteristic (p40/p63 positive, transcription             termination factor [TTF1] negative) if required for diagnosis; mixed histologies are             not allowed          -  Patients must either be eligible to be screened at progression on prior treatment or             to be pre-screened prior to progression on current treatment; patients will either             consent to the screening consent or the pre-screening consent, not both; these             criteria are:               -  Screening at progression on prior treatment: to be eligible for screening at                  progression, patients must have received at least one line of systemic therapy                  for any stage of disease (stages I-IV); at least one of these lines of therapy                  must have been a platinum-based chemotherapy regimen; patients must have                  progressed following the most recent line of therapy; for patients whose prior                  systemic therapy was for stage I-III disease only (i.e. patient has not received                  any treatment for stage IV disease), disease progression on platinum-based                  chemotherapy must have occurred within one year from the last date that patient                  received that therapy               -  Pre-screening prior to progression on current treatment: to be eligible for                  pre-screening, current treatment must be for stage IV disease and patient must                  have received at least one dose of the current regimen; patients must have                  previously received or currently be receiving a platinum-based chemotherapy                  regimen; patients on first-line platinum-based treatment are eligible upon                  receiving Cycle 1, Day 1 infusion; Note: patients will not receive their                  sub-study assignment until they progress and the S1400 Notice of Progression is                  submitted          -  Patients must have adequate tumor tissue available, defined as >= 20% tumor cells and             >= 0.2 mm^3 tumor volume; the local interpreting pathologist must review and sign off             on the S1400 Local Pathology Review Form prior to screening/pre-screening             registration; patients must agree to have this tissue submitted to Foundation             Medicine for common broad platform Clinical Laboratory Improvement Amendments (CLIA)             biomarker profiling; if archival tumor material is exhausted, then a new fresh tumor             biopsy that is formalin-fixed and paraffin-embedded (FFPE) must be obtained; a tumor             block or FFPE slides 4-5 microns thick must be submitted; bone biopsies are not             allowed; if FFPE slides are to be submitted, at least 12 unstained slides plus an H&E             stained slide, or 13 unstained slides must be submitted; however it is strongly             recommended that 20 FFPE slides be submitted; Note: previous next-generation             deoxyribonucleic acid (DNA) sequencing (NGS) will be repeated if done outside this             study for sub-study assignment          -  Patients must not have a known epidermal growth factor receptor (EGFR) mutation or             anaplastic lymphoma kinase (ALK) fusion          -  Patients must have Zubrod performance status 0-1 documented within 28 days prior to             screening/pre-screening registration          -  Patients must also be offered participation in banking for future use of specimens          -  Patients must be willing to provide prior smoking history as required on the S1400             Onstudy Form          -  As a part of the Oncology Patient Enrollment Network (OPEN) registration process the             treating institution's identity is provided in order to ensure that the current             (within 365 days) date of institutional review board approval for this study has been             entered in the system          -  Patients must be informed of the investigational nature of this study and must sign             and give written informed consent in accordance with institutional and federal             guidelines          -  SUB-STUDY REGISTRATION:          -  Patients whose biomarker profiling results indicate the presence of an EGFR mutation             or echinoderm microtubule-associated protein-like 4 (EML4)/ALK fusion are not             eligible          -  Patients must have progressed per RECIST 1.1 following the most recent line of             therapy          -  Patients must not have received any prior systemic therapy (systemic chemotherapy,             immunotherapy or investigational drug) within 21 days prior to sub-study             registration; patients must have recovered (=< grade 1) from any side effects of             prior therapy; localized palliative radiation therapy is allowed for symptom             management, provided treatment is completed >= 14 days prior to sub-study             registration; all other types of radiation must be completed >= 28 days prior to             sub-study registration          -  Patients must have measurable disease documented by computed tomography (CT) or             magnetic resonance imaging (MRI); the CT from a combined positron emission tomography             (PET)/CT may be used to document only non-measurable disease unless it is of             diagnostic quality; measurable disease must be assessed within 28 days prior to             sub-study registration; pleural effusions, ascites and laboratory parameters are not             acceptable as the only evidence of disease; non-measurable disease must be assessed             within 42 days prior to sub-study registration; all disease must be assessed and             documented on the Baseline Tumor Assessment Form; patients whose only measurable             disease is within a previous radiation therapy port must demonstrate clearly             progressive disease (in the opinion of the treating investigator) prior to             registration          -  Patients must have a CT or MRI scan of the brain to evaluate for central nervous             system (CNS) disease within 42 days prior to sub-study registration; patient must not             have leptomeningeal disease, spinal cord compression or brain metastases unless: (1)             metastases have been locally treated and have remained clinically controlled and             asymptomatic for at least 14 days following treatment, AND (2) patient has no             residual neurological dysfunction and has been off corticosteroids for at least 1 day             prior to sub-study registration          -  Patient must have fully recovered from the effects of prior surgery at least 14 days             prior to sub-study registration          -  Patients must not be planning to receive any concurrent chemotherapy, immunotherapy,             biologic or hormonal therapy for cancer treatment; concurrent use of hormones for             non-cancer-related conditions (e.g., insulin for diabetes and hormone replacement             therapy) is acceptable          -  Absolute neutrophil count (ANC) >= 1,500/mcl obtained within 28 days prior to             sub-study registration          -  Platelet count >= 100,000 mcl obtained within 28 days prior to sub-study registration          -  Hemoglobin >= 9 g/dL obtained within 28 days prior to sub-study registration          -  Serum bilirubin =< institutional upper limit of normal (IULN) within 28 days prior to             sub-study registration; for patients with liver metastases, bilirubin must be =< 5 x             IULN          -  Either alanine aminotransferase (ALT) or aspartate aminotransferase (AST) =< 2 x IULN             within 28 days prior to sub-study registration (if both ALT and AST are done, both             must be =< 2 IULN); for patients with liver metastases, either ALT or AST must be =<             5 x IULN (if both ALT and AST are done, both must be =< 5 x IULN)          -  Serum creatinine =< the IULN OR measured or calculated creatinine clearance >= 50             mL/min using the following Cockcroft-Gault Formula within 28 days prior to sub-study             registration          -  Patients must have Zubrod performance status 0-1 documented within 28 days prior to             sub-study registration          -  Patients must not have any grade III/IV cardiac disease as defined by the New York             Heart Association Criteria (i.e., patients with cardiac disease resulting in marked             limitation of physical activity or resulting in inability to carry on any physical             activity without discomfort), unstable angina pectoris, and myocardial infarction             within 6 months, or serious uncontrolled cardiac arrhythmia          -  Patients must not have documented evidence of acute hepatitis or have an active or             uncontrolled infection          -  Patients with a known history of human immunodeficiency virus (HIV) seropositivity             must: 1) have undetectable viral load using standard HIV assays in clinical practice,             2) have cluster of differentiation (CD)4 count >= 400/mcL, 3) not require prophylaxis             for any opportunistic infections (i.e., fungal, Mycobacterium avium complex [mAC], or             pneumocystis jiroveci pneumonia [PCP] prophylaxis), and 4) not be newly diagnosed             within 12 months prior to sub-study registration          -  Prestudy history and physical exam must be obtained within 28 days prior to sub-study             registration          -  No other prior malignancy is allowed except for the following: adequately treated             basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated             stage I or II cancer from which the patient is currently in complete remission, or             any other cancer from which the patient has been disease free for five years          -  Patients must not be pregnant or nursing; women/men of reproductive potential must             have agreed to use an effective contraceptive method; a woman is considered to be of             ""reproductive potential"" if she has had menses at any time in the preceding 12             consecutive months; in addition to routine contraceptive methods, ""effective             contraception"" also includes heterosexual celibacy and surgery intended to prevent             pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy,             bilateral oophorectomy or bilateral tubal ligation; however, if at any point a             previously celibate patient chooses to become heterosexually active during the time             period for use of contraceptive measures outlined in the protocol, he/she is             responsible for beginning contraceptive measures          -  As part of the OPEN registration process the treating institution's identity is             provided in order to ensure that the current (within 365 days) date of institutional             review board approval for this study has been entered into the system          -  Patients with impaired decision-making capacity are eligible as long as their             neurological or psychological condition does not preclude their safe participation in             the study (e.g., tracking pill consumption and reporting adverse events to the             investigator)          -  Patients must be informed of the investigational nature of this study and must sign             and give written informed consent in accordance with institutional and federal             guidelines.      "
NCT02154490,Phase 2/Phase 3,Southwest Oncology Group,Other,A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-MAP),2,18,150,,,include,,include,include,include,,,,,require,,exclude,exclude,,,,require,,,,,,"        Inclusion Criteria:          -  SCREENING/PRE-SCREENING REGISTRATION:          -  Patients must have pathologically proven squamous cell carcinoma (SCCA) cancer of the             lung confirmed by tumor biopsy and/or fine-needle aspiration; disease must be stage             IV SCCA, or recurrent; the primary diagnosis of SCCA should be established using the             current World Health Organization (WHO)/International Association for the Study of             Lung Cancer (IASLC)-classification of Thoracic Malignancies; the diagnosis is based             on hematoxylin and eosin (H&E) stained slides with or without specific defined             immunohistochemistry (IHC) characteristic (p40/p63 positive, transcription             termination factor [TTF1] negative) if required for diagnosis; mixed histologies are             not allowed          -  Patients must either be eligible to be screened at progression on prior treatment or             to be pre-screened prior to progression on current treatment; patients will either             consent to the screening consent or the pre-screening consent, not both; these             criteria are:               -  Screening at progression on prior treatment: to be eligible for screening at                  progression, patients must have received at least one line of systemic therapy                  for any stage of disease (stages I-IV); at least one of these lines of therapy                  must have been a platinum-based chemotherapy regimen; patients must have                  progressed following the most recent line of therapy; for patients whose prior                  systemic therapy was for stage I-III disease only (i.e. patient has not received                  any treatment for stage IV disease), disease progression on platinum-based                  chemotherapy must have occurred within one year from the last date that patient                  received that therapy               -  Pre-screening prior to progression on current treatment: to be eligible for                  pre-screening, current treatment must be for stage IV disease and patient must                  have received at least one dose of the current regimen; patients must have                  previously received or currently be receiving a platinum-based chemotherapy                  regimen; patients on first-line platinum-based treatment are eligible upon                  receiving Cycle 1, Day 1 infusion; Note: patients will not receive their                  sub-study assignment until they progress and the S1400 Notice of Progression is                  submitted          -  Patients must have adequate tumor tissue available, defined as >= 20% tumor cells and             >= 0.2 mm^3 tumor volume; the local interpreting pathologist must review and sign off             on the S1400 Local Pathology Review Form prior to screening/pre-screening             registration; patients must agree to have this tissue submitted to Foundation             Medicine for common broad platform Clinical Laboratory Improvement Amendments (CLIA)             biomarker profiling; if archival tumor material is exhausted, then a new fresh tumor             biopsy that is formalin-fixed and paraffin-embedded (FFPE) must be obtained; a tumor             block or FFPE slides 4-5 microns thick must be submitted; bone biopsies are not             allowed; if FFPE slides are to be submitted, at least 12 unstained slides plus an H&E             stained slide, or 13 unstained slides must be submitted; however it is strongly             recommended that 20 FFPE slides be submitted; Note: previous next-generation             deoxyribonucleic acid (DNA) sequencing (NGS) will be repeated if done outside this             study for sub-study assignment          -  Patients must not have a known epidermal growth factor receptor (EGFR) mutation or             anaplastic lymphoma kinase (ALK) fusion          -  Patients must have Zubrod performance status 0-1 documented within 28 days prior to             screening/pre-screening registration          -  Patients must also be offered participation in banking for future use of specimens          -  Patients must be willing to provide prior smoking history as required on the S1400             Onstudy Form          -  As a part of the Oncology Patient Enrollment Network (OPEN) registration process the             treating institution's identity is provided in order to ensure that the current             (within 365 days) date of institutional review board approval for this study has been             entered in the system          -  Patients must be informed of the investigational nature of this study and must sign             and give written informed consent in accordance with institutional and federal             guidelines          -  SUB-STUDY REGISTRATION:          -  Patients whose biomarker profiling results indicate the presence of an EGFR mutation             or echinoderm microtubule-associated protein-like 4 (EML4)/ALK fusion are not             eligible          -  Patients must have progressed per RECIST 1.1 following the most recent line of             therapy          -  Patients must not have received any prior systemic therapy (systemic chemotherapy,             immunotherapy or investigational drug) within 21 days prior to sub-study             registration; patients must have recovered (=< grade 1) from any side effects of             prior therapy; localized palliative radiation therapy is allowed for symptom             management, provided treatment is completed >= 14 days prior to sub-study             registration; all other types of radiation must be completed >= 28 days prior to             sub-study registration          -  Patients must have measurable disease documented by computed tomography (CT) or             magnetic resonance imaging (MRI); the CT from a combined positron emission tomography             (PET)/CT may be used to document only non-measurable disease unless it is of             diagnostic quality; measurable disease must be assessed within 28 days prior to             sub-study registration; pleural effusions, ascites and laboratory parameters are not             acceptable as the only evidence of disease; non-measurable disease must be assessed             within 42 days prior to sub-study registration; all disease must be assessed and             documented on the Baseline Tumor Assessment Form; patients whose only measurable             disease is within a previous radiation therapy port must demonstrate clearly             progressive disease (in the opinion of the treating investigator) prior to             registration          -  Patients must have a CT or MRI scan of the brain to evaluate for central nervous             system (CNS) disease within 42 days prior to sub-study registration; patient must not             have leptomeningeal disease, spinal cord compression or brain metastases unless: (1)             metastases have been locally treated and have remained clinically controlled and             asymptomatic for at least 14 days following treatment, AND (2) patient has no             residual neurological dysfunction and has been off corticosteroids for at least 1 day             prior to sub-study registration          -  Patient must have fully recovered from the effects of prior surgery at least 14 days             prior to sub-study registration          -  Patients must not be planning to receive any concurrent chemotherapy, immunotherapy,             biologic or hormonal therapy for cancer treatment; concurrent use of hormones for             non-cancer-related conditions (e.g., insulin for diabetes and hormone replacement             therapy) is acceptable          -  Absolute neutrophil count (ANC) >= 1,500/mcl obtained within 28 days prior to             sub-study registration          -  Platelet count >= 100,000 mcl obtained within 28 days prior to sub-study registration          -  Hemoglobin >= 9 g/dL obtained within 28 days prior to sub-study registration          -  Serum bilirubin =< institutional upper limit of normal (IULN) within 28 days prior to             sub-study registration; for patients with liver metastases, bilirubin must be =< 5 x             IULN          -  Either alanine aminotransferase (ALT) or aspartate aminotransferase (AST) =< 2 x IULN             within 28 days prior to sub-study registration (if both ALT and AST are done, both             must be =< 2 IULN); for patients with liver metastases, either ALT or AST must be =<             5 x IULN (if both ALT and AST are done, both must be =< 5 x IULN)          -  Serum creatinine =< the IULN OR measured or calculated creatinine clearance >= 50             mL/min using the following Cockcroft-Gault Formula within 28 days prior to sub-study             registration          -  Patients must have Zubrod performance status 0-1 documented within 28 days prior to             sub-study registration          -  Patients must not have any grade III/IV cardiac disease as defined by the New York             Heart Association Criteria (i.e., patients with cardiac disease resulting in marked             limitation of physical activity or resulting in inability to carry on any physical             activity without discomfort), unstable angina pectoris, and myocardial infarction             within 6 months, or serious uncontrolled cardiac arrhythmia          -  Patients must not have documented evidence of acute hepatitis or have an active or             uncontrolled infection          -  Patients with a known history of human immunodeficiency virus (HIV) seropositivity             must: 1) have undetectable viral load using standard HIV assays in clinical practice,             2) have cluster of differentiation (CD)4 count >= 400/mcL, 3) not require prophylaxis             for any opportunistic infections (i.e., fungal, Mycobacterium avium complex [mAC], or             pneumocystis jiroveci pneumonia [PCP] prophylaxis), and 4) not be newly diagnosed             within 12 months prior to sub-study registration          -  Prestudy history and physical exam must be obtained within 28 days prior to sub-study             registration          -  No other prior malignancy is allowed except for the following: adequately treated             basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated             stage I or II cancer from which the patient is currently in complete remission, or             any other cancer from which the patient has been disease free for five years          -  Patients must not be pregnant or nursing; women/men of reproductive potential must             have agreed to use an effective contraceptive method; a woman is considered to be of             ""reproductive potential"" if she has had menses at any time in the preceding 12             consecutive months; in addition to routine contraceptive methods, ""effective             contraception"" also includes heterosexual celibacy and surgery intended to prevent             pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy,             bilateral oophorectomy or bilateral tubal ligation; however, if at any point a             previously celibate patient chooses to become heterosexually active during the time             period for use of contraceptive measures outlined in the protocol, he/she is             responsible for beginning contraceptive measures          -  As part of the OPEN registration process the treating institution's identity is             provided in order to ensure that the current (within 365 days) date of institutional             review board approval for this study has been entered into the system          -  Patients with impaired decision-making capacity are eligible as long as their             neurological or psychological condition does not preclude their safe participation in             the study (e.g., tracking pill consumption and reporting adverse events to the             investigator)          -  Patients must be informed of the investigational nature of this study and must sign             and give written informed consent in accordance with institutional and federal             guidelines.      "
NCT02438722,Phase 2/Phase 3,Southwest Oncology Group,Other,"A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients With Advanced, EGFR Mutation Positive Non-small Cell Lung Cancer (NSCLC)",1,0,150,include,include,include,,,,,include,,,,,,,require,,,,exclude,1800,exclude,12,exclude,1800,"        Inclusion Criteria:          -  Patients must have histologically or cytologically confirmed stage IV (American Joint             Committee on Cancer [AJCC] 7th Edition) or recurrent non-small cell lung cancer             (NSCLC)          -  Patients must have documented presence of an EGFR exon 19 deltion or exon 21 (L858R)             substitution mutation; T790M mutation or other molecular abnormality will be allowed             as long as it accompanies one of the mutations listed above; EGFR testing must be             performed using a Food and Drug Administration (FDA)-approved test or in a Clinical             Laboratory Improvement Amendments (CLIA)-certified laboratory.          -  Patients must have tissue available and must agree to submission of tissue and blood;             one to two paraffin-embedded tissue blocks or 15-20 unstained slides are requested (a             minimum of 12 slides is required); cytology (i.e. fine-needle aspirations, pleural             effusion specimens) is acceptable if a cell block or sufficient unstained slides are             available; tumor material must be reviewed by a local pathologist who must confirm             that at least 100 viable tumor cells are present in the sample and sign the S1403             Pathology Review Form; patients must also be willing to submit blood samples for             correlative research at baseline, during treatment and at progression          -  Patients enrolled at sites participating in the Repeat Biopsy Study must agree to             submission of tissue obtained by a repeat biopsy performed at the time of disease             progression          -  Patients must not have received any prior systemic anticancer therapy for advanced or             metastatic disease including chemotherapy or EGFR tyrosine kinase inhibitor therapy             (including gefitinib, erlotinib, afatinib, or any experimental EGFR tyrosine kinase             inhibitors [TKI] agents); prior chemotherapy for non-metastatic disease (i.e.             adjuvant therapy or concurrent chemo-radiotherapy) is allowed as long as > 12 months             has passed since completion of therapy; adjuvant EGFR-directed therapy is not             allowed; local therapy (i.e. palliative radiotherapy) is allowed as long as a period             of 7 days has passed since the last dose was received and the patient has recovered             from any associated toxicity at the time of registration          -  Patients may have measurable or non-measurable disease documented by computed             tomography (CT) or magnetic resonance imaging (MRI) within 42 days prior to             registration; the CT from a combined positron emission tomography (PET)/CT may be             used only if it is of diagnostic quality; laboratory parameters are not acceptable as             the only evidence of disease; in order to qualify as measurable, measurable disease             must be outside previous radiation field; all disease must be assessed and documented             on the Baseline Tumor Assessment Form (Response Evaluation Criteria in Solid Tumors             [RECIST] 1.1)          -  Patients must have a CT or MRI scan of the brain to evaluate for central nervous             system (CNS) disease within 42 days prior to registration; patient must not have             symptomatic brain metastases or evidence of leptomeningeal carcinomatosis; patients             with asymptomatic brain metastases are eligible if off of steroids for at least 7             days prior to registration without development of symptoms          -  Patients must not have any known clinically active interstitial lung disease          -  Absolute neutrophil count (ANC) >= 1,500/mcL          -  Platelets >= 75,000/mcL          -  Hemoglobin >= 9 g/dL          -  Total bilirubin =< 1.5 x institutional upper limit of normal (IULN)          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x IULN (or             =< 5 x IULN for patients with known liver metastases)          -  Serum creatinine =< 1.5 x IULN OR measured or calculated creatinine clearance >= 60             mL/min          -  Patients must not have significant gastrointestinal disorders with diarrhea as a             major symptom (e.g. Crohn's disease, malabsorption, etc)          -  Patients must be able to swallow medication by oral route          -  Patients must not have a history of clinically relevant cardiovascular abnormalities             such as uncontrolled hypertension, congestive heart failure New York Heart             Association (NYHA) classification of 3, unstable angina or poorly controlled             arrhythmia or myocardial infarction within 6 months prior to registration; if             clinically indicated, echocardiogram or multigated acquisition (MUGA) must be             performed and cardiac ejection fraction must be >= 50%          -  Patients must not have had major surgery within 28 days prior to registration or be             scheduled for surgery during the projected course of protocol treatment; tumor biopsy             is allowed          -  Patients must not have a known history of active hepatitis B infection (defined as             presence of hepatitis B surface antigen [Hep B sAg] and/ or Hep B deoxyribonucleic             acid [DNA]), active hepatitis C infection (defined as presence of hepatitis C [Hep C]             ribonucleic acid [RNA]) and/or known human immunodeficiency virus (HIV) seropositive          -  Patients must not have any other concomitant serious illness or organ system             dysfunction which in the opinion of the investigator would either compromise patient             safety or interfere with the evaluation of the safety of the study drug          -  Patients must not be planning to receive any other investigational agents during the             course of protocol treatment          -  Patients must not have a history of allergic reactions attributed to compounds of             similar chemical or biologic composition to afatinib and/or cetuximab          -  Prestudy history and physical must be obtained with 28 days prior to registration          -  Patients must have Zubrod performance status of 0 - 2          -  No other prior malignancy is allowed except for the following: adequately treated             basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated             stage I or II cancer from which the patient is currently in complete remission, or             any other cancer from which the patient has been disease free for three years          -  Patients must not be pregnant or nursing; women/men of reproductive potential must             have agreed to use an effective contraceptive method; a woman is considered to be of             ""reproductive potential"" if she has had menses at any time in the preceding 12             consecutive months; in addition to routine contraceptive methods, ""effective             contraception"" also includes heterosexual celibacy and surgery intended to prevent             pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy,             bilateral oophorectomy or bilateral tubal ligation; however, if at any point a             previously celibate patient chooses to become heterosexually active during the time             period for use of contraceptive measures outlined in the protocol, he/she is             responsible for beginning contraceptive measures          -  Patients must be informed of the investigational nature of this study and must sign             and give written informed consent in accordance with institutional and federal             guidelines          -  As a part of the Oncology Patient Enrollment Network (OPEN) registration process the             treating institution's identity is provided in order to ensure that the current             (within 365 days) date of institutional review board approval for this study has been             entered in the system      "
NCT02438722,Phase 2/Phase 3,Southwest Oncology Group,Other,"A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients With Advanced, EGFR Mutation Positive Non-small Cell Lung Cancer (NSCLC)",2,0,150,include,include,include,,include,include,include,,,,,require,,,require,,,,exclude,1800,exclude,12,exclude,1800,"        Inclusion Criteria:          -  Patients must have histologically or cytologically confirmed stage IV (American Joint             Committee on Cancer [AJCC] 7th Edition) or recurrent non-small cell lung cancer             (NSCLC)          -  Patients must have documented presence of an EGFR exon 19 deltion or exon 21 (L858R)             substitution mutation; T790M mutation or other molecular abnormality will be allowed             as long as it accompanies one of the mutations listed above; EGFR testing must be             performed using a Food and Drug Administration (FDA)-approved test or in a Clinical             Laboratory Improvement Amendments (CLIA)-certified laboratory.          -  Patients must have tissue available and must agree to submission of tissue and blood;             one to two paraffin-embedded tissue blocks or 15-20 unstained slides are requested (a             minimum of 12 slides is required); cytology (i.e. fine-needle aspirations, pleural             effusion specimens) is acceptable if a cell block or sufficient unstained slides are             available; tumor material must be reviewed by a local pathologist who must confirm             that at least 100 viable tumor cells are present in the sample and sign the S1403             Pathology Review Form; patients must also be willing to submit blood samples for             correlative research at baseline, during treatment and at progression          -  Patients enrolled at sites participating in the Repeat Biopsy Study must agree to             submission of tissue obtained by a repeat biopsy performed at the time of disease             progression          -  Patients must not have received any prior systemic anticancer therapy for advanced or             metastatic disease including chemotherapy or EGFR tyrosine kinase inhibitor therapy             (including gefitinib, erlotinib, afatinib, or any experimental EGFR tyrosine kinase             inhibitors [TKI] agents); prior chemotherapy for non-metastatic disease (i.e.             adjuvant therapy or concurrent chemo-radiotherapy) is allowed as long as > 12 months             has passed since completion of therapy; adjuvant EGFR-directed therapy is not             allowed; local therapy (i.e. palliative radiotherapy) is allowed as long as a period             of 7 days has passed since the last dose was received and the patient has recovered             from any associated toxicity at the time of registration          -  Patients may have measurable or non-measurable disease documented by computed             tomography (CT) or magnetic resonance imaging (MRI) within 42 days prior to             registration; the CT from a combined positron emission tomography (PET)/CT may be             used only if it is of diagnostic quality; laboratory parameters are not acceptable as             the only evidence of disease; in order to qualify as measurable, measurable disease             must be outside previous radiation field; all disease must be assessed and documented             on the Baseline Tumor Assessment Form (Response Evaluation Criteria in Solid Tumors             [RECIST] 1.1)          -  Patients must have a CT or MRI scan of the brain to evaluate for central nervous             system (CNS) disease within 42 days prior to registration; patient must not have             symptomatic brain metastases or evidence of leptomeningeal carcinomatosis; patients             with asymptomatic brain metastases are eligible if off of steroids for at least 7             days prior to registration without development of symptoms          -  Patients must not have any known clinically active interstitial lung disease          -  Absolute neutrophil count (ANC) >= 1,500/mcL          -  Platelets >= 75,000/mcL          -  Hemoglobin >= 9 g/dL          -  Total bilirubin =< 1.5 x institutional upper limit of normal (IULN)          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x IULN (or             =< 5 x IULN for patients with known liver metastases)          -  Serum creatinine =< 1.5 x IULN OR measured or calculated creatinine clearance >= 60             mL/min          -  Patients must not have significant gastrointestinal disorders with diarrhea as a             major symptom (e.g. Crohn's disease, malabsorption, etc)          -  Patients must be able to swallow medication by oral route          -  Patients must not have a history of clinically relevant cardiovascular abnormalities             such as uncontrolled hypertension, congestive heart failure New York Heart             Association (NYHA) classification of 3, unstable angina or poorly controlled             arrhythmia or myocardial infarction within 6 months prior to registration; if             clinically indicated, echocardiogram or multigated acquisition (MUGA) must be             performed and cardiac ejection fraction must be >= 50%          -  Patients must not have had major surgery within 28 days prior to registration or be             scheduled for surgery during the projected course of protocol treatment; tumor biopsy             is allowed          -  Patients must not have a known history of active hepatitis B infection (defined as             presence of hepatitis B surface antigen [Hep B sAg] and/ or Hep B deoxyribonucleic             acid [DNA]), active hepatitis C infection (defined as presence of hepatitis C [Hep C]             ribonucleic acid [RNA]) and/or known human immunodeficiency virus (HIV) seropositive          -  Patients must not have any other concomitant serious illness or organ system             dysfunction which in the opinion of the investigator would either compromise patient             safety or interfere with the evaluation of the safety of the study drug          -  Patients must not be planning to receive any other investigational agents during the             course of protocol treatment          -  Patients must not have a history of allergic reactions attributed to compounds of             similar chemical or biologic composition to afatinib and/or cetuximab          -  Prestudy history and physical must be obtained with 28 days prior to registration          -  Patients must have Zubrod performance status of 0 - 2          -  No other prior malignancy is allowed except for the following: adequately treated             basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated             stage I or II cancer from which the patient is currently in complete remission, or             any other cancer from which the patient has been disease free for three years          -  Patients must not be pregnant or nursing; women/men of reproductive potential must             have agreed to use an effective contraceptive method; a woman is considered to be of             ""reproductive potential"" if she has had menses at any time in the preceding 12             consecutive months; in addition to routine contraceptive methods, ""effective             contraception"" also includes heterosexual celibacy and surgery intended to prevent             pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy,             bilateral oophorectomy or bilateral tubal ligation; however, if at any point a             previously celibate patient chooses to become heterosexually active during the time             period for use of contraceptive measures outlined in the protocol, he/she is             responsible for beginning contraceptive measures          -  Patients must be informed of the investigational nature of this study and must sign             and give written informed consent in accordance with institutional and federal             guidelines          -  As a part of the Oncology Patient Enrollment Network (OPEN) registration process the             treating institution's identity is provided in order to ensure that the current             (within 365 days) date of institutional review board approval for this study has been             entered in the system      "
NCT02635009,Phase 2/Phase 3,NRG Oncology,Other,Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer,1,18,150,,,,include,,,,,include,include,,,,,,,,,,,,,,,"        Inclusion Criteria:          -  PRIOR TO STEP 1 REGISTRATION          -  Histologic proof or unequivocal cytologic proof (fine needle aspiration, biopsy or             two positive sputa) of SCLC within 250 days prior to Step 1 registration          -  Patients must have a three-dimensional (3D), T1-weighted, spoiled gradient (SPGR),             magnetization-prepared rapid gradient echo (MP-RAGE), or turbo field echo (TFE) MRI             scan without and with gadolinium contrast-enhanced T1-weighted axial, coronal, and             sagittal sequence acquisitions and standard T2-weighted axial and coronal fluid             attenuation inversion recovery (FLAIR) sequence acquisitions within 28 days of Step 1             registration; to yield acceptable image quality, the pre-contrast-enhanced should             have a resolution of 1 x 1 x 1.2 mm and should follow the protocols established by             the Alzheimer's Disease Neuroimaging Initiative (ADNI); performance of this sequence             at a 3 Tesla field strength is recommended; sites may contact the Imaging Co-Chair,             Dr. Tammie Benzinger, for further information or assistance if needed; to yield             acceptable image quality, the gadolinium contrast-enhanced T1-weighted scan should             use the smallest possible axial slice thickness not exceeding 1.5 mm; the associated             coronal and sagittal sequences can be up to 2.5 mm in slice thickness; this imaging             is considered standard of care          -  Note: The MRI study as part of response assessment following chemotherapy can be used             for this purpose, but the appropriate sequences must be obtained; this sequence             cannot be obtained prior to chemotherapy and is mandatory irrespective of             randomization to the experimental or control arm of this study          -  Patients must sign a study-specific informed consent prior to study entry          -  PRIOR TO STEP 2 REGISTRATION          -  The following baseline neurocognitive assessments must be completed within 14 days             prior to Step 2 registration: HVLT-R, TMT, and COWA; the neurocognitive assessments             will be uploaded into the National Surgical Adjuvant Breast and Bowel Project,             Radiation Therapy Oncology Group, and Gynecologic Oncology Group (NRG) Oncology RAVE             system for evaluation by Dr. Wefel; once the upload is complete, a notification will             be sent to the site to proceed to Step 2; note: completed baseline neurocognitive             assessments can be uploaded at the time of Step 1 registration          -  Patients must have a baseline raw score greater than 2 on the HVLT-R delayed recall          -  Prior to chemotherapy or thoracic radiotherapy, patients must be defined as             limited-stage or extensive-stage SCLC after clinical staging evaluation involving the             following:               -  History/physical examination;               -  Computed tomography (CT) of the chest and abdomen with contrast (does not have                  to be done if the patient has had a positron emission tomography (PET)/CT scan                  within 8 weeks prior to initiating chemotherapy or thoracic radiotherapy)               -  MRI of the brain               -  For patients without evidence of extensive-stage SCLC on chest and abdomen CT                  and brain MRI, a PET/CT or bone scan is required to confirm limited-stage SCLC          -  Patients must be registered on study no earlier than 1 week and no later than 8 weeks             after completing chemotherapy (+/- thoracic radiotherapy)          -  After chemotherapy, patients must be restaged using the same diagnostic work-up as             required pre-chemotherapy; repeat PET/CT or bone scan is not required; patients must             have:               -  No central nervous system (CNS) metastases               -  Radiographic partial or complete response to chemotherapy in at least one                  disease site using Response Evaluation Criteria in Solid Tumors (RECIST)                  criteria               -  No progression in any site          -  Zubrod performance status 0-2          -  Women of childbearing potential and male participants must practice adequate             contraception          -  Women of childbearing potential must have a negative qualitative serum pregnancy test             =< 2 weeks prior to study entry          -  Patients who are primary English or French speakers are eligible        Exclusion Criteria:          -  Prior radiotherapy to the head or neck (except for T1 glottic cancer), resulting in             overlap of radiation fields          -  Radiographic evidence of CNS metastases          -  Radiographic evidence of hydrocephalus          -  Planned concurrent chemotherapy or anti-tumor agent during PCI          -  Concomitant invasive malignancy or invasive malignancy within the past five years             other than non-melanomatous skin cancer; history of in situ carcinoma (e.g. ductal             carcinoma in situ of breast, in situ carcinoma of the cervix, vulva or larynx) is             permitted          -  Contraindication to MR imaging, such as implanted metal devices or foreign bodies or             severe claustrophobia          -  Severe, active comorbidity, defined as follows:               -  Unstable angina and/or congestive heart failure requiring hospitalization within                  the last 6 months               -  Transmural myocardial infarction within the last 6 months               -  Acute bacterial or fungal infection requiring intravenous antibiotics at the                  time of registration               -  Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects               -  Chronic obstructive pulmonary disease exacerbation or other respiratory illness                  requiring hospitalization or precluding study therapy at the time of                  registration               -  Uncontrolled, clinically significant cardiac arrhythmias          -  Women of childbearing potential and male participants who are sexually active and not             willing/able to use medically acceptable forms of contraception      "
NCT02186847,Phase 2,NRG Oncology,Other,Randomized Phase II Trial of Concurrent Chemoradiotherapy +/- Metformin HCL in Locally Advanced NSCLC,1,18,150,include,include,include,,,,include,,,,,,,,,,,,exclude,1800,,,,,"        Inclusion Criteria:          -  Pathologically (histologically or cytologically) proven diagnosis of stage IIIA or             IIIB non-small cell lung cancer within 84 days of registration; eligible histologies             include adenocarcinoma, adenosquamous, large cell carcinoma, squamous carcinoma,             non-lobar and non-diffuse bronchoalveolar cell carcinoma or non-small cell lung             cancer not otherwise specified [NOS])          -  Patients must have measurable disease          -  Patients must have unresectable disease, be medically inoperable, or unwilling to             undergo surgical management          -  Appropriate stage for protocol entry, including no distant metastases, based upon the             following minimum diagnostic workup:               -  History/physical examination, including documentation of height, weight, body                  surface area [BSA], and vital signs, within 30 days prior to registration               -  Computed tomography (CT) with IV contrast or magnetic resonance imaging (MRI)                  imaging (if CT scan with contrast is medically contraindicated) of the lung and                  upper abdomen through the adrenal glands, required within 45 days prior to                  registration (recommended within 30 days prior to registration               -  MRI of the brain with contrast (or CT with contrast if MRI is medically                  contraindicated) within 30 days prior to registration; note: the use of                  intravenous contrast is required for the MRI or CT; an MRI without contrast is                  only permitted if the patient has a contrast allergy               -  Whole-body fludeoxyglucose F 18 (FDG)-positron emission tomography (PET)/CT                  required within 45 days prior to registration (recommended within 30 days prior                  to registration; note: patients do not need to have a separate CT of the chest                  and upper abdomen with contrast if PET/CT imaging includes a high quality CT                  with contrast          -  Zubrod performance status 0-1          -  Absolute neutrophil count (ANC) >= 1,500 cells/mm^3          -  Platelets >= 100,000 cells/mm^3          -  Hemoglobin >= 8.0 g/dl (note: the use of transfusion or other intervention to achieve             hemoglobin [Hgb] >= 8.0 g/dl is acceptable)          -  Serum creatinine within normal institutional limits or creatinine clearance must be             at least 60 ml/min          -  Total bilirubin =< 1.5 x upper limit of normal (ULN) for the institution          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN for             the institution          -  Alkaline phosphatase =< 2.5 x ULN for the institution          -  Fasting blood glucose =< 125 mg/dL within 14 days prior to registration          -  Serum albumin > 3.0 g/dl within 14 days prior to registration          -  For women of childbearing potential, a serum pregnancy test within 72 hours prior to             registration          -  Patients with post-obstructive pneumonia are eligible provided they no longer require             intravenous antibiotics at registration          -  Patients must be at least 3 weeks from prior thoracotomy (if performed)          -  If a pleural effusion is present, the following criteria must be met at registration             to exclude malignant involvement (incurable M1a disease):               -  When pleural fluid is visible on both the CT scan and on a chest x-ray, a                  pleuracentesis is required to confirm that the pleural fluid is cytologically                  negative               -  Effusions that are minimal (i.e. not visible under ultrasound guidance) and that                  are too small to safely tap are eligible          -  Women of childbearing potential and male participants must practice adequate             contraception throughout the study          -  Patient must provide study specific informed consent prior to study entry        Exclusion Criteria:          -  Patients with mixed small cell and non-small cell histologies          -  Patients with distant metastasis          -  Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free             for a minimum of 3 years (for example, carcinoma in situ of the breast, oral cavity,             or cervix are all permissible)          -  Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a             different cancer is allowable          -  Prior radiotherapy to the region of the study cancer that would result in overlap of             radiation therapy fields          -  Patients currently using metformin (metformin hydrochloride), other oral hypoglycemic             agents or insulin          -  Patients with any history of allergic reaction to paclitaxel or other taxanes or             carboplatin          -  Patients with a history of chronic kidney disease or lactic acidosis          -  Patients with >= 10% weight loss within the past month          -  Severe, active co-morbidity, defined as follows:               -  Diagnosis of type I or type II diabetes mellitus               -  Uncontrolled neuropathy >= grade 2 regardless of cause               -  Unstable angina and/or congestive heart failure requiring hospitalization within                  the last 6 months               -  Transmural myocardial infarction within the last 6 months               -  Acute bacterial or fungal infection requiring intravenous antibiotics at the                  time of registration               -  Chronic obstructive pulmonary disease exacerbation or other respiratory illness                  requiring hospitalization or precluding study therapy within 30 days of                  registration               -  Severe hepatic disease, defined as a diagnosis of Child-Pugh class B or C                  hepatic disease               -  Human immunodeficiency virus (HIV) positive with cluster of differentiation                  (CD)4 count < 200 cells/microliter; note that patients who are HIV positive are                  eligible, provided they are under treatment with highly active antiretroviral                  therapy (HAART) and have a CD4 count >= 200 cells/microliter within 30 days                  prior to registration; note also that HIV testing is not required for                  eligibility for this protocol               -  End-stage renal disease (ie, on dialysis or dialysis has been recommended)          -  Pregnancy or women of childbearing potential and men who are sexually active and not             willing/able to use medically acceptable forms of contraception      "
NCT02134912,Phase 2,Southwest Oncology Group,Other,"S1300: A Randomized, Phase II Trial of Crizotinib Plus Pemetrexed Versus Pemetrexed Monotherapy in ALK-Positive Non-squamous NSCLC Patients Who Have Progressed Systemically After Previous Clinical Benefit From Crizotinib Monotherapy",1,18,150,include,include,,,,,,include,,,,,,require,,,,,,,,,,,"        Inclusion Criteria:          -  Patients must have histologically or cytologically proven primary non-squamous             non-small cell lung cancer (adenocarcinoma, large cell carcinoma, adenocarcinoma in             situ, mixed histology with < 50% squamous or unspecified); patients with tumors             having squamous cell components >= 50% are not eligible; disease must be stage IV          -  Patients must have documented ALK positivity at the time of initial crizotinib             monotherapy using the Vysis Break-Apart FISH assay (or other Food and Drug             Administration [FDA]-approved diagnostic test); samples are deemed to be             FISH-positive if greater than or equal to 15% of scored tumor cells had split ALK 5'             and 3' probe signals or had isolated 3' signal; FISH status must be documented on the             Onstudy Form and a copy of the pathology report from the Vysis Break-Apart FISH assay             (or other FDA-approved diagnostic test) must be submitted          -  Prior to registration, patients must have achieved clinical benefit with crizotinib             monotherapy and subsequently have systemically progressed; clinical benefit is             defined as having stable disease on crizotinib monotherapy for at least 90 days or             achieving a confirmed partial or complete response; systemic progression is defined             as progressive disease based on Response Evaluation Criteria in Solid Tumors (RECIST)             version 1.1, excluding progression based on brain/CNS metastases alone          -  Patients must have received crizotinib monotherapy at 250 mg BID on a continuous             dosing schedule for at least 90 days; patients must be planning to start treatment at             least three days, but no more than 30 days after discontinuing crizotinib             monotherapy; patients who were not able to tolerate 250 mg BID of crizotinib are not             eligible for this study          -  Patients must be pemetrexed-naÌøve; patients may have received any number of prior             chemotherapy or molecularly targeted agents; if crizotinib was used in the 1st line             setting then chemotherapy naive patients are also eligible; if patient received             crizotinib in combination with chemotherapy, prior chemotherapy must have been             discontinued at least 14 days prior to registration and all adverse events must have             resolved to =< grade 1          -  Patients must have measurable disease per RECIST documented by computed tomography             (CT) or magnetic resonance imaging (MRI); the CT from a combined positron emission             tomography (PET)/CT may be used to document only non-measurable disease unless it is             of diagnostic quality; measurable disease must be assessed within 28 days prior to             registration; pleural effusions, ascites and laboratory parameters are not acceptable             as the only evidence of disease; non-measurable disease must be assessed within 42             days prior to registration; all disease must be assessed and documented on the             Baseline Tumor Assessment Form RECIST 1.1          -  Patients must have a CT or MRI scan of the brain to evaluate for CNS disease within             42 days prior to registration; patient must not have brain metastases unless: (1)             metastases have been treated and have remained controlled for at least 14 days             following treatment or was not treated, but is asymptomatic, AND (2) patient has no             residual neurological dysfunction off corticosteroids or anti-convulsants for at             least 14 days          -  Patients may have received palliative radiotherapy to non-target lesions within 14             days prior to registration provided all radiotherapy related toxicities have resolved             to =< grade 1 prior to registration; patients must not have received any major             surgery within 28 days prior to registration          -  Patients must not have had any prior exposure to heat shock protein (HSP)90             inhibitors (such as IPI-504 or ganetespib) or non-crizotinib ALK inhibitors (such as             AP26113 or LDK378)          -  Patients must be offered participation in the translational medicine studies;             additionally if patient has biopsy accessible disease they must be offered             participation in the translational medicine studies          -  Absolute neutrophil count (ANC) >= 1,500/ul          -  Platelet count >= 100,000/ul          -  Hemoglobin >= 9 g/dL          -  Serum bilirubin =< 2 X institutional upper limit of normal (IULN)          -  Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) or             serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 2.5             x IULN          -  Estimated (calculated) or measured glomerular filtration rate >= 45 mL/min (or 45             mL/min/1.73 m^2); creatinine (mg/dl) used in calculation (Cockroft-Gault) must be             obtained within 28 days prior to registration          -  Male patients must have free and total testosterone level obtained within 28 days             prior to registration          -  Pre-study history and physical must be obtained with 28 days prior to registration          -  Patients must have Zubrod performance status 0-2 within 28 days prior to registration          -  Patients must be able to swallow capsules          -  Patients must have corrected QT (QTC) interval =< 480 msec on electrocardiogram (EKG)             at baseline; patient with congenital long QT syndrome are not eligible          -  No other prior malignancy is allowed except for the following: adequately treated             basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated             stage I or II cancer from which the patient is currently in complete remission, or             any other cancer from which the patient has been disease free for five years          -  Patients must not be pregnant or nursing; women/men of reproductive potential must             have agreed to use an effective contraceptive method; a woman is considered to be of             ""reproductive potential"" if she has had menses at any time in the preceding 12             consecutive months; in addition to routine contraceptive methods, ""effective             contraception"" also includes heterosexual celibacy and surgery intended to prevent             pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy,             bilateral oophorectomy or bilateral tubal ligation; however, if at any point a             previously celibate patient chooses to become heterosexually active during the time             period for use of contraceptive measures outlined in the protocol, he/she is             responsible for beginning contraceptive measures          -  REGULATORY CRITERIA: Patients or their legally authorized representative must be             informed of the investigational nature of this study and must sign and give written             informed consent in accordance with institutional and federal guidelines          -  REGULATORY CRITERIA: As a part of the Oncology Patient Enrollment Network (OPEN)             registration process the treating institution's identity is provided in order to             ensure that the current (within 365 days) date of institutional review board approval             for this study has been entered in the system          -  CROSSOVER (STEP 2) REGISTRATION: Patients must have progressed systemically on Arm 2             of this study (pemetrexed monotherapy)          -  CROSSOVER (STEP 2) REGISTRATION: Patients must be registered to crossover (Step 2)             within 30 days of discontinuing treatment on Arm 2 of this study          -  CROSSOVER (STEP 2) REGISTRATION: ANC >= 1,500/ul          -  CROSSOVER (STEP 2) REGISTRATION: Platelet count >= 100,000/ul          -  CROSSOVER (STEP 2) REGISTRATION: Serum bilirubin =< 2 X IULN          -  CROSSOVER (STEP 2) REGISTRATION: SGOT (AST) or SGPT (ALT) =< 2.5 x IULN          -  CROSSOVER (STEP 2) REGISTRATION: estimated (calculated) or measured glomerular             filtration rate >= 45 mL/min (or 45 mL/min/1.73 m^2) within 28 days prior to             registration; creatinine (mg/dl) used in calculation (Cockroft-Gault) must be             obtained within 28 days prior to registration          -  CROSSOVER (STEP 2) REGISTRATION: male patients must have free and total testosterone             level obtained within 28 days prior to Crossover (Step 2) Registration          -  CROSSOVER (STEP 2) REGISTRATION: patients must have Zubrod performance status 0-2             within 28 days prior to Crossover (Step 2) Registration      "
NCT00828009,Phase 2,Eastern Cooperative Oncology Group,Other,A Phase II Study of L-BLP25 and Bevacizumab in Unresectable Stage IIIA and IIIB Non-Squamous Non-Small Cell Lung Cancer After Definitive Chemoradiation,1,18,150,include,include,,,,,include,,,,require,exclude,,,,,exclude,1800,exclude,1800,exclude,1800,,,"        DISEASE CHARACTERISTICS:          -  Histologically confirmed newly diagnosed nonsquamous cell non-small cell lung cancer             (NSCLC), including the following subtypes:               -  Adenocarcinoma               -  Large cell undifferentiated               -  Bronchoalveolar cell               -  NSCLC, not otherwise specified          -  Unresectable stage IIIA or stage IIIB disease               -  Patients with stage IIIA disease with mediastinal lymph node enlargement between                  1 cm and 2.0 cm on CT scan must have these nodes biopsied (pathologic                  confirmation) to rule out resectability               -  Metastases to contralateral mediastinal or supraclavicular nodes allowed          -  Measurable or non-measurable disease, as defined by RECIST criteria          -  No significant pleural effusion as defined by either of the following:               -  Pleural effusion is seen on CT scan only (not seen on chest x-ray)               -  Pleural effusion does not reaccumulate within 1 week after thoracentesis AND is                  cytologically negative          -  No CNS metastases by head CT scan or MRI within the past 4 weeks        PATIENT CHARACTERISTICS:          -  ECOG performance status 0-1          -  WBC ‰ä´ 4,000/mmå_ OR ANC ‰ä´ 2,000/mmå_          -  Platelet count ‰ä´ 140,000/mmå_          -  Hemoglobin ‰ä´ 9.0 g/dL          -  Total bilirubin ‰ä_ 1.5 mg/dL          -  AST/ALT ‰ä_ 2.5 times upper limit of normal          -  Serum creatinine ‰ä_ 1.5 mg/mL OR creatinine clearance ‰ä´ 45 mL/min          -  Urine protein:creatinine ratio < 1.0 by urine dipstick OR < 1 g of protein by 24-hour             urine collection          -  INR ‰ä_ 1.5 OR ‰ä_ 3.0 if patient is on therapeutic anticoagulation          -  PTT normal          -  Not pregnant or nursing          -  Negative pregnancy test          -  Fertile patients must use effective contraception before, during, and for ‰ä´ 6 months             after completion of bevacizumab          -  No other active malignancies          -  No known hepatitis B or C          -  No ongoing (lasting > 14 days) or active infection or ongoing (lasting > 14 days)             fever within the past 6 months          -  No gross hemoptysis ‰ä´ grade 2 (defined as ‰ä´ å_ teaspoon of bright red blood per             episode) within the past 3 months               -  No pulmonary hemoptysis                    -  Confirmed extrapulmonary hemoptysis allowed          -  No bleeding ‰ä´ grade 2 or any bleeding requiring intervention          -  No history of bleeding diathesis or coagulopathy          -  No cardiac dysfunction, including any of the following:               -  Clinically significant cardiovascular disease               -  Myocardial infarction within the past 6 months               -  New York Heart Association class III-IV congestive heart failure               -  Unstable angina pectoris               -  Serious cardiac arrhythmia requiring medication within the past 4 weeks               -  History of hypertensive crisis or hypertensive encephalopathy               -  Stroke or transient ischemic attack within the past 6 months               -  Peripheral vascular disease ‰ä´ grade 2 within the past 6 months          -  No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within             the past 6 months          -  No psychiatric illness or social situation that would limit compliance with study             requirements          -  No history of uncontrolled hypertension (i.e., blood pressure ‰ä´ 150/100 mm Hg) while             on stable regimen of antihypertensive therapy          -  No significant traumatic injury or serious non-healing wound, ulcer, or bone fracture             within the past 4 weeks          -  No recognized immunodeficiency disease, including cellular immunodeficiencies,             hypogammaglobulinemia or dysgammaglobulinemia, or hereditary or congenital             immunodeficiencies          -  No pre-existing medical condition requiring chronic steroids or immunosuppressive             therapy          -  No autoimmune disease          -  No known hypersensitivity to any component of bevacizumab        PRIOR CONCURRENT THERAPY:          -  See Disease Characteristics          -  More than 4 weeks since prior open biopsy or major surgical procedure          -  More than 28 days since prior immunotherapy (e.g., interferon, interleukin,             sargramostim [GM-CSF], or filgrastim [G-CSF])          -  Patients must not have had prior chemotherapy or monoclonal antibodies for other             cancers within 5 years prior to registration          -  More than 7 says since prior core biopsy or any other minor surgical procedure,             excluding the placement of a vascular access device          -  No prior chemotherapy for lung cancer          -  No prior chest radiotherapy          -  No prior splenectomy          -  Concurrent stable regimen of therapeutic anticoagulation or prophylactic             anticoagulation for venous access devices allowed provided coagulation studies met             entry criteria          -  No concurrent daily aspirin (> 325 mg/day) or nonsteroidal anti-inflammatory agents             (NSAIDs) known to inhibit platelet function          -  No concurrent dipyridamole (Persantine), ticlopidine (Ticlid), clopidogrel bisulfate             (Plavix), and/or cilostazol (Pletal)          -  No concurrent major surgical procedure      "
NCT01532089,Phase 2,Academic and Community Cancer Research United,Other,A Randomized Phase II Trial of Erlotinib Alone or in Combination With Bevacizumab in Patients With Non-small Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations,1,18,150,include,include,,,,,,include,,,,,,,require,,,,exclude,1800,,,,,"        Inclusion Criteria:          -  Histologic documentation of primary lung carcinoma, non-squamous histology with             activating epidermal growth factor receptor (defined as deletion 19 or exon 21 L858R             mutation); Note: EGFR mutation testing must be performed at a Clinical Laboratory             Improvement Amendments (CLIA) certified lab; either institutional or through a             commercial laboratory (e.g. Genzyme, Response Genetics, etc); the laboratory report             from the commercial laboratories report the specific mutations detected, and the             method of detecting the exon 19 and exon 21 L858R point mutations must be available          -  Stage IV disease according to the 7th Edition of the American Joint Committee on             Cancer staging system          -  Measurable disease          -  Life expectancy of >= 12 months          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1          -  Absolute neutrophil count (ANC) >= 1,500/mm^3          -  Platelet count >= 100,000/mm^3          -  Hemoglobin >= 9.0 g/dL          -  Total bilirubin =< 1.5 x upper limit of normal (ULN)          -  Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) and             serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 2.5             x ULN in patients without liver or bone metastases; < 5 x ULN in patients with liver             or bone metastases          -  Cockcroft-Gault calculated creatinine clearance of >= 45 ml/min or creatinine =< 1.5             x ULN          -  Urine dipstick proteinuria < 2+ or urine protein/creatinine (UPC) ratio =< 1.0               -  Note: patients discovered to have >= 2 + proteinuria on dipstick urinalysis at                  baseline should undergo a 24-hour urine collection and must demonstrate =< 1 g                  of protein in 24 hours          -  Negative pregnancy test done =< 7 days prior to randomization, for women of             childbearing potential only          -  Provide informed written consent          -  Willing to return to Academic and Community Cancer Research United (ACCRU) enrolling             institution for follow-up          -  Willing to provide tissue and blood samples for correlative research purposes        Exclusion Criteria:          -  Mixed, non-small cell and small cell tumors or mixed adenosquamous carcinomas with a             predominant squamous component          -  Prior chemotherapy or treatment for metastatic non-small cell lung cancer          -  Any of the following:               -  Pregnant women               -  Nursing women               -  Men or women of childbearing potential who are unwilling to employ adequate                  contraception          -  Co-morbid systemic illnesses or other severe concurrent disease which, in the             judgment of the investigator, would make the patient inappropriate for entry into             this study or interfere significantly with the proper assessment of safety and             toxicity of the prescribed regimens          -  Immunocompromised patients (other than that related to the use of corticosteroids)             including patients known to be human immunodeficiency virus (HIV) positive, per             medical doctor (MD) discretion          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active             infection, or psychiatric illness/social situations, or any other medical condition             that would limit compliance with study requirements          -  Receiving any other investigational agent which would be considered as a treatment             for the primary neoplasm          -  Other active malignancy =< 3 years prior to randomization; EXCEPTIONS: non melanotic             skin cancer or carcinoma-in-situ of the cervix; Note: if there is a history of prior             malignancy, they must not be receiving other specific treatment (i.e. hormonal             therapy) for their cancer          -  History of myocardial infarction or other evidence of arterial thrombotic disease             (angina), symptomatic congestive heart failure (New York Heart Association >= grade             2), unstable angina pectoris, or cardiac arrhythmia; Note: allowed only if patient             has no evidence of active disease for at least 6 months prior to randomization          -  History of cerebral vascular accident (CVA) or transient ischemic attack (TIA) =< 6             months prior to randomization          -  History of bleeding diathesis or coagulopathy          -  Inadequately controlled hypertension (systolic blood pressure of > 150 mmHg or             diastolic pressure > 100 mmHg on anti-hypertensive medications); Note: history of             hypertensive crisis or hypertensive encephalopathy not allowed          -  Current or recent (=< 10 days prior to randomization) use of aspirin (> 325 mg/day),             clopidogrel (> 75 mg/day), or prasugrel (> 10 mg/day)          -  Serious non-healing wound, ulcer, bone fracture, or have undergone a major surgical             procedure, open biopsy, or significant traumatic injury =< 28 days or core biopsy =<             7 days prior to randomization          -  History of abdominal fistula, gastrointestinal perforation, or intraabdominal abscess             =< 6 months prior to randomization          -  Known hypersensitivity to Chinese hamster ovary cell products or other recombinant             human antibodies          -  History of hemoptysis >= grade 2 (defined as bright red blood of at least 2.5 mL) =<             3 months prior to randomization          -  Known central nervous system (CNS) disease, except for treated brain metastasis;             Note: treatment for brain metastases may include whole brain radiotherapy (WBRT),             radiosurgery (RS); Gamma Knife, linear accelerator (LINAC), or equivalent or a             combination as deemed appropriate by the treating physician; patients with CNS             metastases treated by neurosurgical resection or brain biopsy performed =< 3 months             prior to randomization will be excluded; Note: craniotomy or intracranial biopsy site             must be adequately healed, free of drainage or cellulitis, and the underlying             cranioplasty must appear intact at the time of randomization; study treatment should             be initiated > 28 days following the last surgical procedure (including biopsy,             surgical resection, wound revision, or any other major surgery involving entry into a             body cavity)          -  Significant vascular disease (e.g. aortic aneurysm surgical repair or recent             peripheral arterial thrombosis) =< 6 months prior to randomization          -  Radiotherapy to any site for any reason =< 14 days prior to randomization          -  Receiving any medications or substances that are strong or moderate inhibitors of             cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4); use of the following             strong or moderate inhibitors are prohibited =< 7 days prior to randomization:               -  Strong inhibitors of CYP3A4: indinavir (Crixivan), nelfinavir (Viracept),                  atazanavir (Reyataz), ritonavir (Norvir), clarithromycin (Biaxin, Biaxin XL),                  itraconazole (Sporanox), ketoconazole (Nizoral), nefazodone (Serzone),                  saquinavir (Fortovase, Invirase), telithromycin (Ketek)               -  Moderate inhibitors of CYP3A4: aprepitant (Emend), erythromycin (Erythrocin,                  E.E.S, Ery-Tab, Eryc, EryPed, PCE, fluconazole (Diflucan), grapefruit juice,                  verapamil (Calan, Calan SR, Covera-HS, Isoptin SR, Verelan, Verelan PM),                  diltiazem (Cardizem, Cardizem CD, Cardizem LA, Cardizem SR, Cartia XT, Dilacor                  XR, Diltia XT, Taztia XT, Tiazac)          -  Receiving any medications or substances that are inducers of CYP3A4; use of the             following inducers are prohibited =< 7 days prior to randomization: efavirenz             (Sustiva), nevirapine (Viramune), carbamazepine (Carbatrol, Epitol, Equetro,             Tegretol, Tegretol-XR), modafinil (Provigil), phenobarbital (Luminal), phenytoin             (Dilantin, Phenytek), pioglitazone (Actos), rifabutin (Mycobutin), rifampin             (Rifadin), St. John's wort      "
NCT01620190,Phase 2,University of Washington,Other,A Phase II Study of Weekly Abraxane for Patients With Advanced NSCLC With EGFR Mutations or With Durable Response to an EGFR Tyrosine Kinase Inhibitor Following Front Line Therapy With EGFR Tyrosine Kinase Inhibitors,1,18,150,include,include,include,,include,include,include,include,,,,,,,require,,,,exclude,1800,exclude,6,require,,"        Inclusion Criteria:          -  Pathologically confirmed non-small cell lung cancer with documented EGFR mutation in             tumor deoxyribonucleic acid (DNA) or complete/partial response to first line EGFR             tyrosine kinase inhibitors with > or = to 6 months duration of response in patients             who do not have a confirmed EGFR mutation          -  At least one site of measurable disease as determined by the Investigator, using             Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria          -  Progressive disease with radiographic evidence of disease progression per             investigator assessment during therapy with an EGFR tyrosine kinase inhibitor in the             metastatic setting; patients may continue EGFR inhibitor therapy throughout the             screening period until the day prior to nab-paclitaxel treatment initiation          -  Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2 at the time of             informed consent          -  Platelet count >= 100,000/uL          -  Absolute neutrophil count >= 1,500/uL          -  Hemoglobin >= 9 g/dL          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) = < 2.5 times             upper limit of normal          -  Alkaline phosphatase =< 2.5 times upper limit of normal, unless bone metastasis is             present in the absence of liver metastasis          -  Bilirubin =< 1.5 mg/dL          -  Creatinine =< 1.5 mg/dL          -  Women of child-bearing potential (WOCP) and sexually active men must agree to use             adequate contraception (hormonal or barrier method of birth control or abstinence)             prior to study entry, during treatment and for three months after completing             treatment          -  Negative serum or urine beta-human chorionic gonadotropin (hCG) pregnancy test at             screening for patients of childbearing potential          -  Life expectancy of > 12 weeks          -  Signed and dated informed consent document indicating that the patient has been             informed of all the pertinent aspects of the trial prior to enrollment        Exclusion Criteria:          -  Prior conventional cytotoxic chemotherapy for metastatic or recurrent disease; prior             adjuvant, neoadjuvant or chemoradiotherapy for NSCLC is permitted, provided at least             6 months elapsed prior to documented metastatic recurrence          -  A single dose of a platinum doublet discontinued due to intolerability without             evidence of disease progression is permitted          -  Patient is < 5 years free of another primary malignancy, except: a) if the other             malignancy is basal cell carcinoma or cervical carcinoma in situ or b) if the other             primary malignancy is not considered clinically significant and is requiring no             active intervention          -  Progressive or symptomatic central nervous system (CNS) metastases; patients with             known brain metastasis must have stable disease following treatment with surgery,             radiation or both; in addition, they must be off corticosteroids          -  Radiotherapy within 7 days of study treatment          -  Peripheral neuropathy grade 2 or greater          -  Grade III/IV congestive heart failure, as defined by New York Heart Association             (NYHA) criteria, or myocardial infarction within 6 months          -  Any serious or uncontrolled concomitant disorder that, in the opinion of the             investigator, would compromise the patient's ability to complete the study          -  Patient has known chronic liver disease, e.g. diagnosis of chronic active hepatitis             or cirrhosis          -  Major surgery within 21 days of study treatment; minor surgery within 2 weeks of             study treatment; placement of vascular access device and biopsies allowed and is not             considered major or minor surgery          -  Patient with any significant history of non-compliance to medical regimens or with             inability to grant reliable informed consent          -  Pregnant or breast feeding females      "
NCT01622621,Phase 2,Mayo Clinic,Other,Randomized Phase II Trial of Stereotactic Body Radiotherapy (SBRT) Versus Sublobar Resection for High-Risk Patients With Early Stage Non-Small Lung Cancer (NSCLC),1,18,150,include,include,include,,include,,,,,,,,,,,,,,,,,,,,"        Inclusion Criteria          -  Patients must have a suspicious lung nodule for clinical stage I NSCLC.          -  Pathologic confirmation at the time of surgery is acceptable. Patients randomized to             SBRT require core biopsy for diagnosis prior to treatment.          -  Patient must have a mass ‰ä_ 5 cm maximum diameter by CT size estimate that is clinical             stage I (T1N0, T2N0)          -  Patient must have a CT scan of the chest and upper abdomen and PET-scan within 60             days prior to date of registration.          -  Patient must have an Eastern Cooperative Oncology Group (ECOG) or Zubrod performance             status 0, 1, or 2.          -  Patient must meet at least one major criteria or meet a minimum of two minor criteria             as described below:        Major Criteria:          -  Forced expiratory volume in one second (FEV1) ‰ä_ 50% predicted          -  Carbon monoxide diffusing capacity (DLCO) ‰ä_ 50% predicted        Minor Criteria:          -  Age ‰ä´75          -  FEV1 51-60% predicted          -  DLCO 51-60% predicted          -  Pulmonary hypertension (defined as a pulmonary artery systolic pressure greater than             40 mmHg) as estimated by echocardiography or right heart catheterization          -  Poor left ventricular function (defined as an ejection fraction of 40% or less)          -  Resting or Exercise Arterial oxygen partial pressure (pO2) ‰ä_ 55 mm Hg or blood oxygen             saturation (SpO2) ‰ä_ 88%          -  pCO2 > 45 mm Hg          -  Modified Medical Research Council (MMRC) Dyspnea Scale ‰ä´ 3.        Exclusion Criteria          -  Patient must not have had previous intra-thoracic radiation therapy.          -  No prior malignancy except adequately treated non-melanoma skin cancer, in situ             cervical cancer, localized prostate cancer, stage 0 Chronic lymphocytic leukemia             (CLL), or other cancer disease-free > 3 yrs.      "